Modulation of BAF53 expression

ABSTRACT

Compounds, compositions and methods are provided for modulating the expression of BAF53. The compositions comprise oligonucleotides, targeted to nucleic acid encoding BAF53. Methods of using these compounds for modulation of BAF53 expression and for diagnosis and treatment of disease associated with expression of BAF53 are provided.

FIELD OF THE INVENTION

[0001] The present invention provides compositions and methods for modulating the expression of BAF53. In particular, this invention relates to compounds, particularly oligonucleotide compounds, which, in preferred embodiments, hybridize with nucleic acid molecules encoding BAF53. Such compounds are shown herein to modulate the expression of BAF53.

BACKGROUND OF THE INVENTION

[0002] Chromatin is a complex formed between nucleic acids and basic proteins (as histone) during interphase which must be remodeled during development to allow access of transcription factors to regulatory DNA sequences. Several of these chromatin remodeling complexes have been identified and are grouped into two categories: the histone acetylaces and the chromatin remodeling “BAF” complex that uses the energy of ATP hydrolysis to weaken the interaction between the histone core particles and the DNA. The BAF complex (BRG1/brm-associated factor) contains 9 to 12 subunits and is so named because it associates with the BRG1 and brm helicase-like proteins. The BAF complex is related to the yeast chromatin remodeling complex SWI/SNF because they carry out the same function and contain some homologous subunits. Initially described as a co-factor for nuclear receptors, the BAF complex is also associated with cell-cycle control and cell growth and possibly the development of tumors. Transcription factors mediate many of the growth-promoting or growth-suppressive signals that are carefully regulated for normal cell-cycle progression. This balance is disrupted in cancer, when mutations that arise either in upstream signaling or checkpoint pathways or in the transcription factor itself lead to unregulated transcription (Muchardt and Yaniv, Semin. Cell Dev. Biol., 1999, 10, 189-195).

[0003] One of the subunits of the BAF complex is a 53-kDa protein named BAF53. The gene encoding BAF53 (also called BAF53a, BRG1-associated factor 53 kDa, BAF complex 53 kDa subunit, actin-related protein, ACTLb, and hArpNbeta) was cloned in 1998 since it was one of the remaining uncharacterized subunits of the BAF complex (Zhao et al., Cell, 1998, 95, 625-636). The gene encoding BAF53 was also cloned the following year when it was given the name hArpNbeta and characterized as an actin-related protein (Harata et al., Biosci. Biotechnol. Biochem., 1999, 63, 917-923). Disclosed in PCT publication WO 01/59155 is a nucleotide sequence encoding BAF53 (Meritet et al., 2001).

[0004] BAF53 has extensive homology with actin and the actin related proteins Act2 and Act3 and is most related to Arp3, which is involved in Listeria motility. Although BAF53 shares high homology with actin, the ATP-binding pocket in actin is poorly conserved in BAF53, suggesting that BAF53 may not have ATP-binding activity. However, BAF53 and beta-actin are required for maximal ATPase activity of BRG1 and require BRG1 for the association of the BAF complex with chromatin (Zhao et al., Cell, 1998, 95, 625-636).

[0005] BAF53 has also been found to interact with c-Myc, a transcription factor that plays a role in both normal and tumor cell proliferation and is among the most frequently disrupted networks in cancer. BAF53 forms a distinct nuclear complex with c-Myc and is crucial for c-Myc-mediated cellular transformation. In addition, BAF53 forms a complex containing TIP49 and TIP48 as well as a complex with TRRAP and a histone acetyltransferase, the first three of which are also c-Myc cofactors (Park et al., Mol. Cell. Biol., 2002, 22, 1307-1316).

[0006] Currently, there are no known therapeutic agents which effectively inhibit the synthesis of BAF53 and to date, investigative strategies aimed at modulating BAF53 function have involved the use of inactive mutants. Deletion mutants of BAF53 were used to demonstrate its functional role in c-Myc-mediated cellular transformation (Park et al., Mol. Cell. Biol., 2002, 22, 1307-1316).

[0007] Consequently, there remains a long felt need for agents capable of effectively inhibiting BAF53 function.

[0008] Antisense technology is emerging as an effective means for reducing the expression of specific gene products and may therefore prove to be uniquely useful in a number of therapeutic, diagnostic, and research applications for the modulation of BAF53 expression.

[0009] The present invention provides compositions and methods for modulating BAF53 expression.

SUMMARY OF THE INVENTION

[0010] The present invention is directed to compounds, especially nucleic acid and nucleic acid-like oligomers, which are targeted to a nucleic acid encoding BAF53, and which modulate the expression of BAF53. Pharmaceutical and other compositions comprising the compounds of the invention are also provided. Further provided are methods of screening for modulators of BAF53 and methods of modulating the expression of BAF53 in cells, tissues or animals comprising contacting said cells, tissues or animals with one or more of the compounds or compositions of the invention. Methods of treating an animal, particularly a human, suspected of having or being prone to a disease or condition associated with expression of BAF53 are also set forth herein. Such methods comprise administering a therapeutically or prophylactically effective amount of one or more of the compounds or compositions of the invention to the person in need of treatment.

DETAILED DESCRIPTION OF THE INVENTION

[0011] A. Overview of the Invention

[0012] The present invention employs compounds, preferably oligonucleotides and similar species for use in modulating the function or effect of nucleic acid molecules encoding BAF53. This is accomplished by providing oligonucleotides which specifically hybridize with one or more nucleic acid molecules encoding BAF53. As used herein, the terms “target nucleic acid” and “nucleic acid molecule encoding BAF53” have been used for convenience to encompass DNA encoding BAF53, RNA (including pre-mRNA and mRNA or portions thereof) transcribed from such DNA, and also cDNA derived from such RNA. The hybridization of a compound of this invention with its target nucleic acid is generally referred to as “antisense”. Consequently, the preferred mechanism believed to be included in the practice of some preferred embodiments of the invention is referred to herein as “antisense inhibition.” Such antisense inhibition is typically based upon hydrogen bonding-based hybridization of oligonucleotide strands or segments such that at least one strand or segment is cleaved, degraded, or otherwise rendered inoperable. In this regard, it is presently preferred to target specific nucleic acid molecules and their functions for such antisense inhibition.

[0013] The functions of DNA to be interfered with can include replication and transcription. Replication and transcription, for example, can be from an endogenous cellular template, a vector, a plasmid construct or otherwise. The functions of RNA to be interfered with can include functions such as translocation of the RNA to a site of protein translation, translocation of the RNA to sites within the cell which are distant from the site of RNA synthesis, translation of protein from the RNA, splicing of the RNA to yield one or more RNA species, and catalytic activity or complex formation involving the RNA which may be engaged in or facilitated by the RNA. One preferred result of such interference with target nucleic acid function is modulation of the expression of BAF53. In the context of the present invention, “modulation” and “modulation of expression” mean either an increase (stimulation) or a decrease (inhibition) in the amount or levels of a nucleic acid molecule encoding the gene, e.g., DNA or RNA. Inhibition is often the preferred form of modulation of expression and mRNA is often a preferred target nucleic acid.

[0014] In the context of this invention, “hybridization” means the pairing of complementary strands of oligomeric compounds. In the present invention, the preferred mechanism of pairing involves hydrogen bonding, which may be Watson-Crick, Hoogsteen or reversed Hoogsteen hydrogen bonding, between complementary nucleoside or nucleotide bases (nucleobases) of the strands of oligomeric compounds. For example, adenine and thymine are complementary nucleobases which pair through the formation of hydrogen bonds. Hybridization can occur under varying circumstances.

[0015] An antisense compound is specifically hybridizable when binding of the compound to the target nucleic acid interferes with the normal function of the target nucleic acid to cause a loss of activity, and there is a sufficient degree of complementarity to avoid non-specific binding of the antisense compound to non-target nucleic acid sequences under conditions in which specific binding is desired, i.e., under physiological conditions in the case of in vivo assays or therapeutic treatment, and under conditions in which assays are performed in the case of in vitro assays.

[0016] In the present invention the phrase “stringent hybridization conditions” or “stringent conditions” refers to conditions under which a compound of the invention will hybridize to its target sequence, but to a minimal number of other sequences. Stringent conditions are sequence-dependent and will be different in different circumstances and in the context of this invention, “stringent conditions” under which oligomeric compounds hybridize to a target sequence are determined by the nature and composition of the oligomeric compounds and the assays in which they are being investigated.

[0017] “Complementary,” as used herein, refers to the capacity for precise pairing between two nucleobases of an oligomeric compound. For example, if a nucleobase at a certain position of an oligonucleotide (an oligomeric compound), is capable of hydrogen bonding with a nucleobase at a certain position of a target nucleic acid, said target nucleic acid being a DNA, RNA, or oligonucleotide molecule, then the position of hydrogen bonding between the oligonucleotide and the target nucleic acid is considered to be a complementary position. The oligonucleotide and the further DNA, RNA, or oligonucleotide molecule are complementary to each other when a sufficient number of complementary positions in each molecule are occupied by nucleobases which can hydrogen bond with each other. Thus, “specifically hybridizable” and “complementary” are terms which are used to indicate a sufficient degree of precise pairing or complementarity over a sufficient number of nucleobases such that stable and specific binding occurs between the oligonucleotide and a target nucleic acid.

[0018] It is understood in the art that the sequence of an antisense compound need not be 100% complementary to that of its target nucleic acid to be specifically hybridizable. Moreover, an oligonucleotide may hybridize over one or more segments such that intervening or adjacent segments are not involved in the hybridization event (e.g., a loop structure or hairpin structure). It is preferred that the antisense compounds of the present invention comprise at least 70% sequence complementarity to a target region within the target nucleic acid, more preferably that they comprise 90% sequence complementarity and even more preferably comprise 95% sequence complementarity to the target region within the target nucleic acid sequence to which they are targeted. For example, an antisense compound in which 18 of 20 nucleobases of the antisense compound are complementary to a target region, and would therefore specifically hybridize, would represent 90 percent complementarity. In this example, the remaining noncomplementary nucleobases may be clustered or interspersed with complementary nucleobases and need not be contiguous to each other or to complementary nucleobases. As such, an antisense compound which is 18 nucleobases in length having 4 (four) noncomplementary nucleobases which are flanked by two regions of complete complementarity with the target nucleic acid would have 77.8% overall complementarity with the target nucleic acid and would thus fall within the scope of the present invention. Percent complementarity of an antisense compound with a region of a target nucleic acid can be determined routinely using BLAST programs (basic local alignment search tools) and PowerBLAST programs known in the art (Altschul et al., J. Mol. Biol., 1990, 215, 403-410; Zhang and Madden, Genome Res., 1997, 7, 649-656).

[0019] B. Compounds of the Invention

[0020] According to the present invention, compounds include antisense oligomeric compounds, antisense oligonucleotides, ribozymes, external guide sequence (EGS) oligonucleotides, alternate splicers, primers, probes, and other oligomeric compounds which hybridize to at least a portion of the target nucleic acid. As such, these compounds may be introduced in the form of single-stranded, double-stranded, circular or hairpin oligomeric compounds and may contain structural elements such as internal or terminal bulges or loops. Once introduced to a system, the compounds of the invention may elicit the action of one or more enzymes or structural proteins to effect modification of the target nucleic acid. One non-limiting example of such an enzyme is RNAse H, a cellular endonuclease which cleaves the RNA strand of an RNA:DNA duplex. It is known in the art that single-stranded antisense compounds which are “DNA-like” elicit RNAse H. Activation of RNase H, therefore, results in cleavage of the RNA target, thereby greatly enhancing the efficiency of oligonucleotide-mediated inhibition of gene expression. Similar roles have been postulated for other ribonucleases such as those in the RNase III and ribonuclease L family of enzymes.

[0021] While the preferred form of antisense compound is a single-stranded antisense oligonucleotide, in many species the introduction of double-stranded structures, such as double-stranded RNA (dsRNA) molecules, has been shown to induce potent and specific antisense-mediated reduction of the function of a gene or its associated gene products. This phenomenon occurs in both plants and animals and is believed to have an evolutionary connection to viral defense and transposon silencing.

[0022] The first evidence that dsRNA could lead to gene silencing in animals came in 1995 from work in the nematode, Caenorhabditis elegans (Guo and Kempheus, Cell, 1995, 81, 611-620). Montgomery et al. have shown that the primary interference effects of dsRNA are posttranscriptional (Montgomery et al., Proc. Natl. Acad. Sci. USA, 1998, 95, 15502-15507). The posttranscriptional antisense mechanism defined in Caenorhabditis elegans resulting from exposure to double-stranded RNA (dsRNA) has since been designated RNA interference (RNAi). This term has been generalized to mean antisense-mediated gene silencing involving the introduction of dsRNA leading to the sequence-specific reduction of endogenous targeted mRNA levels (Fire et al., Nature, 1998, 391, 806-811). Recently, it has been shown that it is, in fact, the single-stranded RNA oligomers of antisense polarity of the dsRNAs which are the potent inducers of RNAi (Tijsterman et al., Science, 2002, 295, 694-697).

[0023] In the context of this invention, the term “oligomeric compound” refers to a polymer or oligomer comprising a plurality of monomeric units. In the context of this invention, the term “oligonucleotide” refers to an oligomer or polymer of ribonucleic acid (RNA) or deoxyribonucleic acid (DNA) or mimetics, chimeras, analogs and homologs thereof. This term includes oligonucleotides composed of naturally occurring nucleobases, sugars and covalent internucleoside (backbone) linkages as well as oligonucleotides having non-naturally occurring portions which function similarly. Such modified or substituted oligonucleotides are often preferred over native forms because of desirable properties such as, for example, enhanced cellular uptake, enhanced affinity for a target nucleic acid and increased stability in the presence of nucleases.

[0024] While oligonucleotides are a preferred form of the compounds of this invention, the present invention comprehends other families of compounds as well, including but not limited to oligonucleotide analogs and mimetics such as those described herein.

[0025] The compounds in accordance with this invention preferably comprise from about 8 to about 80 nucleobases (i.e. from about 8 to about 80 linked nucleosides). One of ordinary skill in the art will appreciate that the invention embodies compounds of 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, or 80 nucleobases in length.

[0026] In one preferred embodiment, the compounds of the invention are 12 to 50 nucleobases in length. One having ordinary skill in the art will appreciate that this embodies compounds of 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 nucleobases in length.

[0027] In another preferred embodiment, the compounds of the invention are 15 to 30 nucleobases in length. One having ordinary skill in the art will appreciate that this embodies compounds of 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 nucleobases in length.

[0028] Particularly preferred compounds are oligonucleotides from about 12 to about 50 nucleobases, even more preferably those comprising from about 15 to about 30 nucleobases.

[0029] Antisense compounds 8-80 nucleobases in length comprising a stretch of at least eight (8) consecutive nucleobases selected from within the illustrative antisense compounds are considered to be suitable antisense compounds as well.

[0030] Exemplary preferred antisense compounds include oligonucleotide sequences that comprise at least the 8 consecutive nucleobases from the 5′-terminus of one of the illustrative preferred antisense compounds (the remaining nucleobases being a consecutive stretch of the same oligonucleotide beginning immediately upstream of the 5′-terminus of the antisense compound which is specifically hybridizable to the target nucleic acid and continuing until the oligonucleotide contains about 8 to about 80 nucleobases). Similarly preferred antisense compounds are represented by oligonucleotide sequences that comprise at least the 8 consecutive nucleobases from the 3′-terminus of one of the illustrative preferred antisense compounds (the remaining nucleobases being a consecutive stretch of the same oligonucleotide beginning immediately downstream of the 3′-terminus of the antisense compound which is specifically hybridizable to the target nucleic acid and continuing until the oligonucleotide contains about 8 to about 80 nucleobases). One having skill in the art armed with the preferred antisense compounds illustrated herein will be able, without undue experimentation, to identify further preferred antisense compounds.

[0031] C. Targets of the Invention

[0032] “Targeting” an antisense compound to a particular nucleic acid molecule, in the context of this invention, can be a multistep process. The process usually begins with the identification of a target nucleic acid whose function is to be modulated. This target nucleic acid may be, for example, a cellular gene (or mRNA transcribed from the gene) whose expression is associated with a particular disorder or disease state, or a nucleic acid molecule from an infectious agent. In the present invention, the target nucleic acid encodes BAF53.

[0033] The targeting process usually also includes determination of at least one target region, segment, or site within the target nucleic acid for the antisense interaction to occur such that the desired effect, e.g., modulation of expression, will result. Within the context of the present invention, the term “region” is defined as a portion of the target nucleic acid having at least one identifiable structure, function, or characteristic. Within regions of target nucleic acids are segments. “Segments” are defined as smaller or sub-portions of regions within a target nucleic acid. “Sites,” as used in the present invention, are defined as positions within a target nucleic acid.

[0034] Since, as is known in the art, the translation initiation codon is typically 5′-AUG (in transcribed mRNA molecules; 5′-ATG in the corresponding DNA molecule), the translation initiation codon is also referred to as the “AUG codon,” the “start codon” or the “AUG start codon”. A minority of genes have a translation initiation codon having the RNA sequence 5′-GUG, 5′-UUG or 5′-CUG, and 5′-AUA, 5′-ACG and 5′-CUG have been shown to function in vivo. Thus, the terms “translation initiation codon” and “start codon” can encompass many codon sequences, even though the initiator amino acid in each instance is typically methionine (in eukaryotes) or formylmethionine (in prokaryotes). It is also known in the art that eukaryotic and prokaryotic genes may have two or more alternative start codons, any one of which may be preferentially utilized for translation initiation in a particular cell type or tissue, or under a particular set of conditions. In the context of the invention, “start codon” and “translation initiation codon” refer to the codon or codons that are used in vivo to initiate translation of an mRNA transcribed from a gene encoding BAF53, regardless of the sequence(s) of such codons. It is also known in the art that a translation termination codon (or “stop codon”) of a gene may have one of three sequences, i.e., 5′-UAA, 5′-UAG and 5′-UGA (the corresponding DNA sequences are 5′-TAA, 5′-TAG and 5′-TGA, respectively).

[0035] The terms “start codon region” and “translation initiation codon region” refer to a portion of such an mRNA or gene that encompasses from about 25 to about 50 contiguous nucleotides in either direction (i.e., 5′ or 3′) from a translation initiation codon. Similarly, the terms “stop codon region” and “translation termination codon region” refer to a portion of such an mRNA or gene that encompasses from about 25 to about 50 contiguous nucleotides in either direction (i.e., 5′ or 3′) from a translation termination codon. Consequently, the “start codon region” (or “translation initiation codon region”) and the “stop codon region” (or “translation termination codon region”) are all regions which may be targeted effectively with the antisense compounds of the present invention.

[0036] The open reading frame (ORF) or “coding region,” which is known in the art to refer to the region between the translation initiation codon and the translation termination codon, is also a region which may be targeted effectively. Within the context of the present invention, a preferred region is the intragenic region encompassing the translation initiation or termination codon of the open reading frame (ORF) of a gene.

[0037] Other target regions include the 5′ untranslated region (5′UTR), known in the art to refer to the portion of an mRNA in the 5′ direction from the translation initiation codon, and thus including nucleotides between the 5′ cap site and the translation initiation codon of an mRNA (or corresponding nucleotides on the gene), and the 3′ untranslated region (3′UTR), known in the art to refer to the portion of an mRNA in the 3′ direction from the translation termination codon, and thus including nucleotides between the translation termination codon and 3′ end of an mRNA (or corresponding nucleotides on the gene). The 5′ cap site of an mRNA comprises an N7-methylated guanosine residue joined to the 5′-most residue of the mRNA via a 5′-5′ triphosphate linkage. The 5′ cap region of an mRNA is considered to include the 5′ cap structure itself as well as the first 50 nucleotides adjacent to the cap site. It is also preferred to target the 5′ cap region.

[0038] Although some eukaryotic mRNA transcripts are directly translated, many contain one or more regions, known as “introns,” which are excised from a transcript before it is translated. The remaining (and therefore translated) regions are known as “exons” and are spliced together to form a continuous mRNA sequence. Targeting splice sites, i.e., intron-exon junctions or exon-intron junctions, may also be particularly useful in situations where aberrant splicing is implicated in disease, or where an overproduction of a particular splice product is implicated in disease. Aberrant fusion junctions due to rearrangements or deletions are also preferred target sites. mRNA transcripts produced via the process of splicing of two (or more) mRNAs from different gene sources are known as “fusion transcripts”. It is also known that introns can be effectively targeted using antisense compounds targeted to, for example, DNA or pre-mRNA.

[0039] It is also known in the art that alternative RNA transcripts can be produced from the same genomic region of DNA. These alternative transcripts are generally known as “variants”. More specifically, “pre-mRNA variants” are transcripts produced from the same genomic DNA that differ from other transcripts produced from the same genomic DNA in either their start or stop position and contain both intronic and exonic sequence.

[0040] Upon excision of one or more exon or intron regions, or portions thereof during splicing, pre-mRNA variants produce smaller “mRNA variants”. Consequently, mRNA variants are processed pre-mRNA variants and each unique pre-mRNA variant must always produce a unique mRNA variant as a result of splicing. These mRNA variants are also known as “alternative splice variants”. If no splicing of the pre-mRNA variant occurs then the pre-mRNA variant is identical to the mRNA variant.

[0041] It is also known in the art that variants can be produced through the use of alternative signals to start or stop transcription and that pre-mRNAs and mRNAs can possess more that one start codon or stop codon. Variants that originate from a pre-mRNA or mRNA that use alternative start codons are known as “alternative start variants” of that pre-mRNA or mRNA. Those transcripts that use an alternative stop codon are known as “alternative stop variants” of that pre-mRNA or mRNA. One specific type of alternative stop variant is the “polyA variant” in which the multiple transcripts produced result from the alternative selection of one of the “polyA stop signals” by the transcription machinery, thereby producing transcripts that terminate at unique polyA sites. Within the context of the invention, the types of variants described herein are also preferred target nucleic acids.

[0042] The locations on the target nucleic acid to which the preferred antisense compounds hybridize are hereinbelow referred to as “preferred target segments.” As used herein the term “preferred target segment” is defined as at least an 8-nucleobase portion of a target region to which an active antisense compound is targeted. While not wishing to be bound by theory, it is presently believed that these target segments represent portions of the target nucleic acid which are accessible for hybridization.

[0043] While the specific sequences of certain preferred target segments are set forth herein, one of skill in the art will recognize that these serve to illustrate and describe particular embodiments within the scope of the present invention. Additional preferred target segments may be identified by one having ordinary skill.

[0044] Target segments 8-80 nucleobases in length comprising a stretch of at least eight (8) consecutive nucleobases selected from within the illustrative preferred target segments are considered to be suitable for targeting as well.

[0045] Target segments can include DNA or RNA sequences that comprise at least the 8 consecutive nucleobases from the 5′-terminus of one of the illustrative preferred target segments (the remaining nucleobases being a consecutive stretch of the same DNA or RNA beginning immediately upstream of the 5′-terminus of the target segment and continuing until the DNA or RNA contains about 8 to about 80 nucleobases). Similarly preferred target segments are represented by DNA or RNA sequences that comprise at least the 8 consecutive nucleobases from the 3′-terminus of one of the illustrative preferred target segments (the remaining nucleobases being a consecutive stretch of the same DNA or RNA beginning immediately downstream of the 3′-terminus of the target segment and continuing until the DNA or RNA contains about 8 to about 80 nucleobases). One having skill in the art armed with the preferred target segments illustrated herein will be able, without undue experimentation, to identify further preferred target segments.

[0046] Once one or more target regions, segments or sites have been identified, antisense compounds are chosen which are sufficiently complementary to the target, i.e., hybridize sufficiently well and with sufficient specificity, to give the desired effect.

[0047] D. Screening and Target Validation

[0048] In a further embodiment, the “preferred target segments” identified herein may be employed in a screen for additional compounds that modulate the expression of BAF53. “Modulators” are those compounds that decrease or increase the expression of a nucleic acid molecule encoding BAF53 and which comprise at least an 8-nucleobase portion which is complementary to a preferred target segment. The screening method comprises the steps of contacting a preferred target segment of a nucleic acid molecule encoding BAF53 with one or more candidate modulators, and selecting for one or more candidate modulators which decrease or increase the expression of a nucleic acid molecule encoding BAF53. Once it is shown that the candidate modulator or modulators are capable of modulating (e.g. either decreasing or increasing) the expression of a nucleic acid molecule encoding BAF53, the modulator may then be employed in further investigative studies of the function of BAF53, or for use as a research, diagnostic, or therapeutic agent in accordance with the present invention.

[0049] The preferred target segments of the present invention may be also be combined with their respective complementary antisense compounds of the present invention to form stabilized double-stranded (duplexed) oligonucleotides.

[0050] Such double stranded oligonucleotide moieties have been shown in the art to modulate target expression and regulate translation as well as RNA processsing via an antisense mechanism. Moreover, the double-stranded moieties may be subject to chemical modifications (Fire et al., Nature, 1998, 391, 806-811; Timmons and Fire, Nature 1998, 395, 854; Timmons et al., Gene, 2001, 263, 103-112; Tabara et al., Science, 1998, 282, 430-431; Montgomery et al., Proc. Natl. Acad. Sci. USA, 1998, 95, 15502-15507; Tuschl et al., Genes Dev., 1999, 13, 3191-3197; Elbashir et al., Nature, 2001, 411, 494-498; Elbashir et al., Genes Dev. 2001, 15, 188-200). For example, such double-stranded moieties have been shown to inhibit the target by the classical hybridization of antisense strand of the duplex to the target, thereby triggering enzymatic degradation of the target (Tijsterman et al., Science, 2002, 295, 694-697).

[0051] The compounds of the present invention can also be applied in the areas of drug discovery and target validation. The present invention comprehends the use of the compounds and preferred target segments identified herein in drug discovery efforts to elucidate relationships that exist between BAF53 and a disease state, phenotype, or condition. These methods include detecting or modulating BAF53 comprising contacting a sample, tissue, cell, or organism with the compounds of the present invention, measuring the nucleic acid or protein level of BAF53 and/or a related phenotypic or chemical endpoint at some time after treatment, and optionally comparing the measured value to a non-treated sample or sample treated with a further compound of the invention. These methods can also be performed in parallel or in combination with other experiments to determine the function of unknown genes for the process of target validation or to determine the validity of a particular gene product as a target for treatment or prevention of a particular disease, condition, or phenotype.

[0052] E. Kits, Research Reagents, Diagnostics, and Therapeutics

[0053] The compounds of the present invention can be utilized for diagnostics, therapeutics, prophylaxis and as research reagents and kits. Furthermore, antisense oligonucleotides, which are able to inhibit gene expression with exquisite specificity, are often used by those of ordinary skill to elucidate the function of particular genes or to distinguish between functions of various members of a biological pathway.

[0054] For use in kits and diagnostics, the compounds of the present invention, either alone or in combination with other compounds or therapeutics, can be used as tools in differential and/or combinatorial analyses to elucidate expression patterns of a portion or the entire complement of genes expressed within cells and tissues.

[0055] As one nonlimiting example, expression patterns within cells or tissues treated with one or more antisense compounds are compared to control cells or tissues not treated with antisense compounds and the patterns produced are analyzed for differential levels of gene expression as they pertain, for example, to disease association, signaling pathway, cellular localization, expression level, size, structure or function of the genes examined. These analyses can be performed on stimulated or unstimulated cells and in the presence or absence of other compounds which affect expression patterns.

[0056] Examples of methods of gene expression analysis known in the art include DNA arrays or microarrays (Brazma and Vilo, FEBS Lett., 2000, 480, 17-24; Celis, et al., FEBS Lett., 2000, 480, 2-16), SAGE (serial analysis of gene expression)(Madden, et al., Drug Discov. Today, 2000, 5, 415-425), READS (restriction enzyme amplification of digested cDNAs) (Prashar and Weissman, Methods Enzymol., 1999, 303, 258-72), TOGA (total gene expression analysis) (Sutcliffe, et al., Proc. Natl. Acad. Sci. U.S. A., 2000, 97, 1976-81), protein arrays and proteomics (Celis, et al., FEBS Lett., 2000, 480, 2-16; Jungblut, et al., Electrophoresis, 1999, 20, 2100-10), expressed sequence tag (EST) sequencing (Celis, et al., FEBS Lett., 2000, 480, 2-16; Larsson, et al., J. Biotechnol., 2000, 80, 143-57), subtractive RNA fingerprinting (SuRF) (Fuchs, et al., Anal. Biochem., 2000, 286, 91-98; Larson, et al., Cytometry, 2000, 41, 203-208), subtractive cloning, differential display (DD) (Jurecic and Belmont, Curr. Opin. Microbiol., 2000, 3, 316-21), comparative genomic hybridization (Carulli, et al., J. Cell Biochem. Suppl., 1998, 31, 286-96), FISH (fluorescent in situ hybridization) techniques (Going and Gusterson, Eur. J. Cancer, 1999, 35, 1895-904) and mass spectrometry methods (To, Comb. Chem. High Throughput Screen, 2000, 3, 235-41).

[0057] The compounds of the invention are useful for research and diagnostics, because these compounds hybridize to nucleic acids encoding BAF53. For example, oligonucleotides that are shown to hybridize with such efficiency and under such conditions as disclosed herein as to be effective BAF53 inhibitors will also be effective primers or probes under conditions favoring gene amplification or detection, respectively. These primers and probes are useful in methods requiring the specific detection of nucleic acid molecules encoding BAF53 and in the amplification of said nucleic acid molecules for detection or for use in further studies of BAF53. Hybridization of the antisense oligonucleotides, particularly the primers and probes, of the invention with a nucleic acid encoding BAF53 can be detected by means known in the art. Such means may include conjugation of an enzyme to the oligonucleotide, radiolabelling of the oligonucleotide or any other suitable detection means. Kits using such detection means for detecting the level of BAF53 in a sample may also be prepared.

[0058] The specificity and sensitivity of antisense is also harnessed by those of skill in the art for therapeutic uses. Antisense compounds have been employed as therapeutic moieties in the treatment of disease states in animals, including humans. Antisense oligonucleotide drugs, including ribozymes, have been safely and effectively administered to humans and numerous clinical trials are presently underway. It is thus established that antisense compounds can be useful therapeutic modalities that can be configured to be useful in treatment regimes for the treatment of cells, tissues and animals, especially humans.

[0059] For therapeutics, an animal, preferably a human, suspected of having a disease or disorder which can be treated by modulating the expression of BAF53 is treated by administering antisense compounds in accordance with this invention. For example, in one non-limiting embodiment, the methods comprise the step of administering to the animal in need of treatment, a therapeutically effective amount of a BAF53 inhibitor. The BAF53 inhibitors of the present invention effectively inhibit the activity of the BAF53 protein or inhibit the expression of the BAF53 protein. In one embodiment, the activity or expression of BAF53 in an animal is inhibited by about 10%. Preferably, the activity or expression of BAF53 in an animal is inhibited by about 30%. More preferably, the activity or expression of BAF53 in an animal is inhibited by 50% or more.

[0060] For example, the reduction of the expression of BAF53 may be measured in serum, adipose tissue, liver or any other body fluid, tissue or organ of the animal. Preferably, the cells contained within said fluids, tissues or organs being analyzed contain a nucleic acid molecule encoding BAF53 protein and/or the BAF53 protein itself.

[0061] The compounds of the invention can be utilized in pharmaceutical compositions by adding an effective amount of a compound to a suitable pharmaceutically acceptable diluent or carrier. Use of the compounds and methods of the invention may also be useful prophylactically.

[0062] F. Modifications

[0063] As is known in the art, a nucleoside is a base-sugar combination. The base portion of the nucleoside is normally a heterocyclic base. The two most common classes of such heterocyclic bases are the purines and the pyrimidines. Nucleotides are nucleosides that further include a phosphate group covalently linked to the sugar portion of the nucleoside. For those nucleosides that include a pentofuranosyl sugar, the phosphate group can be linked to either the 2′, 3′ or 5′ hydroxyl moiety of the sugar. In forming oligonucleotides, the phosphate groups covalently link adjacent nucleosides to one another to form a linear polymeric compound. In turn, the respective ends of this linear polymeric compound can be further joined to form a circular compound, however, linear compounds are generally preferred. In addition, linear compounds may have internal nucleobase complementarity and may therefore fold in a manner as to produce a fully or partially double-stranded compound. Within oligonucleotides, the phosphate groups are commonly referred to as forming the internucleoside backbone of the oligonucleotide. The normal linkage or backbone of RNA and DNA is a 3′ to 5′ phosphodiester linkage.

[0064] Modified Internucleoside Linkages (Backbones)

[0065] Specific examples of preferred antisense compounds useful in this invention include oligonucleotides containing modified backbones or non-natural internucleoside linkages. As defined in this specification, oligonucleotides having modified backbones include those that retain a phosphorus atom in the backbone and those that do not have a phosphorus atom in the backbone. For the purposes of this specification, and as sometimes referenced in the art, modified oligonucleotides that do not have a phosphorus atom in their internucleoside backbone can also be considered to be oligonucleosides.

[0066] Preferred modified oligonucleotide backbones containing a phosphorus atom therein include, for example, phosphorothioates, chiral phosphorothioates, phosphorodithioates, phosphotriesters, aminoalkylphosphotriesters, methyl and other alkyl phosphonates including 3′-alkylene phosphonates, 5′-alkylene phosphonates and chiral phosphonates, phosphinates, phosphoramidates including 3′-amino phosphoramidate and aminoalkylphosphoramidates, thionophosphoramidates, thionoalkylphosphonates, thionoalkylphosphotriesters, selenophosphates and boranophosphates having normal 3′-5′ linkages, 2′-5′ linked analogs of these, and those having inverted polarity wherein one or more internucleotide linkages is a 3′ to 3′, 5′ to 5′ or 2′ to 2′ linkage. Preferred oligonucleotides having inverted polarity comprise a single 3′ to 3′ linkage at the 3′-most internucleotide linkage i.e. a single inverted nucleoside residue which may be abasic (the nucleobase is missing or has a hydroxyl group in place thereof). Various salts, mixed salts and free acid forms are also included.

[0067] Representative United States patents that teach the preparation of the above phosphorus-containing linkages include, but are not limited to, U.S. Pat. Nos. 3,687,808; 4,469,863; 4,476,301; 5,023,243; 5,177,196; 5,188,897; 5,264,423; 5,276,019; 5,278,302; 5,286,717; 5,321,131; 5,399,676; 5,405,939; 5,453,496; 5,455,233; 5,466,677; 5,476,925; 5,519,126; 5,536,821; 5,541,306; 5,550,111; 5,563,253; 5,571,799; 5,587,361; 5,194,599; 5,565,555; 5,527,899; 5,721,218; 5,672,697 and 5,625,050, certain of which are commonly owned with this application, and each of which is herein incorporated by reference.

[0068] Preferred modified oligonucleotide backbones that do not include a phosphorus atom therein have backbones that are formed by short chain alkyl or cycloalkyl internucleoside linkages, mixed heteroatom and alkyl or cycloalkyl internucleoside linkages, or one or more short chain heteroatomic or heterocyclic internucleoside linkages. These include those having morpholino linkages (formed in part from the sugar portion of a nucleoside); siloxane backbones; sulfide, sulfoxide and sulfone backbones; formacetyl and thioformacetyl backbones; methylene formacetyl and thioformacetyl backbones; riboacetyl backbones; alkene containing backbones; sulfamate backbones; methyleneimino and methylenehydrazino backbones; sulfonate and sulfonamide backbones; amide backbones; and others having mixed N, O, S and CH₂ component parts.

[0069] Representative United States patents that teach the preparation of the above oligonucleosides include, but are not limited to, U.S. Pat. Nos. 5,034,506; 5,166,315; 5,185,444; 5,214,134; 5,216,141; 5,235,033; 5,264,562; 5,264,564; 5,405,938; 5,434,257; 5,466,677; 5,470,967; 5,489,677; 5,541,307; 5,561,225; 5,596,086; 5,602,240; 5,610,289; 5,602,240; 5,608,046; 5,610,289; 5,618,704; 5,623,070; 5,663,312; 5,633,360; 5,677,437; 5,792,608; 5,646,269 and 5,677,439, certain of which are commonly owned with this application, and each of which is herein incorporated by reference.

[0070] Modified Sugar and Internucleoside Linkages-Mimetics

[0071] In other preferred oligonucleotide mimetics, both the sugar and the internucleoside linkage (i.e. the backbone), of the nucleotide units are replaced with novel groups. The nucleobase units are maintained for hybridization with an appropriate target nucleic acid. One such compound, an oligonucleotide mimetic that has been shown to have excellent hybridization properties, is referred to as a peptide nucleic acid (PNA). In PNA compounds, the sugar-backbone of an oligonucleotide is replaced with an amide containing backbone, in particular an aminoethylglycine backbone. The nucleobases are retained and are bound directly or indirectly to aza nitrogen atoms of the amide portion of the backbone. Representative United States patents that teach the preparation of PNA compounds include, but are not limited to, U.S. Pat. Nos. 5,539,082; 5,714,331; and 5,719,262, each of which is herein incorporated by reference. Further teaching of PNA compounds can be found in Nielsen et al., Science, 1991, 254, 1497-1500.

[0072] Preferred embodiments of the invention are oligonucleotides with phosphorothioate backbones and oligonucleosides with heteroatom backbones, and in particular —CH₂—NH—O—CH₂—, —CH₂—N(CH₃)—O—CH₂— [known as a methylene (methylimino) or MMI backbone], —CH₂—O—N(CH₃)—CH₂—, —CH₂—N(CH₃)—N(CH₃)—CH₂— and —O—N(CH₃)—CH₂—CH₂— [wherein the native phosphodiester backbone is represented as —O—P—O—CH₂—] of the above referenced U.S. Pat. No. 5,489,677, and the amide backbones of the above referenced U.S. Pat. No. 5,602,240. Also preferred are oligonucleotides having morpholino backbone structures of the above-referenced U.S. Pat. No. 5,034,506.

[0073] Modified Sugars

[0074] Modified oligonucleotides may also contain one or more substituted sugar moieties. Preferred oligonucleotides comprise one of the following at the 2′ position: OH; F; O-, S-, or N-alkyl; O-, S-, or N-alkenyl; O-, S- or N-alkynyl; or O-alkyl-O-alkyl, wherein the alkyl, alkenyl and alkynyl may be substituted or unsubstituted C₁ to C₁₀ alkyl or C₂ to C₁₀ alkenyl and alkynyl. Particularly preferred are O[(CH₂)_(n)O]_(m)CH₃, O(CH₂)_(n)OCH₃, O(CH₂)_(n)NH₂, O(CH₂)_(n)CH₃, O(CH₂)_(n)ONH₂, and O(CH₂)_(n)ON[(CH₂)_(n)CH₃]₂, where n and m are from 1 to about 10. Other preferred oligonucleotides comprise one of the following at the 2′ position: C₁ to C₁₀ lower alkyl, substituted lower alkyl, alkenyl, alkynyl, alkaryl, aralkyl, O-alkaryl or O-aralkyl, SH, SCH₃, OCN, Cl, Br, CN, CF₃, OCF₃, SOCH₃, SO₂CH₃, ONO₂, NO₂, N₃, NH₂, heterocycloalkyl, heterocycloalkaryl, aminoalkylamino, polyalkylamino, substituted silyl, an RNA cleaving group, a reporter group, an intercalator, a group for improving the pharmacokinetic properties of an oligonucleotide, or a group for improving the pharmacodynamic properties of an oligonucleotide, and other substituents having similar properties. A preferred modification includes 2′-methoxyethoxy (2′-O—CH₂CH₂OCH₃, also known as 2′-O-(2-methoxyethyl) or 2′-MOE) (Martin et al., Helv. Chim. Acta, 1995, 78, 486-504) i.e., an alkoxyalkoxy group. A further preferred modification includes 2′-dimethylaminooxyethoxy, i.e., a O(CH₂)₂ON(CH₃)₂ group, also known as 2′-DMAOE, as described in examples hereinbelow, and 2′-dimethylaminoethoxyethoxy (also known in the art as 2′-O-dimethyl-amino-ethoxy-ethyl or 2′-DMAEOE), i.e., 2′-O—CH₂—O—CH₂—N(CH₃)₂, also described in examples hereinbelow.

[0075] Other preferred modifications include 2′-methoxy (2′-O—CH₃), 2′-aminopropoxy (2′-OCH₂CH₂CH₂NH₂), 2′-allyl (2′-CH₂—CH═CH₂), 2′-O-allyl (2′-O—CH₂—CH═CH₂) and 2′-fluoro (2′-F). The 2′-modification may be in the arabino (up) position or ribo (down) position. A preferred 2′-arabino modification is 2′-F. Similar modifications may also be made at other positions on the oligonucleotide, particularly the 3′ position of the sugar on the 3′ terminal nucleotide or in 2′-5′ linked oligonucleotides and the 5′ position of 5′ terminal nucleotide. Oligonucleotides may also have sugar mimetics such as cyclobutyl moieties in place of the pentofuranosyl sugar. Representative United States patents that teach the preparation of such modified sugar structures include, but are not limited to, U.S. Pat. Nos. 4,981,957; 5,118,800; 5,319,080; 5,359,044; 5,393,878; 5,446,137; 5,466,786; 5,514,785; 5,519,134; 5,567,811; 5,576,427; 5,591,722; 5,597,909; 5,610,300; 5,627,053; 5,639,873; 5,646,265; 5,658,873; 5,670,633; 5,792,747; and 5,700,920, certain of which are commonly owned with the instant application, and each of which is herein incorporated by reference in its entirety.

[0076] A further preferred modification of the sugar includes Locked Nucleic Acids (LNAs) in which the 2′-hydroxyl group is linked to the 3′ or 4′ carbon atom of the sugar ring, thereby forming a bicyclic sugar moiety. The linkage is preferably a methylene (—CH₂—)_(n) group bridging the 2′ oxygen atom and the 4′ carbon atom wherein n is 1 or 2. LNAs and preparation thereof are described in WO 98/39352 and WO 99/14226.

[0077] Natural and Modified Nucleobases

[0078] Oligonucleotides may also include nucleobase (often referred to in the art simply as “base”) modifications or substitutions. As used herein, “unmodified” or “natural” nucleobases include the purine bases adenine (A) and guanine (G), and the pyrimidine bases thymine (T), cytosine (C) and uracil (U). Modified nucleobases include other synthetic and natural nucleobases such as 5-methylcytosine (5-me-C), 5-hydroxymethyl cytosine, xanthine, hypoxanthine, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 2-thiouracil, 2-thiothymine and 2-thiocytosine, 5-halouracil and cytosine, 5-propynyl (—C≡C—CH₃) uracil and cytosine and other alkynyl derivatives of pyrimidine bases, 6-azo uracil, cytosine and thymine, 5-uracil (pseudouracil), 4-thiouracil, 8-halo, 8-amino, 8-thiol, 8-thioalkyl, 8-hydroxyl and other 8-substituted adenines and guanines, 5-halo particularly 5-bromo, 5-trifluoromethyl and other 5-substituted uracils and cytosines, 7-methylguanine and 7-methyladenine, 2-F-adenine, 2-amino-adenine, 8-azaguanine and 8-azaadenine, 7-deazaguanine and 7-deazaadenine and 3-deazaguanine and 3-deazaadenine. Further modified nucleobases include tricyclic pyrimidines such as phenoxazine cytidine(1H-pyrimido[5,4-b][1,4]benzoxazin-2(3H)-one), phenothiazine cytidine (1H-pyrimido[5,4-b][1,4]benzothiazin-2(3H)-one), G-clamps such as a substituted phenoxazine cytidine (e.g. 9-(2-aminoethoxy)-H-pyrimido[5,4-b][1,4]benzoxazin-2(3H)-one), carbazole cytidine (2H-pyrimido[4,5-b]indol-2-one), pyridoindole cytidine (H-pyrido[3′,2′:4,5]pyrrolo[2,3-d]pyrimidin-2-one). Modified nucleobases may also include those in which the purine or pyrimidine base is replaced with other heterocycles, for example 7-deaza-adenine, 7-deazaguanosine, 2-aminopyridine and 2-pyridone. Further nucleobases include those disclosed in U.S. Pat. No. 3,687,808, those disclosed in The Concise Encyclopedia Of Polymer Science And Engineering, pages 858-859, Kroschwitz, J. I., ed. John Wiley & Sons, 1990, those disclosed by Englisch et al., Angewandte Chemie, International Edition, 1991, 30, 613, and those disclosed by Sanghvi, Y. S., Chapter 15, Antisense Research and Applications, pages 289-302, Crooke, S. T. and Lebleu, B. ed., CRC Press, 1993. Certain of these nucleobases are particularly useful for increasing the binding affinity of the compounds of the invention. These include 5-substituted pyrimidines, 6-azapyrimidines and N-2, N-6 and O-6 substituted purines, including 2-aminopropyladenine, 5-propynyluracil and 5-propynylcytosine. 5-methylcytosine substitutions have been shown to increase nucleic acid duplex stability by 0.6-1.2° C. and are presently preferred base substitutions, even more particularly when combined with 2′-O-methoxyethyl sugar modifications.

[0079] Representative United States patents that teach the preparation of certain of the above noted modified nucleobases as well as other modified nucleobases include, but are not limited to, the above noted U.S. Pat. No. 3,687,808, as well as U.S. Pat. Nos. 4,845,205; 5,130,302; 5,134,066; 5,175,273; 5,367,066; 5,432,272; 5,457,187; 5,459,255; 5,484,908; 5,502,177; 5,525,711; 5,552,540; 5,587,469; 5,594,121, 5,596,091; 5,614,617; 5,645,985; 5,830,653; 5,763,588; 6,005,096; and 5,681,941, certain of which are commonly owned with the instant application, and each of which is herein incorporated by reference, and U.S. Pat. No. 5,750,692, which is commonly owned with the instant application and also herein incorporated by reference.

[0080] Conjugates

[0081] Another modification of the oligonucleotides of the invention involves chemically linking to the oligonucleotide one or more moieties or conjugates which enhance the activity, cellular distribution or cellular uptake of the oligonucleotide. These moieties or conjugates can include conjugate groups covalently bound to functional groups such as primary or secondary hydroxyl groups. Conjugate groups of the invention include intercalators, reporter molecules, polyamines, polyamides, polyethylene glycols, polyethers, groups that enhance the pharmacodynamic properties of oligomers, and groups that enhance the pharmacokinetic properties of oligomers. Typical conjugate groups include cholesterols, lipids, phospholipids, biotin, phenazine, folate, phenanthridine, anthraquinone, acridine, fluoresceins, rhodamines, coumarins, and dyes. Groups that enhance the pharmacodynamic properties, in the context of this invention, include groups that improve uptake, enhance resistance to degradation, and/or strengthen sequence-specific hybridization with the target nucleic acid. Groups that enhance the pharmacokinetic properties, in the context of this invention, include groups that improve uptake, distribution, metabolism or excretion of the compounds of the present invention. Representative conjugate groups are disclosed in International Patent Application PCT/US92/09196, filed Oct. 23, 1992, and U.S. Pat. No. 6,287,860, the entire disclosure of which are incorporated herein by reference. Conjugate moieties include but are not limited to lipid moieties such as a cholesterol moiety, cholic acid, a thioether, e.g., hexyl-S-tritylthiol, a thiocholesterol, an aliphatic chain, e.g., dodecandiol or undecyl residues, a phospholipid, e.g., di-hexadecyl-rac-glycerol or triethyl-ammonium 1,2-di-O-hexadecyl-rac-glycero-3-H-phosphonate, a polyamine or a polyethylene glycol chain, or adamantane acetic acid, a palmityl moiety, or an octadecylamine or hexylamino-carbonyl-oxycholesterol moiety. Oligonucleotides of the invention may also be conjugated to active drug substances, for example, aspirin, warfarin, phenylbutazone, ibuprofen, suprofen, fenbufen, ketoprofen, (S)-(+)-pranoprofen, carprofen, dansylsarcosine, 2,3,5-triiodobenzoic acid, flufenamic acid, folinic acid, a benzothiadiazide, chlorothiazide, a diazepine, indomethicin, a barbiturate, a cephalosporin, a sulfa drug, an antidiabetic, an antibacterial or an antibiotic. Oligonucleotide-drug conjugates and their preparation are described in U.S. patent application Ser. No. 09/334,130 (filed Jun. 15, 1999) which is incorporated herein by reference in its entirety.

[0082] Representative United States patents that teach the preparation of such oligonucleotide conjugates include, but are not limited to, U.S. Pat. Nos. 4,828,979; 4,948,882; 5,218,105; 5,525,465; 5,541,313; 5,545,730; 5,552,538; 5,578,717, 5,580,731; 5,580,731; 5,591,584; 5,109,124; 5,118,802; 5,138,045; 5,414,077; 5,486,603; 5,512,439; 5,578,718; 5,608,046; 4,587,044; 4,605,735; 4,667,025; 4,762,779; 4,789,737; 4,824,941; 4,835,263; 4,876,335; 4,904,582; 4,958,013; 5,082,830; 5,112,963; 5,214,136; 5,082,830; 5,112,963; 5,214,136; 5,245,022; 5,254,469; 5,258,506; 5,262,536; 5,272,250; 5,292,873; 5,317,098; 5,371,241, 5,391,723; 5,416,203, 5,451,463; 5,510,475; 5,512,667; 5,514,785; 5,565,552; 5,567,810; 5,574,142; 5,585,481; 5,587,371; 5,595,726; 5,597,696; 5,599,923; 5,599,928 and 5,688,941, certain of which are commonly owned with the instant application, and each of which is herein incorporated by reference.

[0083] Chimeric Compounds

[0084] It is not necessary for all positions in a given compound to be uniformly modified, and in fact more than one of the aforementioned modifications may be incorporated in a single compound or even at a single nucleoside within an oligonucleotide.

[0085] The present invention also includes antisense compounds which are chimeric compounds. “Chimeric” antisense compounds or “chimeras,” in the context of this invention, are antisense compounds, particularly oligonucleotides, which contain two or more chemically distinct regions, each made up of at least one monomer unit, i.e., a nucleotide in the case of an oligonucleotide compound. These oligonucleotides typically contain at least one region wherein the oligonucleotide is modified so as to confer upon the oligonucleotide increased resistance to nuclease degradation, increased cellular uptake, increased stability and/or increased binding affinity for the target nucleic acid. An additional region of the oligonucleotide may serve as a substrate for enzymes capable of cleaving RNA:DNA or RNA:RNA hybrids. By way of example, RNAse H is a cellular endonuclease which cleaves the RNA strand of an RNA:DNA duplex. Activation of RNase H, therefore, results in cleavage of the RNA target, thereby greatly enhancing the efficiency of oligonucleotide-mediated inhibition of gene expression. The cleavage of RNA:RNA hybrids can, in like fashion, be accomplished through the actions of endoribonucleases, such as RNAseL which cleaves both cellular and viral RNA. Cleavage of the RNA target can be routinely detected by gel electrophoresis and, if necessary, associated nucleic acid hybridization techniques known in the art.

[0086] Chimeric antisense compounds of the invention may be formed as composite structures of two or more oligonucleotides, modified oligonucleotides, oligonucleosides and/or oligonucleotide mimetics as described above. Such compounds have also been referred to in the art as hybrids or gapmers. Representative United States patents that teach the preparation of such hybrid structures include, but are not limited to, U.S. Pat. Nos. 5,013,830; 5,149,797; 5,220,007; 5,256,775; 5,366,878; 5,403,711; 5,491,133; 5,565,350; 5,623,065; 5,652,355; 5,652,356; and 5,700,922, certain of which are commonly owned with the instant application, and each of which is herein incorporated by reference in its entirety.

[0087] G. Formulations

[0088] The compounds of the invention may also be admixed, encapsulated, conjugated or otherwise associated with other molecules, molecule structures or mixtures of compounds, as for example, liposomes, receptor-targeted molecules, oral, rectal, topical or other formulations, for assisting in uptake, distribution and/or absorption. Representative United States patents that teach the preparation of such uptake, distribution and/or absorption-assisting formulations include, but are not limited to, U.S. Pat. Nos. 5,108,921; 5,354,844; 5,416,016; 5,459,127; 5,521,291; 5,543,158; 5,547,932; 5,583,020; 5,591,721; 4,426,330; 4,534,899; 5,013,556; 5,108,921; 5,213,804; 5,227,170; 5,264,221; 5,356,633; 5,395,619; 5,416,016; 5,417,978; 5,462,854; 5,469,854; 5,512,295; 5,527,528; 5,534,259; 5,543,152; 5,556,948; 5,580,575; and 5,595,756, each of which is herein incorporated by reference.

[0089] The antisense compounds of the invention encompass any pharmaceutically acceptable salts, esters, or salts of such esters, or any other compound which, upon administration to an animal, including a human, is capable of providing (directly or indirectly) the biologically active metabolite or residue thereof. Accordingly, for example, the disclosure is also drawn to prodrugs and pharmaceutically acceptable salts of the compounds of the invention, pharmaceutically acceptable salts of such prodrugs, and other bioequivalents.

[0090] The term “prodrug” indicates a therapeutic agent that is prepared in an inactive form that is converted to an active form (i.e., drug) within the body or cells thereof by the action of endogenous enzymes or other chemicals and/or conditions. In particular, prodrug versions of the oligonucleotides of the invention are prepared as SATE [(S-acetyl-2-thioethyl) phosphate] derivatives according to the methods disclosed in WO 93/24510 to Gosselin et al., published Dec. 9, 1993 or in WO 94/26764 and U.S. Pat. No. 5,770,713 to Imbach et al.

[0091] The term “pharmaceutically acceptable salts” refers to physiologically and pharmaceutically acceptable salts of the compounds of the invention: i.e., salts that retain the desired biological activity of the parent compound and do not impart undesired toxicological effects thereto. For oligonucleotides, preferred examples of pharmaceutically acceptable salts and their uses are further described in U.S. Pat. No. 6,287,860, which is incorporated herein in its entirety.

[0092] The present invention also includes pharmaceutical compositions and formulations which include the antisense compounds of the invention. The pharmaceutical compositions of the present invention may be administered in a number of ways depending upon whether local or systemic treatment is desired and upon the area to be treated. Administration may be topical (including ophthalmic and to mucous membranes including vaginal and rectal delivery), pulmonary, e.g., by inhalation or insufflation of powders or aerosols, including by nebulizer; intratracheal, intranasal, epidermal and transdermal), oral or parenteral. Parenteral administration includes intravenous, intraarterial, subcutaneous, intraperitoneal or intramuscular injection or infusion; or intracranial, e.g., intrathecal or intraventricular, administration. Oligonucleotides with at least one 2′-O-methoxyethyl modification are believed to be particularly useful for oral administration. Pharmaceutical compositions and formulations for topical administration may include transdermal patches, ointments, lotions, creams, gels, drops, suppositories, sprays, liquids and powders. Conventional pharmaceutical carriers, aqueous, powder or oily bases, thickeners and the like may be necessary or desirable. Coated condoms, gloves and the like may also be useful.

[0093] The pharmaceutical formulations of the present invention, which may conveniently be presented in unit dosage form, may be prepared according to conventional techniques well known in the pharmaceutical industry. Such techniques include the step of bringing into association the active ingredients with the pharmaceutical carrier(s) or excipient(s). In general, the formulations are prepared by uniformly and intimately bringing into association the active ingredients with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product.

[0094] The compositions of the present invention may be formulated into any of many possible dosage forms such as, but not limited to, tablets, capsules, gel capsules, liquid syrups, soft gels, suppositories, and enemas. The compositions of the present invention may also be formulated as suspensions in aqueous, non-aqueous or mixed media. Aqueous suspensions may further contain substances which increase the viscosity of the suspension including, for example, sodium carboxymethylcellulose, sorbitol and/or dextran. The suspension may also contain stabilizers.

[0095] Pharmaceutical compositions of the present invention include, but are not limited to, solutions, emulsions, foams and liposome-containing formulations. The pharmaceutical compositions and formulations of the present invention may comprise one or more penetration enhancers, carriers, excipients or other active or inactive ingredients.

[0096] Emulsions are typically heterogenous systems of one liquid dispersed in another in the form of droplets usually exceeding 0.1 μm in diameter. Emulsions may contain additional components in addition to the dispersed phases, and the active drug which may be present as a solution in either the aqueous phase, oily phase or itself as a separate phase. Microemulsions are included as an embodiment of the present invention. Emulsions and their uses are well known in the art and are further described in U.S. Pat. No. 6,287,860, which is incorporated herein in its entirety.

[0097] Formulations of the present invention include liposomal formulations. As used in the present invention, the term “liposome” means a vesicle composed of amphiphilic lipids arranged in a spherical bilayer or bilayers. Liposomes are unilamellar or multilamellar vesicles which have a membrane formed from a lipophilic material and an aqueous interior that contains the composition to be delivered. Cationic liposomes are positively charged liposomes which are believed to interact with negatively charged DNA molecules to form a stable complex. Liposomes that are pH-sensitive or negatively-charged are believed to entrap DNA rather than complex with it. Both cationic and noncationic liposomes have been used to deliver DNA to cells.

[0098] Liposomes also include “sterically stabilized” liposomes, a term which, as used herein, refers to liposomes comprising one or more specialized lipids that, when incorporated into liposomes, result in enhanced circulation lifetimes relative to liposomes lacking such specialized lipids. Examples of sterically stabilized liposomes are those in which part of the vesicle-forming lipid portion of the liposome comprises one or more glycolipids or is derivatized with one or more hydrophilic polymers, such as a polyethylene glycol (PEG) moiety. Liposomes and their uses are further described in U.S. Pat. No. 6,287,860, which is incorporated herein in its entirety.

[0099] The pharmaceutical formulations and compositions of the present invention may also include surfactants. The use of surfactants in drug products, formulations and in emulsions is well known in the art. Surfactants and their uses are further described in U.S. Pat. No. 6,287,860, which is incorporated herein in its entirety.

[0100] In one embodiment, the present invention employs various penetration enhancers to effect the efficient delivery of nucleic acids, particularly oligonucleotides. In addition to aiding the diffusion of non-lipophilic drugs across cell membranes, penetration enhancers also enhance the permeability of lipophilic drugs. Penetration enhancers may be classified as belonging to one of five broad categories, i.e., surfactants, fatty acids, bile salts, chelating agents, and non-chelating non-surfactants. Penetration enhancers and their uses are further described in U.S. Pat. No. 6,287,860, which is incorporated herein in its entirety.

[0101] One of skill in the art will recognize that formulations are routinely designed according to their intended use, i.e. route of administration.

[0102] Preferred formulations for topical administration include those in which the oligonucleotides of the invention are in admixture with a topical delivery agent such as lipids, liposomes, fatty acids, fatty acid esters, steroids, chelating agents and surfactants. Preferred lipids and liposomes include neutral (e.g. dioleoylphosphatidyl DOPE ethanolamine, dimyristoylphosphatidyl choline DMPC, distearolyphosphatidyl choline) negative (e.g. dimyristoylphosphatidyl glycerol DMPG) and cationic (e.g. dioleoyltetramethylaminopropyl DOTAP and dioleoylphosphatidyl ethanolamine DOTMA).

[0103] For topical or other administration, oligonucleotides of the invention may be encapsulated within liposomes or may form complexes thereto, in particular to cationic liposomes. Alternatively, oligonucleotides may be complexed to lipids, in particular to cationic lipids. Preferred fatty acids and esters, pharmaceutically acceptable salts thereof, and their uses are further described in U.S. Pat. No. 6,287,860, which is incorporated herein in its entirety. Topical formulations are described in detail in U.S. patent application Ser. No. 09/315,298 filed on May 20, 1999, which is incorporated herein by reference in its entirety.

[0104] Compositions and formulations for oral administration include powders or granules, microparticulates, nanoparticulates, suspensions or solutions in water or non-aqueous media, capsules, gel capsules, sachets, tablets or minitablets. Thickeners, flavoring agents, diluents, emulsifiers, dispersing aids or binders may be desirable. Preferred oral formulations are those in which oligonucleotides of the invention are administered in conjunction with one or more penetration enhancers surfactants and chelators. Preferred surfactants include fatty acids and/or esters or salts thereof, bile acids and/or salts thereof. Preferred bile acids/salts and fatty acids and their uses are further described in U.S. Pat. No. 6,287,860, which is incorporated herein in its entirety. Also preferred are combinations of penetration enhancers, for example, fatty acids/salts in combination with bile acids/salts. A particularly preferred combination is the sodium salt of lauric acid, capric acid and UDCA. Further penetration enhancers include polyoxyethylene-9-lauryl ether, polyoxyethylene-20-cetyl ether. Oligonucleotides of the invention may be delivered orally, in granular form including sprayed dried particles, or complexed to form micro or nanoparticles. Oligonucleotide complexing agents and their uses are further described in U.S. Pat. No. 6,287,860, which is incorporated herein in its entirety. Oral formulations for oligonucleotides and their preparation are described in detail in U.S. application Ser. Nos. 09/108,673 (filed Jul. 1, 1998), Ser. No. 09/315,298 (filed May 20, 1999) and Ser. No. 10/071,822, filed Feb. 8, 2002, each of which is incorporated herein by reference in their entirety.

[0105] Compositions and formulations for parenteral, intrathecal or intraventricular administration may include sterile aqueous solutions which may also contain buffers, diluents and other suitable additives such as, but not limited to, penetration enhancers, carrier compounds and other pharmaceutically acceptable carriers or excipients.

[0106] Certain embodiments of the invention provide pharmaceutical compositions containing one or more oligomeric compounds and one or more other chemotherapeutic agents which function by a non-antisense mechanism. Examples of such chemotherapeutic agents include but are not limited to cancer chemotherapeutic drugs such as daunorubicin, daunomycin, dactinomycin, doxorubicin, epirubicin, idarubicin, esorubicin, bleomycin, mafosfamide, ifosfamide, cytosine arabinoside, bis-chloroethylnitrosurea, busulfan, mitomycin C, actinomycin D, mithramycin, prednisone, hydroxyprogesterone, testosterone, tamoxifen, dacarbazine, procarbazine, hexamethylmelamine, pentamethylmelamine, mitoxantrone, amsacrine, chlorambucil, methylcyclohexylnitrosurea, nitrogen mustards, melphalan, cyclophosphamide, 6-mercaptopurine, 6-thioguanine, cytarabine, 5-azacytidine, hydroxyurea, deoxycoformycin, 4-hydroxyperoxycyclophosphoramide, 5-fluorouracil (5-FU), 5-fluorodeoxyuridine (5-FUdR), methotrexate (MTX), colchicine, taxol, vincristine, vinblastine, etoposide (VP-16), trimetrexate, irinotecan, topotecan, gemcitabine, teniposide, cisplatin and diethylstilbestrol (DES). When used with the compounds of the invention, such chemotherapeutic agents may be used individually (e.g., 5-FU and oligonucleotide), sequentially (e.g., 5-FU and oligonucleotide for a period of time followed by MTX and oligonucleotide), or in combination with one or more other such chemotherapeutic agents (e.g., 5-FU, MTX and oligonucleotide, or 5-FU, radiotherapy and oligonucleotide). Anti-inflammatory drugs, including but not limited to nonsteroidal anti-inflammatory drugs and corticosteroids, and antiviral drugs, including but not limited to ribivirin, vidarabine, acyclovir and ganciclovir, may also be combined in compositions of the invention. Combinations of antisense compounds and other non-antisense drugs are also within the scope of this invention. Two or more combined compounds may be used together or sequentially.

[0107] In another related embodiment, compositions of the invention may contain one or more antisense compounds, particularly oligonucleotides, targeted to a first nucleic acid and one or more additional antisense compounds targeted to a second nucleic acid target. Alternatively, compositions of the invention may contain two or more antisense compounds targeted to different regions of the same nucleic acid target. Numerous examples of antisense compounds are known in the art. Two or more combined compounds may be used together or sequentially.

[0108] H. Dosing

[0109] The formulation of therapeutic compositions and their subsequent administration (dosing) is believed to be within the skill of those in the art. Dosing is dependent on severity and responsiveness of the disease state to be treated, with the course of treatment lasting from several days to several months, or until a cure is effected or a diminution of the disease state is achieved. Optimal dosing schedules can be calculated from measurements of drug accumulation in the body of the patient. Persons of ordinary skill can easily determine optimum dosages, dosing methodologies and repetition rates. Optimum dosages may vary depending on the relative potency of individual oligonucleotides, and can generally be estimated based on EC₅₀s found to be effective in in vitro and in vivo animal models. In general, dosage is from 0.01 ug to 100 g per kg of body weight, and may be given once or more daily, weekly, monthly or yearly, or even once every 2 to 20 years. Persons of ordinary skill in the art can easily estimate repetition rates for dosing based on measured residence times and concentrations of the drug in bodily fluids or tissues. Following successful treatment, it may be desirable to have the patient undergo maintenance therapy to prevent the recurrence of the disease state, wherein the oligonucleotide is administered in maintenance doses, ranging from 0.01 ug to 100 g per kg of body weight, once or more daily, to once every 20 years.

[0110] While the present invention has been described with specificity in accordance with certain of its preferred embodiments, the following examples serve only to illustrate the invention and are not intended to limit the same.

EXAMPLES Example 1

[0111] Synthesis of Nucleoside Phosphoramidites

[0112] The following compounds, including amidites and their intermediates were prepared as described in U.S. Pat. No. 6,426,220 and published PCT WO 02/36743; 5′-O-Dimethoxytrityl-thymidine intermediate for 5-methyl dC amidite, 5′-O-Dimethoxytrityl-2′-deoxy-5-methylcytidine intermediate for 5-methyl-dC amidite, 5′-O-Dimethoxytrityl-2′-deoxy-N-4-benzoyl-5-methylcytidine penultimate intermediate for 5-methyl dC amidite, [5′-O-(4,4′-Dimethoxytriphenylmethyl)-2′-deoxy-N⁴-benzoyl-5-methylcytidin-3′-O-yl]-2-cyanoethyl-N,N-diisopropylphosphoramidite (5-methyl dC amidite), 2′-Fluorodeoxyadenosine, 2′-Fluorodeoxyguanosine, 2′-Fluorouridine, 2′-Fluorodeoxycytidine, 2′-O-(2-Methoxyethyl) modified amidites, 2′-O-(2-methoxyethyl)-5-methyluridine intermediate, 5′-O-DMT-2′-O-(2-methoxyethyl)-5-methyluridine penultimate intermediate, [5′-O-(4,4′-Dimethoxytriphenylmethyl)-2′-O-(2-methoxyethyl)-5-methyluridin-3′-O-yl]-2-cyanoethyl-N,N-diisopropylphosphoramidite (MOE T amidite), 5′-O-Dimethoxytrityl-2′-O-(2-methoxyethyl)-5-methylcytidine intermediate, 5′-O-dimethoxytrityl-2′-O-(2-methoxyethyl)-N⁴-benzoyl-5-methyl-cytidine penultimate intermediate, [5′-O-(4,4′-Dimethoxytriphenylmethyl)-2′-O-(2-methoxyethyl)-N⁴-benzoyl-5-methylcytidin-3′-O-yl]-2-cyanoethyl-N,N-diisopropylphosphoramidite (MOE 5-Me-C amidite), [5′-O-(4,4′-Dimethoxytriphenylmethyl)-2′-O-(2-methoxyethyl)-N⁶-benzoyladenosin-3′-O-yl]-2-cyanoethyl-N,N-diisopropylphosphoramidite (MOE A amdite), [5′-O-(4,4′-Dimethoxytriphenylmethyl)-2′-O-(2-methoxyethyl)-N⁴isobutyrylguanosin-3′-O-yl]-2-cyanoethyl-N,N-diisopropylphosphoramidite (MOE G amidite), 2′-O-(Aminooxyethyl) nucleoside amidites and 2′-O-(dimethylaminooxyethyl) nucleoside amidites, 2′-(Dimethylaminooxyethoxy) nucleoside amidites, 5′-O-tert-Butyldiphenylsilyl-O²-2′-anhydro-5-methyluridine, 5′-O-tert-Butyldiphenylsilyl-2′-O-(2-hydroxyethyl)-5-methyluridine, 2′-O-([2-phthalimidoxy)ethyl]-5′-t-butyldiphenylsilyl-5-methyluridine, 5′-O-tert-butyldiphenylsilyl-2′-O-[(2-formadoximinooxy)ethyl]-5-methyluridine, 5′-O-tert-Butyldiphenylsilyl-2′-O-[N,N dimethylaminooxyethyl]-5-methyluridine, 2′-O-(dimethylaminooxyethyl)-5-methyluridine, 5′-O-DMT-2′-O-(dimethylaminooxyethyl)-5-methyluridine, 5′-O-DMT-2′-O-(2-N,N-dimethylaminooxyethyl)-5-methyluridine-3′-[(2-cyanoethyl)-N,N-diisopropylphosphoramidite], 2′-(Aminooxyethoxy) nucleoside amidites, N2-isobutyryl-6-O-diphenylcarbamoyl-2′-O-(2-ethylacetyl)-5′-O-(4,4′-dimethoxytrityl)guanosine-3′-[(2-cyanoethyl)-N,N-diisopropylphosphoramidite], 2′-dimethylaminoethoxyethoxy (2′-DMAEOE) nucleoside amidites, 2′-O-[2(2-N,N-dimethylaminoethoxy)ethyl]-5-methyl uridine, 5′-O-dimethoxytrityl-2′-O-[2(2-N,N-dimethylaminoethoxy)-ethyl)]-5-methyl uridine and 5′-O-Dimethoxytrityl-2′-O-[2(2-N,N-dimethylaminoethoxy)-ethyl)]-5-methyl uridine-3′-O-(cyanoethyl-N,N-diisopropyl)phosphoramidite.

Example 2

[0113] Oligonucleotide and Oligonucleoside Synthesis

[0114] The antisense compounds used in accordance with this invention may be conveniently and routinely made through the well-known technique of solid phase synthesis. Equipment for such synthesis is sold by several vendors including, for example, Applied Biosystems (Foster City, Calif.). Any other means for such synthesis known in the art may additionally or alternatively be employed. It is well known to use similar techniques to prepare oligonucleotides such as the phosphorothioates and alkylated derivatives.

[0115] Oligonucleotides: Unsubstituted and substituted phosphodiester (P═O) oligonucleotides are synthesized on an automated DNA synthesizer (Applied Biosystems model 394) using standard phosphoramidite chemistry with oxidation by iodine.

[0116] Phosphorothioates (P═S) are synthesized similar to phosphodiester oligonucleotides with the following exceptions: thiation was effected by utilizing a 10% w/v solution of 3,H-1,2-benzodithiole-3-one 1,1-dioxide in acetonitrile for the oxidation of the phosphite linkages. The thiation reaction step time was increased to 180 sec and preceded by the normal capping step. After cleavage from the CPG column and deblocking in concentrated ammonium hydroxide at 55° C. (12-16 hr), the oligonucleotides were recovered by precipitating with >3 volumes of ethanol from a 1 M NH₄OAc solution. Phosphinate oligonucleotides are prepared as described in U.S. Pat. No. 5,508,270, herein incorporated by reference.

[0117] Alkyl phosphonate oligonucleotides are prepared as described in U.S. Pat. No. 4,469,863, herein incorporated by reference.

[0118] 3′-Deoxy-3′-methylene phosphonate oligonucleotides are prepared as described in U.S. Pat. No. 5,610,289 or 5,625,050, herein incorporated by reference.

[0119] Phosphoramidite oligonucleotides are prepared as described in U.S. Pat. No. 5,256,775 or 5,366,878, herein incorporated by reference.

[0120] Alkylphosphonothioate oligonucleotides are prepared as described in published PCT applications PCT/US94/00902 and PCT/US93/06976 (published as WO 94/17093 and WO 94/02499, respectively), herein incorporated by reference.

[0121] 3′-Deoxy-3′-amino phosphoramidate oligonucleotides are prepared as described in U.S. Pat. No. 5,476,925, herein incorporated by reference.

[0122] Phosphotriester oligonucleotides are prepared as described in U.S. Pat. No. 5,023,243, herein incorporated by reference.

[0123] Borano phosphate oligonucleotides are prepared as described in U.S. Pat. Nos. 5,130,302 and 5,177,198, both herein incorporated by reference.

[0124] Oligonucleosides: Methylenemethylimino linked oligonucleosides, also identified as MMI linked oligonucleosides, methylenedimethylhydrazo linked oligonucleosides, also identified as MDH linked oligonucleosides, and methylenecarbonylamino linked oligonucleosides, also identified as amide-3 linked oligonucleosides, and methyleneaminocarbonyl linked oligonucleosides, also identified as amide-4 linked oligonucleosides, as well as mixed backbone compounds having, for instance, alternating MMI and P═O or P═S linkages are prepared as described in U.S. Pat. Nos. 5,378,825, 5,386,023, 5,489,677, 5,602,240 and 5,610,289, all of which are herein incorporated by reference.

[0125] Formacetal and thioformacetal linked oligonucleosides are prepared as described in U.S. Pat. Nos. 5,264,562 and 5,264,564, herein incorporated by reference.

[0126] Ethylene oxide linked oligonucleosides are prepared as described in U.S. Pat. No. 5,223,618, herein incorporated by reference.

Example 3

[0127] RNA Synthesis

[0128] In general, RNA synthesis chemistry is based on the selective incorporation of various protecting groups at strategic intermediary reactions. Although one of ordinary skill in the art will understand the use of protecting groups in organic synthesis, a useful class of protecting groups includes silyl ethers. In particular bulky silyl ethers are used to protect the 5′-hydroxyl in combination with an acid-labile orthoester protecting group on the 2′-hydroxyl. This set of protecting groups is then used with standard solid-phase synthesis technology. It is important to lastly remove the acid labile orthoester protecting group after all other synthetic steps. Moreover, the early use of the silyl protecting groups during synthesis ensures facile removal when desired, without undesired deprotection of 2′ hydroxyl.

[0129] Following this procedure for the sequential protection of the 5′-hydroxyl in combination with protection of the 2′-hydroxyl by protecting groups that are differentially removed and are differentially chemically labile, RNA oligonucleotides were synthesized.

[0130] RNA oligonucleotides are synthesized in a stepwise fashion. Each nucleotide is added sequentially (3′- to 5′-direction) to a solid support-bound oligonucleotide. The first nucleoside at the 3′-end of the chain is covalently attached to a solid support. The nucleotide precursor, a ribonucleoside phosphoramidite, and activator are added, coupling the second base onto the 5′-end of the first nucleoside. The support is washed and any unreacted 5′-hydroxyl groups are capped with acetic anhydride to yield 5′-acetyl moieties. The linkage is then oxidized to the more stable and ultimately desired P(V) linkage. At the end of the nucleotide addition cycle, the 5′-silyl group is cleaved with fluoride. The cycle is repeated for each subsequent nucleotide.

[0131] Following synthesis, the methyl protecting groups on the phosphates are cleaved in 30 minutes utilizing 1 M disodium-2-carbamoyl-2-cyanoethylene-1,1-dithiolate trihydrate (S₂Na₂) in DMF. The deprotection solution is washed from the solid support-bound oligonucleotide using water. The support is then treated with 40% methylamine in water for 10 minutes at 55° C. This releases the RNA oligonucleotides into solution, deprotects the exocyclic amines, and modifies the 2′-groups. The oligonucleotides can be analyzed by anion exchange HPLC at this stage.

[0132] The 2′-orthoester groups are the last protecting groups to be removed. The ethylene glycol monoacetate orthoester protecting group developed by Dharmacon Research, Inc. (Lafayette, Colo.), is one example of a useful orthoester protecting group which, has the following important properties. It is stable to the conditions of nucleoside phosphoramidite synthesis and oligonucleotide synthesis. However, after oligonucleotide synthesis the oligonucleotide is treated with methylamine which not only cleaves the oligonucleotide from the solid support but also removes the acetyl groups from the orthoesters. The resulting 2-ethyl-hydroxyl substituents on the orthoester are less electron withdrawing than the acetylated precursor. As a result, the modified orthoester becomes more labile to acid-catalyzed hydrolysis. Specifically, the rate of cleavage is approximately 10 times faster after the acetyl groups are removed. Therefore, this orthoester possesses sufficient stability in order to be compatible with oligonucleotide synthesis and yet, when subsequently modified, permits deprotection to be carried out under relatively mild aqueous conditions compatible with the final RNA oligonucleotide product.

[0133] Additionally, methods of RNA synthesis are well known in the art (Scaringe, S. A. Ph.D. Thesis, University of Colorado, 1996; Scaringe, S. A., et al., J. Am. Chem. Soc., 1998, 120, 11820-11821; Matteucci, M. D. and Caruthers, M. H. J. Am. Chem. Soc., 1981, 103, 3185-3191; Beaucage, S. L. and Caruthers, M. H. Tetrahedron Lett., 1981, 22, 1859-1862; Dahl, B. J., et al., Acta Chem. Scand, 1990, 44, 639-641; Reddy, M. P., et al., Tetrahedrom Lett., 1994, 25, 4311-4314; Wincott, F. et al., Nucleic Acids Res., 1995, 23, 2677-2684; Griffin, B. E., et al., Tetrahedron, 1967, 23, 2301-2313; Griffin, B. E., et al., Tetrahedron, 1967, 23, 2315-2331).

[0134] RNA antisense compounds (RNA oligonucleotides) of the present invention can be synthesized by the methods herein or purchased from Dharmacon Research, Inc (Lafayette, Colo.). Once synthesized, complementary RNA antisense compounds can then be annealed by methods known in the art to form double stranded (duplexed) antisense compounds. For example, duplexes can be formed by combining 30 μl of each of the complementary strands of RNA oligonucleotides (50 uM RNA oligonucleotide solution) and 15 μl of 5× annealing buffer (100 mM potassium acetate, 30 mM HEPES-KOH pH 7.4, 2 mM magnesium acetate) followed by heating for 1 minute at 90° C., then 1 hour at 37° C. The resulting duplexed antisense compounds can be used in kits, assays, screens, or other methods to investigate the role of a target nucleic acid.

Example 4

[0135] Synthesis of Chimeric Oligonucleotides

[0136] Chimeric oligonucleotides, oligonucleosides or mixed oligonucleotides/oligonucleosides of the invention can be of several different types. These include a first type wherein the “gap” segment of linked nucleosides is positioned between 5′ and 3′ “wing” segments of linked nucleosides and a second “open end” type wherein the “gap” segment is located at either the 3′ or the 5′ terminus of the oligomeric compound. Oligonucleotides of the first type are also known in the art as “gapmers” or gapped oligonucleotides. Oligonucleotides of the second type are also known in the art as “hemimers” or “wingmers”.

[0137] [2′-O-Me]-[2′-deoxy]-[2′-O-Me] Chimeric Phosphorothioate Oligonucleotides

[0138] Chimeric oligonucleotides having 2′-O-alkyl phosphorothioate and 2′-deoxy phosphorothioate oligonucleotide segments are synthesized using an Applied Biosystems automated DNA synthesizer Model 394, as above. Oligonucleotides are synthesized using the automated synthesizer and 2′-deoxy-5′-dimethoxytrityl-3′-O-phosphoramidite for the DNA portion and 5′-dimethoxytrityl-2′-O-methyl-3′-O-phosphoramidite for 5′ and 3′ wings. The standard synthesis cycle is modified by incorporating coupling steps with increased reaction times for the 5′-dimethoxytrityl-2′-O-methyl-3′-O-phosphoramidite. The fully protected oligonucleotide is cleaved from the support and deprotected in concentrated ammonia (NH₄OH) for 12-16 hr at 55° C. The deprotected oligo is then recovered by an appropriate method (precipitation, column chromatography, volume reduced in vacuo and analyzed spetrophotometrically for yield and for purity by capillary electrophoresis and by mass spectrometry.

[0139] [2′-O-(2-Methoxyethyl)]-[2′-deoxy][2′-O-(Methoxyethyl)] Chimeric Phosphorothioate Oligonucleotides

[0140] [2′-O-(2-methoxyethyl)]-[2′-deoxy]-[-2′-O-(methoxyethyl)] chimeric phosphorothioate oligonucleotides were prepared as per the procedure above for the 2′-O-methyl chimeric oligonucleotide, with the substitution of 2′-O-(methoxyethyl) amidites for the 2′-O-methyl amidites.

[0141] [2′-O-(2-Methoxyethyl)Phosphodiester]-[2′-deoxy Phosphorothioate]-[2′-O-(2-Methoxyethyl) Phosphodiester] Chimeric Oligonucleotides

[0142] [2′-O-(2-methoxyethyl phosphodiester]-[2′-deoxy phosphorothioate]-[2′-O-(methoxyethyl) phosphodiester] chimeric oligonucleotides are prepared as per the above procedure for the 2′-O-methyl chimeric oligonucleotide with the substitution of 2′-O-(methoxyethyl) amidites for the 2′-O-methyl amidites, oxidation with iodine to generate the phosphodiester internucleotide linkages within the wing portions of the chimeric structures and sulfurization utilizing 3,H-1,2 benzodithiole-3-one 1,1 dioxide (Beaucage Reagent) to generate the phosphorothioate internucleotide linkages for the center gap.

[0143] Other chimeric oligonucleotides, chimeric oligonucleosides and mixed chimeric oligonucleotides/oligonucleosides are synthesized according to U.S. Pat. No. 5,623,065, herein incorporated by reference.

Example 5

[0144] Design and Screening of Duplexed Antisense Compounds Targeting BAF53

[0145] In accordance with the present invention, a series of nucleic acid duplexes comprising the antisense compounds of the present invention and their complements can be designed to target BAF53. The nucleobase sequence of the antisense strand of the duplex comprises at least a portion of an oligonucleotide in Table 1. The ends of the strands may be modified by the addition of one or more natural or modified nucleobases to form an overhang. The sense strand of the dsRNA is then designed and synthesized as the complement of the antisense strand and may also contain modifications or additions to either terminus. For example, in one embodiment, both strands of the dsRNA duplex would be complementary over the central nucleobases, each having overhangs at one or both termini.

[0146] For example, a duplex comprising an antisense strand having the sequence CGAGAGGCGGACGGGACCG and having a two-nucleobase overhang of deoxythymidine(dT) would have the following structure:   cgagaggcggacgggaccgTT Antisense Strand   ||||||||||||||||||| TTgctctccgcctgccctggc Complement

[0147] RNA strands of the duplex can be synthesized by methods disclosed herein or purchased from Dharmacon Research Inc., (Lafayette, Colo.). Once synthesized, the complementary strands are annealed. The single strands are aliquoted and diluted to a concentration of 50 uM. Once diluted, 30 uL of each strand is combined with 15 uL of a 5× solution of annealing buffer. The final concentration of said buffer is 100 mM potassium acetate, 30 mM HEPES-KOH pH 7.4, and 2 mM magnesium acetate. The final volume is 75 uL. This solution is incubated for 1 minute at 90° C. and then centrifuged for 15 seconds. The tube is allowed to sit for 1 hour at 37° C. at which time the dsRNA duplexes are used in experimentation. The final concentration of the dsRNA duplex is 20 uM. This solution can be stored frozen (−20° C.) and freeze-thawed up to 5 times.

[0148] Once prepared, the duplexed antisense compounds are evaluated for their ability to modulate BAF53 expression.

[0149] When cells reached 80% confluency, they are treated with duplexed antisense compounds of the invention. For cells grown in 96-well plates, wells are washed once with 200 uL OPTI-MEM-1 reduced-serum medium (Gibco BRL) and then treated with 130 μL of OPTI-MEM-1 containing 12 μg/mL LIPOFECTIN (Gibco BRL) and the desired duplex antisense compound at a final concentration of 200 nM. After 5 hours of treatment, the medium is replaced with fresh medium. Cells are harvested 16 hours after treatment, at which time RNA is isolated and target reduction measured by RT-PCR.

Example 6

[0150] Oligonucleotide Isolation

[0151] After cleavage from the controlled pore glass solid support and deblocking in concentrated ammonium hydroxide at 55° C. for 12-16 hours, the oligonucleotides or oligonucleosides are recovered by precipitation out of 1 M NH₄OAc with >3 volumes of ethanol. Synthesized oligonucleotides were analyzed by electrospray mass spectroscopy (molecular weight determination) and by capillary gel electrophoresis and judged to be at least 70% full length material. The relative amounts of phosphorothioate and phosphodiester linkages obtained in the synthesis was determined by the ratio of correct molecular weight relative to the −16 amu product (+/−32+/−48). For some studies oligonucleotides were purified by HPLC, as described by Chiang et al., J. Biol. Chem. 1991, 266, 18162-18171. Results obtained with HPLC-purified material were similar to those obtained with non-HPLC purified material.

Example 7

[0152] Oligonucleotide Synthesis—96 Well Plate Format

[0153] Oligonucleotides were synthesized via solid phase P(III) phosphoramidite chemistry on an automated synthesizer capable of assembling 96 sequences simultaneously in a 96-well format. Phosphodiester internucleotide linkages were afforded by oxidation with aqueous iodine. Phosphorothioate internucleotide linkages were generated by sulfurization utilizing 3,H-1,2 benzodithiole-3-one 1,1 dioxide (Beaucage Reagent) in anhydrous acetonitrile. Standard base-protected beta-cyanoethyl-diiso-propyl phosphoramidites were purchased from commercial vendors (e.g. PE-Applied Biosystems, Foster City, Calif., or Pharmacia, Piscataway, N.J.). Non-standard nucleosides are synthesized as per standard or patented methods. They are utilized as base protected beta-cyanoethyldiisopropyl phosphoramidites.

[0154] Oligonucleotides were cleaved from support and deprotected with concentrated NH₄OH at elevated temperature (55-60° C.) for 12-16 hours and the released product then dried in vacuo. The dried product was then re-suspended in sterile water to afford a master plate from which all analytical and test plate samples are then diluted utilizing robotic pipettors.

Example 8

[0155] Oligonucleotide Analysis—96-Well Plate Format

[0156] The concentration of oligonucleotide in each well was assessed by dilution of samples and UV absorption spectroscopy. The full-length integrity of the individual products was evaluated by capillary electrophoresis (CE) in either the 96-well format (Beckman P/ACE™ MDQ) or, for individually prepared samples, on a commercial CE apparatus (e.g., Beckman P/ACE™ 5000, ABI 270). Base and backbone composition was confirmed by mass analysis of the compounds utilizing electrospray-mass spectroscopy. All assay test plates were diluted from the master plate using single and multi-channel robotic pipettors. Plates were judged to be acceptable if at least 85% of the compounds on the plate were at least 85% full length.

Example 9

[0157] Cell Culture and Oligonucleotide Treatment

[0158] The effect of antisense compounds on target nucleic acid expression can be tested in any of a variety of cell types provided that the target nucleic acid is present at measurable levels. This can be routinely determined using, for example, PCR or Northern blot analysis. The following cell types are provided for illustrative purposes, but other cell types can be routinely used, provided that the target is expressed in the cell type chosen. This can be readily determined by methods routine in the art, for example Northern blot analysis, ribonuclease protection assays, or RT-PCR.

[0159] T-24 Cells:

[0160] The human transitional cell bladder carcinoma cell line T-24 was obtained from the American Type Culture Collection (ATCC) (Manassas, Va.). T-24 cells were routinely cultured in complete McCoy's 5A basal media (Invitrogen Corporation, Carlsbad, Calif.) supplemented with 10% fetal calf serum (Invitrogen Corporation, Carlsbad, Calif.), penicillin 100 units per mL, and streptomycin 100 micrograms per mL (Invitrogen Corporation, Carlsbad, Calif.). Cells were routinely passaged by trypsinization and dilution when they reached 90% confluence. Cells were seeded into 96-well plates (Falcon-Primaria #353872) at a density of 7000 cells/well for use in RT-PCR analysis.

[0161] For Northern blotting or other analysis, cells may be seeded onto 100 mm or other standard tissue culture plates and treated similarly, using appropriate volumes of medium and oligonucleotide.

[0162] A549 Cells:

[0163] The human lung carcinoma cell line A549 was obtained from the American Type Culture Collection (ATCC) (Manassas, Va.). A549 cells were routinely cultured in DMEM basal media (Invitrogen Corporation, Carlsbad, Calif.) supplemented with 10% fetal calf serum (Invitrogen Corporation, Carlsbad, Calif.), penicillin 100 units per mL, and streptomycin 100 micrograms per mL (Invitrogen Corporation, Carlsbad, Calif.). Cells were routinely passaged by trypsinization and dilution when they reached 90% confluence.

[0164] NHDF Cells:

[0165] Human neonatal dermal fibroblast (NHDF) were obtained from the Clonetics Corporation (Walkersville, Md.). NHDFs were routinely maintained in Fibroblast Growth Medium (Clonetics Corporation, Walkersville, Md.) supplemented as recommended by the supplier. Cells were maintained for up to 10 passages as recommended by the supplier.

[0166] HEK Cells:

[0167] Human embryonic keratinocytes (HEK) were obtained from the Clonetics Corporation (Walkersville, Md.). HEKs were routinely maintained in Keratinocyte Growth Medium (Clonetics Corporation, Walkersville, Md.) formulated as recommended by the supplier. Cells were routinely maintained for up to 10 passages as recommended by the supplier.

[0168] Treatment with Antisense Compounds:

[0169] When cells reached 65-75% confluency, they were treated with oligonucleotide. For cells grown in 96-well plates, wells were washed once with 100 μL OPTI-MEM™-1 reduced-serum medium (Invitrogen Corporation, Carlsbad, Calif.) and then treated with 130 μL of OPTI-MEM™-1 containing 3.75 μg/mL LIPOFECTIN™ (Invitrogen Corporation, Carlsbad, Calif.) and the desired concentration of oligonucleotide. Cells are treated and data are obtained in triplicate. After 4-7 hours of treatment at 37° C., the medium was replaced with fresh medium. Cells were harvested 16-24 hours after oligonucleotide treatment.

[0170] The concentration of oligonucleotide used varies from cell line to cell line. To determine the optimal oligonucleotide concentration for a particular cell line, the cells are treated with a positive control oligonucleotide at a range of concentrations. For human cells the positive control oligonucleotide is selected from either ISIS 13920 (TCCGTCATCGCTCCTCAGGG, SEQ ID NO: 1) which is targeted to human H-ras, or ISIS 18078, (GTGCGCGCGAGCCCGAAATC, SEQ ID NO: 2) which is targeted to human Jun-N-terminal kinase-2 (JNK2). Both controls are 2′-O-methoxyethyl gapmers (2′-O-methoxyethyls shown in bold) with a phosphorothioate backbone. For mouse or rat cells the positive control oligonucleotide is ISIS 15770, ATGCATTCTGCCCCCAAGGA, SEQ ID NO: 3, a 2′-O-methoxyethyl gapmer (2′-O-methoxyethyls shown in bold) with a phosphorothioate backbone which is targeted to both mouse and rat c-raf. The concentration of positive control oligonucleotide that results in 80% inhibition of c-H-ras (for ISIS 13920), JNK2 (for ISIS 18078) or c-raf (for ISIS 15770) mRNA is then utilized as the screening concentration for new oligonucleotides in subsequent experiments for that cell line. If 80% inhibition is not achieved, the lowest concentration of positive control oligonucleotide that results in 60% inhibition of c-H-ras, JNK2 or c-raf mRNA is then utilized as the oligonucleotide screening concentration in subsequent experiments for that cell line. If 60% inhibition is not achieved, that particular cell line is deemed as unsuitable for oligonucleotide transfection experiments. The concentrations of antisense oligonucleotides used herein are from 50 nM to 300 nM.

Example 10

[0171] Analysis of Oligonucleotide Inhibition of BAF53 Expression

[0172] Antisense modulation of BAF53 expression can be assayed in a variety of ways known in the art. For example, BAF53 mRNA levels can be quantitated by, e.g., Northern blot analysis, competitive polymerase chain reaction (PCR), or real-time PCR (RT-PCR). Real-time quantitative PCR is presently preferred. RNA analysis can be performed on total cellular RNA or poly(A)+ mRNA. The preferred method of RNA analysis of the present invention is the use of total cellular RNA as described in other examples herein. Methods of RNA isolation are well known in the art. Northern blot analysis is also routine in the art. Real-time quantitative (PCR) can be conveniently accomplished using the commercially available ABI PRISM™ 7600, 7700, or 7900 Sequence Detection System, available from PE-Applied Biosystems, Foster City, Calif. and used according to manufacturer's instructions.

[0173] Protein levels of BAF53 can be quantitated in a variety of ways well known in the art, such as immunoprecipitation, Western blot analysis (immunoblotting), enzyme-linked immunosorbent assay (ELISA) or fluorescence-activated cell sorting (FACS). Antibodies directed to BAF53 can be identified and obtained from a variety of sources, such as the MSRS catalog of antibodies (Aerie Corporation, Birmingham, MI), or can be prepared via conventional monoclonal or polyclonal antibody generation methods well known in the art.

Example 11

[0174] Design of Phenotypic Assays and In Vivo Studies for the use of BAF53 Inhibitors

[0175] Phenotypic Assays

[0176] Once BAF53 inhibitors have been identified by the methods disclosed herein, the compounds are further investigated in one or more phenotypic assays, each having measurable endpoints predictive of efficacy in the treatment of a particular disease state or condition.

[0177] Phenotypic assays, kits and reagents for their use are well known to those skilled in the art and are herein used to investigate the role and/or association of BAF53 in health and disease. Representative phenotypic assays, which can be purchased from any one of several commercial vendors, include those for determining cell viability, cytotoxicity, proliferation or cell survival (Molecular Probes, Eugene, Oreg.; PerkinElmer, Boston, Mass.), protein-based assays including enzymatic assays (Panvera, LLC, Madison, Wis.; BD Biosciences, Franklin Lakes, N.J.; Oncogene Research Products, San Diego, Calif.), cell regulation, signal transduction, inflammation, oxidative processes and apoptosis (Assay Designs Inc., Ann Arbor, Mich.), triglyceride accumulation (Sigma-Aldrich, St. Louis, Mo.), angiogenesis assays, tube formation assays, cytokine and hormone assays and metabolic assays (Chemicon International Inc., Temecula, Calif.; Amersham Biosciences, Piscataway, N.J.).

[0178] In one non-limiting example, cells determined to be appropriate for a particular phenotypic assay (i.e., MCF-7 cells selected for breast cancer studies; adipocytes for obesity studies) are treated with BAF53 inhibitors identified from the in vitro studies as well as control compounds at optimal concentrations which are determined by the methods described above. At the end of the treatment period, treated and untreated cells are analyzed by one or more methods specific for the assay to determine phenotypic outcomes and endpoints.

[0179] Phenotypic endpoints include changes in cell morphology over time or treatment dose as well as changes in levels of cellular components such as proteins, lipids, nucleic acids, hormones, saccharides or metals. Measurements of cellular status which include pH, stage of the cell cycle, intake or excretion of biological indicators by the cell, are also endpoints of interest.

[0180] Analysis of the geneotype of the cell (measurement of the expression of one or more of the genes of the cell) after treatment is also used as an indicator of the efficacy or potency of the BAF53 inhibitors. Hallmark genes, or those genes suspected to be associated with a specific disease state, condition, or phenotype, are measured in both treated and untreated cells.

[0181] In Vivo Studies

[0182] The individual subjects of the in vivo studies described herein are warm-blooded vertebrate animals, which includes humans.

[0183] The clinical trial is subjected to rigorous controls to ensure that individuals are not unnecessarily put at risk and that they are fully informed about their role in the study. To account for the psychological effects of receiving treatments, volunteers are randomly given placebo or BAF53 inhibitor. Furthermore, to prevent the doctors from being biased in treatments, they are not informed as to whether the medication they are administering is a BAF53 inhibitor or a placebo. Using this randomization approach, each volunteer has the same chance of being given either the new treatment or the placebo.

[0184] Volunteers receive either the BAF53 inhibitor or placebo for eight week period with biological parameters associated with the indicated disease state or condition being measured at the beginning (baseline measurements before any treatment), end (after the final treatment), and at regular intervals during the study period. Such measurements include the levels of nucleic acid molecules encoding BAF53 or BAF53 protein levels in body fluids, tissues or organs compared to pre-treatment levels. Other measurements include, but are not limited to, indices of the disease state or condition being treated, body weight, blood pressure, serum titers of pharmacologic indicators of disease or toxicity as well as ADME (absorption, distribution, metabolism and excretion) measurements.

[0185] Information recorded for each patient includes age (years), gender, height (cm), family history of disease state or condition (yes/no), motivation rating (some/moderate/great) and number and type of previous treatment regimens for the indicated disease or condition.

[0186] Volunteers taking part in this study are healthy adults (age 18 to 65 years) and roughly an equal number of males and females participate in the study. Volunteers with certain characteristics are equally distributed for placebo and BAF53 inhibitor treatment. In general, the volunteers treated with placebo have little or no response to treatment, whereas the volunteers treated with the BAF53 inhibitor show positive trends in their disease state or condition index at the conclusion of the study.

Example 12

[0187] RNA Isolation

[0188] Poly(A)+ mRNA Isolation

[0189] Poly(A)+ mRNA was isolated according to Miura et al., (Clin. Chem., 1996, 42, 1758-1764). Other methods for poly(A)+ mRNA isolation are routine in the art. Briefly, for cells grown on 96-well plates, growth medium was removed from the cells and each well was washed with 200 μL cold PBS. 60 μL lysis buffer (10 mM Tris-HCl, pH 7.6, 1 mM EDTA, 0.5 M NaCl, 0.5% NP-40, 20 mM vanadyl-ribonucleoside complex) was added to each well, the plate was gently agitated and then incubated at room temperature for five minutes. 55 μL of lysate was transferred to Oligo d(T) coated 96-well plates (AGCT Inc., Irvine Calif.). Plates were incubated for 60 minutes at room temperature, washed 3 times with 200 μL of wash buffer (10 mM Tris-HCl pH 7.6, 1 mM EDTA, 0.3 M NaCl). After the final wash, the plate was blotted on paper towels to remove excess wash buffer and then air-dried for 5 minutes. 60 μL of elution buffer (5 mM Tris-HCl pH 7.6), preheated to 70° C., was added to each well, the plate was incubated on a 90° C. hot plate for 5 minutes, and the eluate was then transferred to a fresh 96-well plate.

[0190] Cells grown on 100 mm or other standard plates may be treated similarly, using appropriate volumes of all solutions.

[0191] Total RNA Isolation

[0192] Total RNA was isolated using an RNEASY 96™ kit and buffers purchased from Qiagen Inc. (Valencia, Calif.) following the manufacturer's recommended procedures. Briefly, for cells grown on 96-well plates, growth medium was removed from the cells and each well was washed with 200 μL cold PBS. 150 μL Buffer RLT was added to each well and the plate vigorously agitated for 20 seconds. 150 μL of 70% ethanol was then added to each well and the contents mixed by pipetting three times up and down. The samples were then transferred to the RNEASY 96™ well plate attached to a QIAVAC™ manifold fitted with a waste collection tray and attached to a vacuum source. Vacuum was applied for 1 minute. 500 μL of Buffer RW1 was added to each well of the RNEASY 96™ plate and incubated for 15 minutes and the vacuum was again applied for 1 minute. An additional 500 μL of Buffer RW1 was added to each well of the RNEASY 96™ plate and the vacuum was applied for 2 minutes. 1 mL of Buffer RPE was then added to each well of the RNEASY 96™ plate and the vacuum applied for a period of 90 seconds. The Buffer RPE wash was then repeated and the vacuum was applied for an additional 3 minutes. The plate was then removed from the QIAVAC™ manifold and blotted dry on paper towels. The plate was then re-attached to the QIAVAC™ manifold fitted with a collection tube rack containing 1.2 mL collection tubes. RNA was then eluted by pipetting 140 μL of RNAse free water into each well, incubating 1 minute, and then applying the vacuum for 3 minutes.

[0193] The repetitive pipetting and elution steps may be automated using a QIAGEN Bio-Robot 9604 (Qiagen, Inc., Valencia Calif.). Essentially, after lysing of the cells on the culture plate, the plate is transferred to the robot deck where the pipetting, DNase treatment and elution steps are carried out.

Example 13

[0194] Real-time Quantitative PCR Analysis of BAF53 mRNA Levels

[0195] Quantitation of BAF53 mRNA levels was accomplished by real-time quantitative PCR using the ABI PRISM™ 7600, 7700, or 7900 Sequence Detection System (PE-Applied Biosystems, Foster City, Calif.) according to manufacturer's instructions. This is a closed-tube, non-gel-based, fluorescence detection system which allows high-throughput quantitation of polymerase chain reaction (PCR) products in real-time. As opposed to standard PCR in which amplification products are quantitated after the PCR is completed, products in real-time quantitative PCR are quantitated as they accumulate. This is accomplished by including in the PCR reaction an oligonucleotide probe that anneals specifically between the forward and reverse PCR primers, and contains two fluorescent dyes. A reporter dye (e.g., FAM or JOE, obtained from either PE-Applied Biosystems, Foster City, Calif., Operon Technologies Inc., Alameda, Calif. or Integrated DNA Technologies Inc., Coralville, Iowa) is attached to the 5′ end of the probe and a quencher dye (e.g., TAMRA, obtained from either PE-Applied Biosystems, Foster City, Calif., Operon Technologies Inc., Alameda, Calif. or Integrated DNA Technologies Inc., Coralville, Iowa) is attached to the 3′ end of the probe. When the probe and dyes are intact, reporter dye emission is quenched by the proximity of the 3′ quencher dye. During amplification, annealing of the probe to the target sequence creates a substrate that can be cleaved by the 5′-exonuclease activity of Taq polymerase. During the extension phase of the PCR amplification cycle, cleavage of the probe by Taq polymerase releases the reporter dye from the remainder of the probe (and hence from the quencher moiety) and a sequence-specific fluorescent signal is generated. With each cycle, additional reporter dye molecules are cleaved from their respective probes, and the fluorescence intensity is monitored at regular intervals by laser optics built into the ABI PRISM™ Sequence Detection System. In each assay, a series of parallel reactions containing serial dilutions of mRNA from untreated control samples generates a standard curve that is used to quantitate the percent inhibition after antisense oligonucleotide treatment of test samples.

[0196] Prior to quantitative PCR analysis, primer-probe sets specific to the target gene being measured are evaluated for their ability to be “multiplexed” with a GAPDH amplification reaction. In multiplexing, both the target gene and the internal standard gene GAPDH are amplified concurrently in a single sample. In this analysis, mRNA isolated from untreated cells is serially diluted. Each dilution is amplified in the presence of primer-probe sets specific for GAPDH only, target gene only (“single-plexing”), or both (multiplexing). Following PCR amplification, standard curves of GAPDH and target mRNA signal as a function of dilution are generated from both the single-plexed and multiplexed samples. If both the slope and correlation coefficient of the GAPDH and target signals generated from the multiplexed samples fall within 10% of their corresponding values generated from the single-plexed samples, the primer-probe set specific for that target is deemed multiplexable. Other methods of PCR are also known in the art.

[0197] PCR reagents were obtained from Invitrogen Corporation, (Carlsbad, Calif.). RT-PCR reactions were carried out by adding 20 μL PCR cocktail (2.5×PCR buffer minus MgCl₂, 6.6 mM MgCl₂, 375 μM each of dATP, dCTP, dCTP and dGTP, 375 nM each of forward primer and reverse primer, 125 nM of probe, 4 Units RNAse inhibitor, 1.25 Units PLATINUM® Taq, 5 Units MuLV reverse transcriptase, and 2.5×ROX dye) to 96-well plates containing 30 μL total RNA solution (20-200 ng). The RT reaction was carried out by incubation for 30 minutes at 48° C. Following a 10 minute incubation at 95° C. to activate the PLATINUM® Taq, 40 cycles of a two-step PCR protocol were carried out: 95° C. for 15 seconds (denaturation) followed by 60° C. for 1.5 minutes (annealing/extension).

[0198] Gene target quantities obtained by real time RT-PCR are normalized using either the expression level of GAPDH, a gene whose expression is constant, or by quantifying total RNA using RiboGreen™ (Molecular Probes, Inc. Eugene, Oreg.). GAPDH expression is quantified by real time RT-PCR, by being run simultaneously with the target, multiplexing, or separately. Total RNA is quantified using RiboGreen™ RNA quantification reagent (Molecular Probes, Inc. Eugene, Oreg.). Methods of RNA quantification by RiboGreen™ are taught in Jones, L. J., et al, (Analytical Biochemistry, 1998, 265, 368-374).

[0199] In this assay, 170 μL of RiboGreen™ working reagent (RiboGreen™ reagent diluted 1:350 in 10 mM Tris-HCl, 1 mM EDTA, pH 7.5) is pipetted into a 96-well plate containing 30 μL purified, cellular RNA. The plate is read in a CytoFluor 4000 (PE Applied Biosystems) with excitation at 485 nm and emission at 530 nm.

[0200] Probes and primers to human BAF53 were designed to hybridize to a human BAF53 sequence, using published sequence information (the complement of nucleotides 102000 to 130000 of the sequence with GenBank accession number NT_(—)005950.1, incorporated herein as SEQ ID NO:4). For human BAF53 the PCR primers were:

[0201] forward primer: GAGTTCCCAAGCTTCTACCTTCCT (SEQ ID NO: 5) reverse primer: CATTCTACAAAAGATGGTCATTCTTTTC (SEQ ID NO: 6) and the PCR probe was: FAM-TTGTCACCTTACGTTTCATAGCTTT-TAMRA (SEQ ID NO: 7) where FAM is the fluorescent dye and TAMRA is the quencher dye. For human GAPDH the PCR primers were:

[0202] forward primer: GAAGGTGAAGGTCGGAGTC (SEQ ID NO:8)

[0203] reverse primer: GAAGATGGTGATGGGATTTC (SEQ ID NO:9) and the PCR probe was: 5′ JOE-CAAGCTTCCCGTTCTCAGCC-TAMRA 3′ (SEQ ID NO: 10) where JOE is the fluorescent reporter dye and TAMRA is the quencher dye.

Example 14

[0204] Northern Blot Analysis of BAF53 mRNA Levels

[0205] Eighteen hours after antisense treatment, cell monolayers were washed twice with cold PBS and lysed in 1 mL RNAZOL™ (TEL-TEST “B” Inc., Friendswood, Tex.). Total RNA was prepared following manufacturer's recommended protocols. Twenty micrograms of total RNA was fractionated by electrophoresis through 1.2% agarose gels containing 1.1% formaldehyde using a MOPS buffer system (AMRESCO, Inc. Solon, Ohio). RNA was transferred from the gel to HYBOND™-N+ nylon membranes (Amersham Pharmacia Biotech, Piscataway, N.J.) by overnight capillary transfer using a Northern/Southern Transfer buffer system (TEL-TEST “B” Inc., Friendswood, Tex.). RNA transfer was confirmed by UV visualization. Membranes were fixed by UV cross-linking using a STRATALINKER™ UV Crosslinker 2400 (Stratagene, Inc, La Jolla, Calif.) and then probed using QUICKHYB™ hybridization solution (Stratagene, La Jolla, Calif.) using manufacturer's recommendations for stringent conditions.

[0206] To detect human BAF53, a human BAF53 specific probe was prepared by PCR using the forward primer GAGTTCCCAAGCTTCTACCTTCCT (SEQ ID NO: 5) and the reverse primer CATTCTACAAAAGATGGTCATTCTTTTC (SEQ ID NO: 6). To normalize for variations in loading and transfer efficiency membranes were stripped and probed for human glyceraldehyde-3-phosphate dehydrogenase (GAPDH) RNA (Clontech, Palo Alto, Calif.).

[0207] Hybridized membranes were visualized and quantitated using a PHOSPHORIMAGER™ and IMAGEQUANT™ Software V3.3 (Molecular Dynamics, Sunnyvale, Calif.). Data was normalized to GAPDH levels in untreated controls.

Example 15

[0208] Antisense Inhibition of Human BAF53 Expression by Chimeric Phosphorothioate Oligonucleotides Having 2′-MOE Wings and a Deoxy Gap

[0209] In accordance with the present invention, a series of antisense compounds were designed to target different regions of the human BAF53 RNA, using published sequences (the complement of nucleotides 102000 to 130000 of the sequence with GenBank accession number NT_(—)005950.1, incorporated herein as SEQ ID NO: 4, GenBank accession number BM837551.1, incorporated herein as SEQ ID NO: 11, GenBank accession number BE867470.1, incorporated herein as SEQ ID NO: 12, GenBank accession number BE798399.1, incorporated herein as SEQ ID NO: 13, GenBank accession number AV717758.1, incorporated herein as SEQ ID NO: 14, GenBank accession number AV714711.1, incorporated herein as SEQ ID NO: 15, GenBank accession number AF285120.1, the complement of which is incorporated herein as SEQ ID NO: 16, GenBank accession number AB061315.1, incorporated herein as SEQ ID NO: 17, GenBank accession number AB060168.1, incorporated herein as SEQ ID NO: 18, and GenBank accession number NM_(—)004301.1, incorporated herein as SEQ ID NO: 19). The compounds are shown in Table 1. “Target site” indicates the first (5′-most) nucleotide number on the particular target sequence to which the compound binds. All compounds in Table 1 are chimeric oligonucleotides (“gapmers”) 20 nucleotides in length, composed of a central “gap” region consisting of ten 2′-deoxynucleotides, which is flanked on both sides (5′ and 3′ directions) by five-nucleotide “wings”. The wings are composed of 2′-methoxyethyl (2′-MOE) nucleotides. The internucleoside (backbone) linkages are phosphorothioate (P═S) throughout the oligonucleotide. All cytidine residues are 5-methylcytidines. The compounds were analyzed for their effect on human BAF53 mRNA levels by quantitative real-time PCR as described in other examples herein. Data are averages from three experiments in which A549 cells were treated with the antisense oligonucleotides of the present invention. The positive control for each datapoint is identified in the table by sequence ID number. If present, “N.D.” indicates “no data”. TABLE 1 Inhibition of human BAF53 mRNA levels by chimeric phosphorothioate oligonucleotides having 2′-MOE wings and a deoxy gap TARGET CONTROL SEQ ID TARGET % SEQ SEQ ID ISIS # REGION NO SITE SEQUENCE INHIB ID NO NO 280326 Start 4 609 gctcatggctgctgccggcg 74 20 1 Codon 280327 Start 4 615 gccgccgctcatggctgctg 86 21 1 Codon 280328 Coding 4 7380 ctcacagtataggatccaat 86 22 1 280329 Coding 4 7630 gtgcttccgtcatctctttc 63 23 1 280330 Coding 4 7736 aggtgaaatggcctccatat 72 24 1 280331 Coding 19 410 ctatcccagtcttcaaccat 71 25 1 280332 Coding 4 10900 ggaaactatcccagtcttca 76 26 1 280333 Coding 4 10949 ctggcttctgatttgacatg 85 27 1 280334 Coding 19 505 tagtattccacggtgcctct 71 28 1 280335 Coding 4 11917 actctgtcagtttctctctc 83 29 1 280336 Coding 4 11944 cagggatgttgtagtgttca 77 30 1 280337 Coding 4 11966 gcagttttgcaaaggaagaa 79 31 1 280338 Coding 4 11971 aaactgcagttttgcaaagg 88 32 1 280339 Coding 19 611 gaacgaccattagcaaatgc 82 33 1 280340 Coding 4 13750 cagtagaacgaccattagca 88 34 1 280341 Coding 4 13755 cagcccagtagaacgaccat 84 35 1 280342 Coding 4 13760 aaaatcagcccagtagaacg 81 36 1 280343 Coding 4 13765 tgtccaaaatcagcccagta 79 37 1 280344 Coding 4 13770 tccactgtccaaaatcagcc 74 38 1 280345 Coding 4 13809 atagccatcgtggactggaa 80 39 1 280346 Coding 4 13814 aggacatagccatcgtggac 82 40 1 280347 Coding 4 13819 gttgaaggacatagccatcg 82 41 1 280348 Coding 19 690 gccttgttgaaggacatagc 81 42 1 280349 Coding 19 695 acaatgccttgttgaaggac 82 43 1 280350 Coding 19 700 atttcacaatgccttgttga 83 44 1 280351 Coding 4 14168 agtaataaagtctccagcaa 83 45 1 280352 Coding 4 14188 aagagttctctgcactgcat 84 46 1 280353 Coding 4 14216 aggaaccaattcaatattca 74 47 1 280354 Coding 4 14402 gacctcgtaacctgaggcaa 81 48 1 280355 Coding 4 19035 gaagcttgaaaatcctggat 85 49 1 280356 Coding 4 19300 gaattcataatgaacagttg 76 50 1 280357 Coding 4 19360 aaataatccttctggaatct 60 51 1 280358 Coding 19 1151 tagagacctggtctgatatc 76 52 1 280359 Coding 19 1244 atacttggaggagttttctg 75 53 1 280360 Coding 19 1249 accgcatacttggaggagtt 74 54 1 280361 Coding 4 24940 ttgcaatcaatttcaaccgc 91 55 1 280362 Coding 4 24993 tagaatggagccgccaatcc 88 56 1 280363 Coding 19 1336 gaaaggtacccaaagaggct 77 57 1 280364 Coding 19 1340 tgttgaaaggtacccaaaga 86 58 1 280365 intron: 4 26318 acatctgttgaaaggtaccc 90 59 1 exon junction 280366 Coding 4 26323 aatccacatctgttgaaagg 77 60 1 280367 Coding 4 26359 acactgcttccctccttctt 86 61 1 280368 Coding 4 26365 ttctacacactgcttccctc 72 62 1 280369 Coding 4 26372 attttctttctacacactgc 82 63 1 280370 Coding 4 26377 agggcattttctttctacac 85 64 1 280371 Stop 4 26389 aactctttctcaagggcatt 81 65 1 Codon 280372 3′UTR 4 26472 attctacaaaagatggtcat 86 66 1 280373 3′UTR 4 26505 agtggaaattgaaatatgca 81 67 1 280374 3′UTR 4 26683 accaatccactggtaattaa 85 68 1 280375 3′UTR 4 26770 ctggaatggctaatttttat 67 69 1 280376 exon 11 38 cttcatctcaggcaacaaag 59 70 1 280377 exon: 11 528 gatgaataaagttcaagagg 49 71 1 exon junction 280378 exon 11 560 ccttgaaggttatcctgttt 79 72 1 280379 exon: 12 448 tgaataaaggctgtcaaaac 59 73 1 exon junction 280380 intron 4 12994 cacagtagacacacaatggt 74 74 1 280381 exon: 12 550 attagcaaatctggcactaa 39 75 1 exon junction 280382 exon 12 765 tgtggagatccttcacgcca 58 76 1 280383 exon: 4 484 ctcaggcaacaaagcggcgt 73 77 1 intron junction 280384 genomic 13 935 gttccccctctaaagtatgc 34 78 1 280385 exon 14 566 tggcccctgaaggttatcct 64 79 1 280386 exon: 14 577 attagcaaatctggcccctg 0 80 1 exon junction 280387 exon: 15 431 tagtattccacgggtaggta 51 81 1 exon junction 280388 exon: 16 1129 aatccacatcccaacacttg 63 82 1 exon junction 280389 exon 4 26937 accgtagtttttgaatttga 67 83 1 280390 exon 4 27120 gttctaagtgtgaatatggc 71 84 1 280391 exon 16 2815 attagaaacatggctgcgac 7 85 1 280392 5′UTR 17 199 ccaacttcattcccatcacg 25 86 1 280393 5′UTR 18 55 tccaacttcatctcaggcaa 71 87 1 280394 exon: 4 491 cacccacctcaggcaacaaa 65 88 1 intron junction 280395 exon: 4 688 gcggttacaaaccccacacg 70 89 1 intron junction 280396 intron 4 10819 ttgagaaattgtttctatga 74 90 1 280397 exon: 4 10936 tgacatgcattttgtaggta 88 91 1 intron junction 280398 exon: 4 12022 tcgtacatacttcaagagga 64 92 1 intron junction 280399 intron: 4 12927 gatgatgaataaagctgtaa 67 93 1 exon junction 280400 exon: 4 12971 ccaaaactgccttttccctg 77 94 1 intron junction 280401 exon: 4 13025 ggctgctcacctggcactaa 56 95 1 intron junction 280402 exon: 4 19575 atcacacatcccaacacttg 84 96 1 intron junction 280403 intron: 4 26324 aaatccacatctgttgaaag 85 97 1 exon junction

[0210] As shown in Table 1, SEQ ID NOs 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 72, 73, 74, 76, 77, 79, 82, 83, 84, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96 and 97 demonstrated at least 55% inhibition of human BAF53 expression in this assay and are therefore preferred. More preferred are SEQ ID NOs 55, 56 and 29. The target regions to which these preferred sequences are complementary are herein referred to as “preferred target segments” and are therefore preferred for targeting by compounds of the present invention. These preferred target segments are shown in Table 2. The sequences represent the reverse complement of the preferred antisense compounds shown in Table 1. “Target site” indicates the first (5′-most) nucleotide number on the particular target nucleic acid to which the oligonucleotide binds. Also shown in Table 2 is the species in which each of the preferred target segments was found. TABLE 2 Sequence and position of preferred target segments identified in BAF53. TARGET SITE SEQ ID TARGET REV COMP SEQ ID ID NO SITE SEQUENCE OF SEQ ID ACTIVE IN NO 196464 4 609 cgccggcagcagccatgagc 20 H. sapiens  98 196465 4 615 cagcagccatgagcggcggc 21 H. sapiens  99 196466 4 7380 attggatcctatactgtgag 22 H. sapiens 100 196467 4 7630 gaaagagatgacggaagcac 23 H. sapiens 101 196468 4 7736 atatggaggccatttcacct 24 H. sapiens 102 196469 19 410 atggttgaagactgggatag 25 H. sapiens 103 196470 4 10900 tgaagactgggatagtttcc 26 H. sapiens 104 196471 4 10949 catgtcaaatcagaagccag 27 H. sapiens 105 196472 19 505 agaggcaccgtggaatacta 28 H. sapiens 106 196473 4 11917 gagagagaaactgacagagt 29 H. sapiens 107 196474 4 11944 tgaacactacaacatccctg 30 H. sapiens 108 196475 4 11966 ttcttcctttgcaaaactgc 31 H. sapiens 109 196476 4 11971 cctttgcaaaactgcagttt 32 H. sapiens 110 196477 19 611 gcatttgctaatggtcgttc 33 H. sapiens 111 196478 4 13750 tgctaatggtcgttctactg 34 H. sapiens 112 196479 4 13755 atggtcgttctactgggctg 35 H. sapiens 113 196480 4 13760 cgttctactgggctgatttt 36 H. sapiens 114 196481 4 13765 tactgggctgattttggaca 37 H. sapiens 115 196482 4 13770 ggctgattttggacagtgga 38 H. sapiens 116 196483 4 13809 ttccagtccacgatggctat 39 H. sapiens 117 196484 4 13814 gtccacgatggctatgtcct 40 H. sapiens 118 196485 4 13819 cgatggctatgtccttcaac 41 H. sapiens 119 196486 19 690 gctatgtccttcaacaaggc 42 H. sapiens 120 196487 19 695 gtccttcaacaaggcattgt 43 H. sapiens 121 196488 19 700 tcaacaaggcattgtgaaat 44 H. sapiens 122 196489 4 14168 ttgctggagactttattact 45 H. sapiens 123 196490 4 14188 atgcagtgcagagaactctt 46 H. sapiens 124 196491 4 14216 tgaatattgaattggttcct 47 H. sapiens 125 196492 4 14402 ttgcctcaggttacgaggtc 48 H. sapiens 126 196493 4 19035 atccaggattttcaagcttc 49 H. sapiens 127 196494 4 19300 caactgttcattatgaattc 50 H. sapiens 128 196495 4 19360 agattccagaaggattattt 51 H. sapiens 129 196496 19 1151 gatatcagaccaggtctcta 52 H. sapiens 130 196497 19 1244 cagaaaactcctccaagtat 53 H. sapiens 131 196498 19 1249 aactcctccaagtatgcggt 54 H. sapiens 132 196499 4 24940 gcggttgaaattgattgcaa 55 H. sapiens 133 196500 4 24993 ggattggcggctccattcta 56 H. sapiens 134 196501 19 1336 agcctctttgggtacctttc 57 H. sapiens 135 196502 19 1340 tctttgggtacctttcaaca 58 H. sapiens 136 196503 4 26318 gggtacctttcaacagatgt 59 H. sapiens 137 196504 4 26323 cctttcaacagatgtggatt 60 H. sapiens 138 196505 4 26359 aagaaggagggaagcagtgt 61 H. sapiens 139 196506 4 26365 gagggaagcagtgtgtagaa 62 H. sapiens 140 196507 4 26372 gcagtgtgtagaaagaaaat 63 H. sapiens 141 196508 4 26377 gtgtagaaagaaaatgccct 64 H. sapiens 142 196509 4 26389 aatgcccttgagaaagagtt 65 H. sapiens 143 196510 4 26472 atgaccatcttttgtagaat 66 H. sapiens 144 196511 4 26505 tgcatatttcaatttccact 67 H. sapiens 145 196512 4 26683 ttaattaccagtggattggt 68 H. sapiens 146 196513 4 26770 ataaaaattagccattccag 69 H. sapiens 147 196514 11 38 ctttgttgcctgagatgaag 70 H. sapiens 148 196516 11 560 aaacaggataaccttcaagg 72 H. sapiens 149 196517 12 448 gttttgacagcctttattca 73 H. sapiens 150 196518 4 12994 accattgtgtgtctactgtg 74 H. sapiens 151 196520 12 765 tggcgtgaaggatctccaca 76 H. sapiens 152 196521 4 484 acgccgctttgttgcctgag 77 H. sapiens 153 196523 14 566 aggataaccttcaggggcca 79 H. sapiens 154 196526 16 1129 caagtgttgggatgtggatt 82 H. sapiens 155 196527 4 26937 tcaaattcaaaaactacggt 83 H. sapiens 156 196528 4 27120 gccatattcacacttagaac 84 H. sapiens 157 196531 18 55 ttgcctgagatgaagttgga 87 H. sapiens 158 196532 4 491 tttgttgcctgaggtgggtg 88 H. sapiens 159 196533 4 688 cgtgtggggtttgtaaccgc 89 H. sapiens 160 196534 4 10819 tcatagaaacaatttctcaa 90 H. sapiens 161 196535 4 10936 tacctacaaaatgcatgtca 91 H. sapiens 162 196536 4 12022 tcctcttgaagtatgtacga 92 H. sapiens 163 196537 4 12927 ttacagctttattcatcatc 93 H. sapiens 164 196538 4 12971 cagggaaaaggcagttttgg 94 H. sapiens 165 196539 4 13025 ttagtgccaggtgagcagcc 95 H. sapiens 166 196540 4 19575 caagtgttgggatgtgtgat 96 H. sapiens 167 196541 4 26324 ctttcaacagatgtggattt 97 H. sapiens 168

[0211] As these “preferred target segments” have been found by experimentation to be open to, and accessible for, hybridization with the antisense compounds of the present invention, one of skill in the art will recognize or be able to ascertain, using no more than routine experimentation, further embodiments of the invention that encompass other compounds that specifically hybridize to these preferred target segments and consequently inhibit the expression of BAF53.

[0212] According to the present invention, antisense compounds include antisense oligomeric compounds, antisense oligonucleotides, ribozymes, external guide sequence (EGS) oligonucleotides, alternate splicers, primers, probes, and other short oligomeric compounds which hybridize to at least a portion of the target nucleic acid.

Example 16

[0213] Western Blot Analysis of BAF53 Protein Levels

[0214] Western blot analysis (immunoblot analysis) is carried out using standard methods. Cells are harvested 16-20 h after oligonucleotide treatment, washed once with PBS, suspended in Laemmli buffer (100 ul/well), boiled for 5 minutes and loaded on a 16% SDS-PAGE gel. Gels are run for 1.5 hours at 150 V, and transferred to membrane for western blotting. Appropriate primary antibody directed to BAF53 is used, with a radiolabeled or fluorescently labeled secondary antibody directed against the primary antibody species. Bands are visualized using a PHOSPHORIMAGER™ (Molecular Dynamics, Sunnyvale Calif.).

Example 17

[0215] Targeting of Individual Oligonucleotides to Specific Variants of BAF53

[0216] It is advantageous to selectively inhibit the expression of one or more variants of BAF53. Consequently, in one embodiment of the present invention are oligonucleotides that selectively target, hybridize to, and specifically inhibit one or more, but fewer than all of the variants of BAF53. A summary of the target sites of the variants is shown in Table 3 and includes GenBank accession number AF285120.1, representing BAF53-b, the complement of which is incorporated herein as SEQ ID NO: 16, GenBank accession number AB061315.1, representing BAF53-c, incorporated herein as SEQ ID NO: 17, GenBank accession number AB060168.1, representing BAF53-d, incorporated herein as SEQ ID NO: 18, and GenBank accession number NM_(—)004301.1, representing BAF53-a, incorporated herein as SEQ ID NO: 19. TABLE 3 Targeting of individual oligonucleotides to specific variants of BAF53 ISIS OLIGO SEQ VARIANT SEQ # ID NO. TARGET SITE VARIANT ID NO. 280326 20 123 BAF53-a 19 280326 20 123 BAF53-b 16 280326 20 120 BAF53-c 17 280327 21 129 BAF53-a 19 280327 21 129 BAF53-b 16 280327 21 126 BAF53-c 17 280356 50 984 BAF53-a 19 280356 50 985 BAF53-b 16 280358 52 1151 BAF53-a 19 280358 52 1198 BAF53-c 17 280358 52 1053 BAF53-d 18 280359 53 1244 BAF53-a 19 280359 53 1291 BAF53-c 17 280359 53 1146 BAF53-d 18 280360 54 1249 BAF53-a 19 280360 54 1296 BAF53-c 17 280360 54 1151 BAF53-d 18 280361 55 1264 BAF53-a 19 280361 55 1311 BAF53-c 17 280361 55 1166 BAF53-d 18 280362 56 1317 BAF53-a 19 280362 56 1364 BAF53-c 17 280362 56 1219 BAF53-d 18 280363 57 1336 BAF53-a 19 280363 57 1383 BAF53-c 17 280363 57 1238 BAF53-d 18 280364 58 1340 BAF53-a 19 280364 58 1387 BAF53-c 17 280364 58 1242 BAF53-d 18 280365 59 1345 BAF53-a 19 280365 59 1392 BAF53-c 17 280365 59 1247 BAF53-d 18 280366 60 1350 BAF53-a 19 280366 60 1397 BAF53-c 17 280366 60 1252 BAF53-d 18 280371 65 1195 BAF53-b 16 280371 65 1463 BAF53-c 17 280372 66 1499 BAF53-a 19 280372 66 1278 BAF53-b 16 280372 66 1546 BAF53-c 17 280373 67 1532 BAF53-a 19 280373 67 1311 BAF53-b 16 280373 67 1579 BAF53-c 17 280374 68 1711 BAF53-a 19 280374 68 1489 BAF53-b 16 280374 68 1757 BAF53-c 17 280375 69 1797 BAF53-a 19 280375 69 1576 BAF53-b 16 280375 69 1844 BAF53-c 17 280376 70 50 BAF53-d 18 280383 77 44 BAF53-d 18 280388 82 1129 BAF53-b 16 280389 83 1743 BAF53-b 16 280390 84 1926 BAF53-b 16 280391 85 2815 BAF53-b 16 280392 86 199 BAF53-c 17 280393 87 55 BAF53-d 18 280394 88 5 BAF53-a 19 280394 88 5 BAF53-b 16 280394 88 3 BAF53-c 17 280402 96 1128 BAF53-a 19 280402 96 1175 BAF53-c 17 280402 96 1030 BAF53-d 18 280403 97 1351 BAF53-a 19 280403 97 1398 BAF53-c 17 280403 97 1253 BAF53-d 18

[0217]

0 SEQUENCE LISTING <160> NUMBER OF SEQ ID NOS: 168 <210> SEQ ID NO 1 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Oligonucleotide <400> SEQUENCE: 1 tccgtcatcg ctcctcaggg 20 <210> SEQ ID NO 2 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Oligonucleotide <400> SEQUENCE: 2 gtgcgcgcga gcccgaaatc 20 <210> SEQ ID NO 3 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Oligonucleotide <400> SEQUENCE: 3 atgcattctg cccccaagga 20 <210> SEQ ID NO 4 <211> LENGTH: 28001 <212> TYPE: DNA <213> ORGANISM: H. sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 17628, 17629, 17630, 17631, 17632, 17633, 17634, 17635, 17636, 17637, 17638, 17639, 17640, 17641, 17642, 17643, 17644, 17645, 17646, 17647, 17648, 17649, 17650, 17651, 17652, 17653, 17654, 17655, 17656, 17657, 17658, 17659, 17660 <223> OTHER INFORMATION: n = A,T,C or G <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 17661, 17662, 17663, 17664, 17665, 17666, 17667, 17668, 17669, 17670, 17671, 17672, 17673, 17674, 17675, 17676, 17677, 17678, 17679, 17680, 17681, 17682, 17683, 17684, 17685, 17686, 17687, 17688, 17689, 17690, 17691, 17692, 17693 <223> OTHER INFORMATION: n = A,T,C or G <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 17694, 17695, 17696, 17697, 17698, 17699, 17700, 17701, 17702, 17703, 17704, 17705, 17706, 17707, 17708, 17709, 17710, 17711, 17712, 17713, 17714, 17715, 17716, 17717, 17718, 17719, 17720, 17721, 17722, 17723, 17724, 17725, 17726 <223> OTHER INFORMATION: n = A,T,C or G <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 17727 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 4 gcgcaaaatt tttacttttt caacataaaa gttagtttaa aatacttttt ctgaagaaaa 60 aaagaaagaa atccgcattc cccacagtca ctggacagga atctcggcgt ggagacaccc 120 gttcaatttc caggggtcta ccttccccta cccgggttcc cgccgctcct cagcgcccag 180 acgcacctcc tagtcccgcc cccatgcttc ttccagcctt cctccttctt ctcccactgc 240 ctccgcccat tccctcgccc acccgggaag ctccgccccc tccagctccg caacccaact 300 ccttctgtcc tgctgtcgct ttcctctttc ccgcccccat ggctgccttc gattggctaa 360 acctgctggg ccgcggcggg gatgcggcgc agccgcattc tgattggcta gacttaggcc 420 tggaccctag tgattggctg ataggaggag ccagcaagtg tggctgagct ccggggtgtg 480 tggacgccgc tttgttgcct gaggtgggtg gcggtggaag ttaagggagt caggggctat 540 cgctcctcga gactcgcagt cgcggccact gcagtcactt cgccagttag cccttagggt 600 aggagtcgcg ccggcagcag ccatgagcgg cggcgtgtac gggggaggtg agtgagtgcg 660 gccggacgag agagcgcgcc ttttcggcgt gtggggtttg taaccgccgc tcccagccct 720 cccctccccg gcgttccctt ccggtctccc cctctcggga ccccggcctc cccgccccgt 780 ccccgcccca cgctctgccc gcccccggag cccacccggc tcgccgtgct cctcgggctc 840 cctgaagtgg cggctctctg tggcctcttc ctgcctctgt ccccggagga gcagggtttt 900 ggggtgcgcg ctcggttctc tagggagcct cggggctggg cgggaggctc agtctagccg 960 gccgccgggc cccggcttgg gtgaccgccc cagggtcgca tctccccgag tgcctcctgg 1020 actcagctgt gtcgggacgc gtgtgcgccc gcctaaactt ggaaggtccc ggcggtttgc 1080 aagcgtggac ggagggttcc cagagtgtcc cataggtggc aaagcgagcc tcaagccgta 1140 gaactgacta gggaagcggc ggccacttag ggtactgcct cctccccgtc tgcgccccat 1200 gcgcgagctg cctcaccttt cagtaactct tgcctgtttt ttggctgcgg agtctccaga 1260 gtgactcgtg ggcgggtctg tttgagatca attcaggagc acgtgtaatt taaggatgcc 1320 cagaaagttt gctgggggtc ctaggcgtgt tattttttca ctttctttga ttagactgtg 1380 gtgtggtagg aagattacca ggtgccgggg gttacagacc tgggttgaaa tatccacctc 1440 actctttatt aagcgctttg gtcttgggca gtttatgtaa ctttccaact tcaggcctca 1500 tttatggaat aattcctagc cgatgggggt gggcatgaag gttaaatgaa ataatgctgc 1560 atttgccact taaagtctgg cccatggacc agcagtgtca gcatcacctg caagcctgtt 1620 agaaatgcag gatctcacgc gtcattcaga atctactgat ttagagcctc catttttgca 1680 agatctgcag gttaatcgaa acactgatac atataattca tgtgttgggt tgtgtttgat 1740 gagttagaga cccagaaaac aaatccagac tattgctgtt gttactgtgt ctagtagtga 1800 tgctgtttct ataaaggatg tcattttaca ggtaggaaac aacaaaaata agatttttcc 1860 ttcatgttcc ccaagaaaat cacatcaccc ctaaacttgg aaggagaaaa acattaaaat 1920 cctcaaaaaa gacaaaagcc tttttagtag agtagaggtt caattcttga ggatttttat 1980 agactagaaa ttgcatccta ggttttaaac atccagaact ctgtggttct attaagcctc 2040 ctgcctccca tggccactct cctactttgg gttcatgggg cttgattttt aatgaagcag 2100 ggtacaggaa ttagatgtat ctcccatcct ggaaaaggaa cagatgtaaa attctgagaa 2160 tttagagtct taaattaaaa ttccaccata tccagtttac taaactaatt aggacaggaa 2220 aatgagctga tatgttggat tttttctatt tcacaaaaat gttttttgag tacttgctat 2280 gtggcaggta taggctcttg tcatcaagaa gctcagtctt gtagatgagt ctgttaggta 2340 aatagacacc gtatttcact gattcttcgt tgtacatttt ttcccacatt taaacagctg 2400 aagttggaat atgtcttttt tttttttttt tttaatagag atgggtcttg aactcctgag 2460 ctcaggcggt cttcccacct cagcctccca aagtgctagg attacaggtt tgagccactg 2520 cccccagtca gaatatgtct taacagtgct ggcgtggcag agtttaattg ccatattatt 2580 ttgttagtga tgcaggaaat agtggtgcat catgtagttg atagcatctt atattgatca 2640 gaaatggtaa ctgtaattca atgagagatg ttcattgata acaatatgta gaaggggccg 2700 ggtgcggtgt aatcccaaca ccttgggagg ccgaggcggg cggatcactt gaggccagga 2760 gttcaagacc agcttggcca acatgacaaa accctgtctc tactaaaaat acaaaaatta 2820 gccaggcgtg gtggtgcatg cctggagtcc cagctgctgg ggaggccgag gcacaagaat 2880 cgctcgaacc tggaactgca ctccagcctg ggtgacagag cgagactcta tcctaaaaaa 2940 aacaaaaaca aacatatata tatgtgtgtt atatatgtta tatatattac atatatgttg 3000 tatatattat atattatatg ttatatatgt cctatatata catatatata gtgcaaaggt 3060 agctcagaga ataaagttat tgattccgtg tggtggagtc aagggacttt acaatagagg 3120 taatggggat gatggaggag gagtggaaag ggacagcata tgcaaaggtt agctgagtga 3180 gagtatgtgg tgcgttcagg agatgacata ttacccagta agttagtgta tgaggcagga 3240 agtgagactg ctaccagatt ttgctacacc ttgaatttca actggctaga gtgatttaaa 3300 ttttatcaaa tacagtgatg agaaaccacg gaatgattca ccccctaatt ttttttgaag 3360 gatttatgta ccaaaataat gacagttaca gtattgaaag atcatagtgc agcagttgga 3420 agggtggatt gaagaggcaa agaggtggag gcacaatatc tgtagggaat tgtagtttcc 3480 cggttgagat aagagctcga ttgaaggcag tggcaatggt attaaaaagg aggggatttg 3540 agaaatactt agcagaaata tttggcagaa cttgaaagat ggaggtgttc acaaaaactc 3600 tcagattttt gccagtgtgg actggtggtc agcaatgtgt taggcaatgc tgagatcagc 3660 agtgcttcag atgtgttgaa tttgagatac ccatgaggca tcagatgcaa ttatgttgat 3720 gtacagtgaa aagttcagga tatggatgta gacactggtt agagcttgag agagagagag 3780 atttgaaatt ggaattatca gtatttaggt agaagttgaa gctataggag tagaatatat 3840 tacccaggaa agggtaaatt agggaaggag ctcctaacat agggtttgtg gccttcccaa 3900 agtttccatg gtagaactat attttattat aattggcttc ttttataaac atttaaaaac 3960 attctaagaa gggattcata atttcctaaa ctgtattagt ttgtagggct gccataataa 4020 agtaccacag tctgtgtggc ttaaacaaca gaaattagtt ttctcacaat tctagaggat 4080 agaggtagat ctaagtgtca gcagagttgg tttcttctga ggtctgtctc tgtgtgtaga 4140 tggccatctc ctcctctgtc ttcacatggc cgtccctctg tacaagtcca agtctgaatt 4200 ttctcttttt gttgttgttg ttgttgttgt tgtttttgag actgagactt gctctgtcac 4260 ccaggctgga gtgcagtagc acgatctcag ctcgttgcag cctccgcctg ccgggttcaa 4320 gcaattctcc tgcctcggcc tccagagtag ctaggactac aggtgcatac ggccacgccc 4380 ggctaatttt ttgtattttg ggtagagttg gggtttcacc atgttggcca ggatggtctt 4440 gatctcctga cctcgtaatc tgcccgcctc tgcctcccaa agtgttgggc ttacaggtgt 4500 gagccaccgc gcgccctgcc tgaattttct cttaaaaaca tcactcatac tggattagga 4560 cccaatctaa tgatttcatt ttaacttaat tacttcttca aagattctgg tttcaccggg 4620 catggtagct cacgtctata atcctagcac tttgggaggg caaggcgagt ggatcacctg 4680 aggtgtggag tttgagacca gcctggccaa catggtgaaa ccccatgtct actaaaaata 4740 taaaacctag ccgggcttgg tggccagcag atgtaatccc agctactcag gaggctgagg 4800 cagaagaatc acttgaaccc cggaggtgga ggttgcaatg agctgagatt gtgccattgc 4860 accccagcct gggcgacagg agtgaaactc tgtctcaaaa cataaaaata aataaataaa 4920 taaagaataa agactctggt ttcaagtaca gtcacattct gaggtactag gggttaggat 4980 tttgacatat gaattttagg gcgacacaat tcagtccaca acactgtcat aagggtccat 5040 aacacagaac aggttaaggg ctcctggcgc agggcaaaag ataaatcctt gaggaacaga 5100 agttgaaatt tttggttaac tatacaatta attcatttaa ttaggatatc tctttaccca 5160 gcattctggt taataaaagt attaaatttt accaactcat attcattgct atacttacga 5220 tttgtactca agtttaggtg ctgtggtgaa aacaaataca gtgttctcct tttaaggacc 5280 ccctagtttc tgacaaaata atttggacca gagaatttca cagggaaggg ttaattatct 5340 tgagaaatgt aacaaatacg taaactttct tttatattag aaattaaaat atgtctctgt 5400 tttatttgaa taaaaatgag aggctgggcg cggtggctaa cacctataat cccagcactt 5460 tgagaggcca aggcgggtgg atcacgaggt caggagtttg agaccagcct ggccaatatg 5520 gtgaaacccc atctctacta aaaatacaaa aattagctgg gcatggtggt gcgcgtctgt 5580 agtcccagct gctcaggagg ctgaggcagg aaaatctgtt gaacctggga ggtagaggtt 5640 gcagtgagcc gagatcacgc cactgcactc cagcctgggc agcaatacag caagactccg 5700 tgtcaaaaaa aaaaaaaaaa aaagagatca ttctgcaaag ctactgtctc ttaactgata 5760 cttgcaaagt aatgggtttg attttaaaaa ttttaagttt ttgaaatatt ttaaacatat 5820 taaaaatatg taagtttgta tgtgatatta ctgtaatcac ctgtaagttt gtatgtaata 5880 caatactgca ttcaccagtg agattaaata gatgtcatat tttgccatat taatacctca 5940 gatattttaa gaataaaaat gttattgata cagatttcct ctctctccct tcttcagttc 6000 atgtaaccac tgaactgaag ttggtatgta acattcccag accccatgca tattttcttt 6060 tttttttttg agacgtgtgt gtgtgtgtat atgtgtatat atgtatgtgt atacatatgg 6120 ttttttgata actagctttt aaaactaagc attcttttag atttattgat gctgacatat 6180 gtagatctaa agtgttcatt tgaactgctg tacaggattc cattgtgtga atatattatt 6240 gcttatctat ttccctgctg agagaccatt agattatttc tgccttttcc tatggcaagc 6300 agtgtgtcaa ttataatagc agcttacact tagcatgtgt attttctaag acttcatata 6360 catgaaagca cttaacatgt ttaatcatta gagtatcctg tgagataaga gctattatgt 6420 acattttaca tattaggaaa ctgaagcaga gaggttaata aattgctcag ttcttgtagc 6480 tgttgaacat tcttttgcat gtctccttgc aacctgtatg agagagtgtc tccagaataa 6540 gtaagtgtaa ttctatgtat gcacaatttc aactttaata gatatgacta aattgcccat 6600 agtggttgtc ccactttgga caataaatta tagaatcacc ctagttgatg gtggagggag 6660 gttgctggta tatttattag cctggttcat tcacctcagg gtaatccatg gctaactgca 6720 tcccctctac taaaagtcac agctcctgtc aggtagccct ccccatacaa ctttctctcc 6780 agattctgat aacagttatt tcttcttgtt tcttcagttt gaagaatggc aatggatcca 6840 ttattattag ttatcattat agtactgggg tactgtactg tcccttctgg ttgtcctgta 6900 tttcacctat atctttgcaa ataattccct ttaataagta aactgaaatt acccagtttt 6960 agtgtaccat ttcttaactg attgaacctc tacttaaata cggtgtatgc cttgttatat 7020 tttaattaaa tgattcttta aggtgtattt gaaactaggt tcaagtgagt aataatatga 7080 atataattgg gctgagtgca gtggctcatg cctgcagcac tttgggatgc tgaggcagag 7140 gattgcttga gccctggagt ttgagtccag cctgggcaac atagtgagac cttatgtcta 7200 caaaaaattt aagaaattca ttgtagtccc agctatttgg aagactgagg cgggaggatt 7260 gcttgagcct aggaggttga ggctgcagtg agctgtgatt ttcatatgat acttttgcaa 7320 gctgttaatg ctaattatct ttaatctttt cagatgaagt tggagccctt gtttttgaca 7380 ttggatccta tactgtgaga gctggttatg ctggtgagga ctgccccaag gtaagtgtaa 7440 tgttagagtt aattggatat gtaaagccat tcatgtaaat taaatttatg cagaaattct 7500 gattcaaaac aaaatataat aaaatacatt aattggggaa aaaatgcctt cttgatgaaa 7560 ggtgaaactt gtatgtcatg tttctgactc ttacaggtgg attttcctac agctattggt 7620 atggtggtag aaagagatga cggaagcaca ttaatggaaa tagatggcga taaaggcaaa 7680 caaggcggtc ccacctacta catagatact aatgctctgc gtgttccgag ggagaatatg 7740 gaggccattt cacctctaaa aaatgggatg ggtatgatgt tttccccatg gaattgatta 7800 tggagtgtac atgttatatt ttagatacaa agtagtagct tcctataagt tgaacatcaa 7860 ccatggtttt ttgttttgtt ttgtttttta ttccacaaac tgatttccag acactgagaa 7920 tacaaagatg cataagaaat gttccttttc attaaaagct tacagttagt tgggggaaat 7980 agatgtatat atacaaataa tggtacactg tgggataagt ggtacaatat aggtatgtgc 8040 aatgagcaat gggattagag aggagaggta tttgactcta gtgttgggag tcagtgatgg 8100 ttttcacaaa ggaggtaaca tgatgaatct tgatcaatga gtaagaatta gcttggctga 8160 caaagctggg taaagcaaag ggaccagcat gtgtgaaggg atggaattgt gaaagaaact 8220 tatgtgcttg aaaatgtaat acaattaagt atggttgcag cattgggctt attagggtca 8280 gtagcaggaa aggtaggcag agagcagtag caggaaaggt aggcagggag cagtcataaa 8340 agggcttgta aaccatccca gggttgtatt aagctagtga ctgaaggata accccaaagg 8400 aatttaaaca gatgtgatgg tcagagtcca gatgagaaat gaaaaaggtt taaactatta 8460 tataatgctg gtagagattc tgaagggact ttcagggtaa ccaggagaca aatggtacta 8520 aatgatcgag ggagtgaaag caagagagaa gttgagaaag tttcctagat ttttggttgg 8580 ggtaactctg aacagagagt accatgcatt gagataggaa tataaaggga aggagcaagt 8640 gttacggttt taaaaggcat ggttggccat gcgtggtggc tcgcgcctat ataatcccag 8700 cactttggga ggctgagact gtgggtggat tgcttgagtc taggagtttg agaccagcct 8760 gggcaacatg gcgaaacccc atctctacta aaaatacaaa aatttgacag gtgtggtgat 8820 gcgtaccacc tgtaattcca gctacttggg aggctgaggc atgagaatca cttgaaccca 8880 ggatgcagag gttgcagctg agatctcatg actacacacc aacctgggtg acagagtgag 8940 actctgtctc aaaaaaaaaa acaaaaaaaa aaaacaagct tatcagggat agccaaaatc 9000 actctcaggt tcaattattc accagcaaga ctcactcaca ggactcagca tatggttgta 9060 ttcacagcta agatttattg tactgaagat tcagatacaa aacaaaatcg acaaagggaa 9120 aagggacagg ggatgatgaa gtccagatac aggctttgga gagtcttctc acagtggagt 9180 cacacaggat gtgcttaatc cctccagcaa caagttatga tctgtgttac cttccaggag 9240 aactctgagg ctcagtaccc aaggatttta cagagggctg gttatgtagg taccatctac 9300 ctggcatgta acaaaatttt agattctcag aaggaaagca agtgttcaga acaaaccaca 9360 ttgtataaac agtgtaggta tagcgagcta cccttaccat ttagggacaa gttttatatg 9420 aacataggga actgtttgcc agtcatgttt ccagacacca gctaagagtc agccttacaa 9480 gcaggccttt ctcaggcttg cagtgttaac tctttcatgt gtagtaagta aatgggttca 9540 ctgagttcaa agtacttaga acatccaggt gataattcag taaacgggaa taaaaggtta 9600 taagaaagat tttaagacat ggagttgcat tttattactc tgaaaaaaat tggaacatga 9660 gaagaggatt gaagatggag ttctagcaaa aacttgttgt atattttaac caatagagaa 9720 taaaaggtac ccttgaagga gaaagaaagg gaacaattag ggatgtagga aaaaaagcag 9780 gggaagaaca agaaaagaaa aagtttctgg aagcataaaa ttccagttat tctcggtgtt 9840 ttctgctgtg acattgaaag ctttacacta agaaagaagt taaaaaaatc caggtgggcc 9900 tgtggaaata tataattaat gacatttttt ctttgggctg tgacagaaaa gtttgtaaac 9960 tcttgtgtag gcaatactgt cataatttag agaagtcaga tgagattaaa aatgttaagt 10020 atccatgaat ttgcctagta gaaggtcatt agtggctggg ggcggtggct cacgcctgta 10080 atcccagcac tttggaggct gaggtgggtg gatcacctga ggtcaggagt tcgagaccag 10140 cctggccaac atggtgaaac cctgtctcta ctaaaaatgc aaaaattagt tgggtacggt 10200 ggcgggcacc tgtaatccca gctactcggg agcctgaggg aggagaattg cttgacccca 10260 ggaggcggag gttgcagtga gctgagattg tgccattgca ctccagtgtg ggggacagaa 10320 cgagactcca tctcaaaaaa aagaaaaaag aaggtcatta gtgacttatg tcagtagttt 10380 taatggaatg tttaggtgga agccaaattg aagacagatg ctcttctttg aatttttaac 10440 atgtctttta gtctttttcc aaatagattg taagtttttt tgagtgtcgg gtctagacca 10500 tacaattctt tctttttttt ttttttttat aaatccagca gtagtatcat cagaaggcca 10560 tacaattctt ctgtacttcc tattatcatt ctgatcacat tctgggcctc taataagtat 10620 ttattgaatt gaataacatt tacttcatat tttaggtctg ttagattaat tacatttggg 10680 acaggtctgg gggctggagg gaccaaaaag aagttctata tatctagaag gcaaaggtaa 10740 tctctatata aagtaatgtg gtatgaagtt gatctgtaaa atcagtaggt tctgtatact 10800 aaagtattaa ttgttaagtc atagaaacaa tttctcaaaa gatgctatat tcatcttcaa 10860 ctatgcatta tttccaagtt actaatctta tattctagtt gaagactggg atagtttcca 10920 agctattttg gatcatacct acaaaatgca tgtcaaatca gaagccagtc tccatcctgt 10980 tctcatgtca gaggcaccgg tgagataaag attttctttt tcacgtttct ctagttgttt 11040 tttttttttc tttttttttt cctttagttt tctactcatt tgatgaacat ttttctttaa 11100 agaggcatag aaattcatat tttgaatttg aaaattaggg aaaaggatta attttttaac 11160 actattataa cttttatttt actattccaa taaataaaat atccagagaa caacaaaaca 11220 ccctaatgga ttcttgtggt tatttatgta tttctaggga tttgtttaac attttatttc 11280 ctaggactgc ttcccatttt gaattatgaa tcatttcttg tgccccaagg gcagcgtata 11340 tctactttta ttcaagtttc caagaaagaa ttgagatgtt gaacaagggc tggaaatttc 11400 tggaccaaag tctcttgtga aatacatttg gtacatagac aaaaaggtcc cagaaagcaa 11460 gcataatggt cataaattat cagtatctta ttgttactaa cttacagtat tcttttatga 11520 ataccaacta taagtgggag aatttggtgg tctaaaattc atacttagga tttggattac 11580 catatttact ctttagattt aataatatgt ttataagaat cctggtttcc tcatatgtgg 11640 aaaagtcagg agcaatttta ttattaaaga attttaattc ttctctgata gatttattaa 11700 atttaatcta catctaaaga aataaatatt atagaggttt ttttattttt atgagatatt 11760 atgaaagatg atttcccatg gtattttatt ctgttcttaa tgttttatat ctttgttaat 11820 atagtgctag attttatctg gagataaatc aactttttaa ttcttaataa cttgcatttc 11880 tttttcccct cttctcaagt ggaatactag agcaaagaga gagaaactga cagagttaat 11940 gtttgaacac tacaacatcc ctgccttctt cctttgcaaa actgcagttt tgacagcgta 12000 tccttgaaag agtaatacct ttcctcttga agtatgtacg atactaatga atatgataac 12060 tctgggagaa gacatacgcc aattattgct tgttccgaag ttgttttttt cccttttctc 12120 ttgcttttta gctattcatc ttttagtatt tcttgttaga actgatgata caccagaagg 12180 tatgagggaa ataaaataac actcaaattc tgagtgttaa gacgtttttg tttttgtttt 12240 taagaagggg catgtggata gaaggcaatg ttttaaccag ttggcttagg tgaattgaaa 12300 gattgccatt ttaaaatctc cttcccttcc aatatcatag aaaactggaa attggctgta 12360 aattcattct ccttcaaatt tagtcagtca tcaaatcctg cctgttcttc cctgctattt 12420 gcttctctct gtcctactgc cacagcatta ggtggaagct atttccagga ttactgaagc 12480 acgtcctctt gtctgcccat tctttacgct gttgctctaa taatctttct atttttattt 12540 atttatttat ttggtagaga tggagtttcg ccatgttgcc caggctgctc tcgaactcct 12600 ggactcaagc gatatgcttg cctcagtctc ccaaagtgct gggattacag gcatgagcca 12660 ccgtgcccag cctctaataa tctttctaaa gtgctagtct gctttaagcc agaatcgtct 12720 tctacatttc ttcctttatt ttactttcag accgtgctga ggtacttgca gttctctgac 12780 ctcgctgtgt tctcttgctt cttggtcttc ccacatgctc ctactcttgc ccatattccc 12840 ttccccagat tttactattg aatatctcag gaataggttt cccttttaca tcaccatctt 12900 ccctgggaca tcctgagctt ttctttttac agctttattc atcatctact tcactaaaca 12960 ggataacctt cagggaaaag gcagttttgg tgcaccattg tgtgtctact gtgttaaagg 13020 aattttagtg ccaggtgagc agcctccctc cttcctccct ccctccttat taagcaccag 13080 acttagtaga cacctaatag atgctcagta aatatttgat gaatgagtga atgtccctac 13140 tcctaaacat cagtttagta tattcaggta gtataggcca tctgcagcac agaactgtgg 13200 aaaatgggat ctgccaatat ttaccaactg tggaattcac ctggaatagt tttcccgctc 13260 attgagttgg aggagatagg aactgccata tggctgccaa actgctgaaa cagctctttt 13320 tcaatgctat gtgagaatgg ttatagtccc tagctcaatt atcacaacct cccactgttc 13380 ttaccaagtt tctgtatatt ttgttaaata aatgcatctc agtttgttgt aagctctttg 13440 atcagtctcc agagactttt agtgattgtg ttaattttga ccagcttaat agtagctgtt 13500 cctaggataa aggtttccct gagtgcctga tacctccatt ctggaattcc tgcctcttac 13560 tatttgtttt taagccagaa atattatttt ataccaattt ttatccctag attcactgta 13620 atacattttt aactataagg tacatgttta agaaatagtt tctgaaacat tataagagcc 13680 tgccctttac aataaacatt attttagcgg ccttgatact ttcttttcct taatgtttta 13740 aactagattt gctaatggtc gttctactgg gctgattttg gacagtggag ccactcatac 13800 cactgcaatt ccagtccacg atggctatgt ccttcaacaa ggtaaatgta tttaaccagg 13860 atacactgag atgattttag atgccatgag gatgcacata atgaaataaa atgatgagta 13920 gcactattaa agcatatcag tttctgaata agattttttt taagtatgtt aaaaatcttt 13980 agtatataat gtatatttaa aactgatgca tggctttatt tatgtgttga aggatagttc 14040 agttcattct acctgaaaaa gttattcaca taaatacacc cacagaggaa attcgttcaa 14100 ggaagtttgg acttactgcc ctcttagcct tgtttcatct gtttcatagg cattgtgaaa 14160 tcccctcttg ctggagactt tattactatg cagtgcagag aactcttcca agaaatgaat 14220 attgaattgg ttcctccata tatgattgca tcaaaagtaa gtaattattg aattttcttt 14280 gtagaactta cttctagctc ccccacccct atgaagtgaa ctccattaac ctagcatctc 14340 ttggtactct caggaagctg ttcgtgaagg atctccagca aactggaaaa gaaaagagaa 14400 gttgcctcag gttacgaggt cttggcacaa ttatatgtgt aatgtaagta accctcattc 14460 tctttacaaa aatgttacag gctttttgca tgagtattaa aaaaagttat atataggctg 14520 taaatccttg agtaaaatat gggcacttta tattttcaag ctctttattt tttttattac 14580 taaatacatt ttgaagatta aatagaacat gatctcaggg tcacactcta tatttttaat 14640 gatattttac taacaaaaga gcttttctgt gagaggcatg cttttcatac ttgccaaaca 14700 aatctctaca aattactaca tactcacttg gattactatg gtgagacctg gaaggaattt 14760 tggttttatg ctattctgaa catttttggc tgagaaaatg gttttaggtt ttgtagaggc 14820 ctactagtat gtctcagtta tgttctgttt cccagcatca gtcagcaata tcaaaaatgt 14880 gtttttgttc agaacaagga acccatgaga gattctcttt actaaaaacc catctctgaa 14940 catatggctt actgatgggg aagaggttag taaaacaacc tgatgccaca gatacgcctt 15000 aatttcttaa aaaaaaaaca aaaaaaaact gttactttag gttcaggggt acatgtgcag 15060 gtttgttaaa tgggtaaact catgtcacgg aagtttgttg tacagattat tgtcccccag 15120 gtactaagcc tagtacccaa tagttatttt ttctgctcca ttccctcgtc cctcagggag 15180 gtccaactgt ctgttgttcc cttctttgtg tccatgtgtt ctcatcatct agctctcact 15240 tgtaagtgag aacgtgctgt atttggtttt ctgttcctgc attagtttgc tgaggataat 15300 ggcctccagc tccatccctg ttccttcaaa ggacatgatc tcattctttt tttttttttt 15360 tcactacata atattctgtg gtctgtatgt accacatttt cttaatccag tcttccaccg 15420 acgggcattt aagttgattc catgtctttg ctattgtgaa tagtggtgca gtgtacatac 15480 acatacatgt gtctttatga taaactgatt tatattcctt tgggtatata cccagtaatg 15540 agattgccag gtcaagtggt agttctgggc caggcatggt ggctcacgcc tgtaatttga 15600 gaggctgagg tgggtggatc ccttgagctc aggagttaga gaccagcctg ggaaacatgg 15660 caaaaccctg tctctacaaa aacagaaaaa ttagctaagt ggggccgggt gcagtggctc 15720 acgcctgtaa tcccagcact tggggaggcc gaggcgggtg gatcacctga ggtcaggagt 15780 tggagaccag cctggccaac atggtgaagc cctgtctcta aaaatataaa aaaattagct 15840 gggtgtggtg gtgggtgcct gtaatcccag ctacttggga ggctgaggca ggagaattgc 15900 ttgaacccag gagatggatg ttgcagtgag ccaacacggt gccactgcgc tcctgcctgg 15960 gcgacagagt gagactccat ttcaaagaaa aagaaaaatt agctaagtgt gggggtgtgc 16020 acctttagtc ccagctactt gggagactga ggtgggagaa tcacctgagc cctgtgaggt 16080 cgaggctgca gtgagctgtg attgtaccag tgccttctag cctgggtaac gagtgagaac 16140 ccatctcaaa aaagaaaaaa aaacaaatgg tagttctgtt tttagctctt tgaggaattg 16200 ccacatggct ttcaacaatg gttgaactaa tttacattct caccaaaagt gaataaacgt 16260 tcgcttttct ctgcagccgt gtcagcagca tctgttattt atttaatttt ttcaagacag 16320 agtcttgctt tgtcacccag gctggagcgc agtggtgcag tctcggctca ctgcaacctc 16380 catctcctgg gttcaagcaa ttctcctacc tcagcctcct gagtagctgg gactacaggt 16440 gtgtgccacc acacctggct aatttttgta ttcttagttg gccaggctgg tctctaaccc 16500 ttgaccttgt gatccacccg cctcagcctc ccaaagtgct gggattacag gcgtgagcca 16560 ctgtgcccgg ccctattttt tcacttttta ataataaata atagccattc tgactggtgt 16620 gagatggtgt atcattgggg ttttgatttt catttatctg atggtcagtg atattgagct 16680 ttttttcata tgctgttggc cgcatgtatg ttttcttttg aagtgtctat tagtgtcctt 16740 tgcccacttt ttaatgaggc tttttgttgt tgttgttcct tatagaagct aggtattaga 16800 cctttgttag atacatagtt tgcaaatatt ttctcctatt ctgtaggttg tttgcttact 16860 ctgttgatag aaattaatgt gtatccagca aaagaaacta agagtaaaat tatatgagtc 16920 ataatttact atgagaggga tcatatctaa caggtttttt aaaaattatt ttatttatat 16980 catatacaca cacacacaca cacacacaca cacacacaca ttttaaagac agggttggct 17040 gggcacggtg gctcatgcct gtaatgccag cactttggga ggccaaggca gtggatcact 17100 tgaggcaagg agttcaagac tatcctggcc aacatggtga gaccccatct ctactaaaaa 17160 tacaaaaatt agctgggttt ggtgctgatc tcctgtaatc cgagctactt gggaggaata 17220 agaagaaaga ttcacataga agagaggaga cgcagatagc cccacccccc agcgccggca 17280 ccgccccaag ggggcggtgg agtgagagta aatgaccaag tgcggccggg cgccccggga 17340 gggaggggaa gggagcgcat atataagagg gcgcgggggg gagtatagag agagagctcg 17400 agcgcgaccg agcgggagga ggagaggaaa gagagaggga gaggagagga atagagaaaa 17460 agtggggagg aagtaaggag aagaggggag ggaaggagag aggacgagca gaaggagaag 17520 gaaggaggga gaggggaaaa gaaaggaaga gaaaagagaa agcgagagag agaggggaga 17580 agagggagga gtgagtaaaa gaggggagaa agtggataga gaaagcannn nnnnnnnnnn 17640 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 17700 nnnnnnnnnn nnnnnnnnnn nnnnnnngta atgagattgc caggtcaagt ggtagttctg 17760 ggccaggcat ggtggctcac gcctgtaatt tgagaggctg aggtgggtgg atcccttgag 17820 ctcaggagtt agagaccagc ctgggaaaca tggcaaaacc ctgtctctac aaaaacagaa 17880 aaattagcta agtggggccg ggtgcagtgg ctcacgcctg taatcccagc acttggggag 17940 gccaaggcgg ggggttccct taagcacaga ggttgaagct ctgctgggcc accagggtag 18000 agcccagttt ttctaaatat acaaaaatta gctgggtgtg gtggtgagcg cctgtaatcc 18060 cagctacttg ggaggctgag gcaggagaat tgcttgaaca tgggagatgg aggttgcatt 18120 gagccaagat tgtgccactg cattccagcc tggacgacaa gagcaagact ctgtctcaaa 18180 aaataaataa agacagggtc tctctctgtc acccaggctg gagtgcagtg gtgcagttgt 18240 agttcactgc agtctcaaac acctgggctc cccctgcctc agcctcctca gtagggagga 18300 ctacaggtgc atgccaccat gcctggctaa ttttttattt ttatagagac agtgtctcgc 18360 tatgttgccc aggctggtct tgaactcctg gcctcaagcg atcctcctgt ctcggcctct 18420 taaagtgctg agattacagg tatgagccac tgcatccagc tctgacagtt tttgcaccta 18480 aagataaaga ttttgtctgt gtgcacatgt aatatacgag gaaaaattag gatgattagt 18540 catttttcct agatattaga caagattttt ctagaggtcg tgttagttca caacatttta 18600 ttaaactgtt ttatactatg tacagtcatt aaaagttgca taaaatgtga tgtacatgca 18660 catgtgtata tgtaggtaat gaaatcttgc ttctaatcta gcttattttt aaggagaaag 18720 tggtgttctg aaattggttt tgttatgcag aactgtggtg caggggttcc tgcacctgca 18780 gttatttatc tctcatttca taactgttgt aacttaaatg tgtgtaatta acttctaatg 18840 caaatgatta gaattaggtt tcttgatact cagaatcctt gttaggtaca tttatactct 18900 tgaaatgatt tacccatcta gaaacatggt ccaatttcat tcagaaaagt atttaaaata 18960 tgttataaaa gtatagatta caaagataaa tctcaacctt gtttgttact tttttctttt 19020 actcacagtg tgttatccag gattttcaag cttcggtact tcaagtgtca gattcaactt 19080 atgatgaaca gtatgttttc ttattaaaat gtatacttta taaatgagga aaggatttgt 19140 ttaaaaaata cttaattgaa taatgtttaa aatattctca ctcccttttt tttttttaca 19200 agtttataat tccctagtag tttataattt tgaagagaat tattttttgt cttttgtgta 19260 atacggttta atatgttttc agagtggctg cacagatgcc aactgttcat tatgaattcc 19320 ccaatggcta caattgtgat tttggtgcag agcggctaaa gattccagaa ggattatttg 19380 acccttccaa tgtaaaggta taaaagctta tttcataatt agcctggctt ttcctatata 19440 ggtaaagagc ttttgtggct aaaatgtttt ggatatgctt tactgtatga agagcttcca 19500 tgtgactact tgttttcttt tgttgtaggg gttatcagga aacacaatgt taggagtcag 19560 tcatgttgtc accacaagtg ttgggatgtg tgatattgac atcagaccag taagtgccag 19620 tctcctgtta cggtttaaag gtatctttta ggggactgaa atgtccccaa atcattgtta 19680 ggttgacagt gatctaatgg ttgtcagtgt cattgacttt gaggttcatt ttataacagt 19740 atatgtaaaa agatgaagta ctagaaaagg aaaaatgtga aactctagag ctatggtgtc 19800 cagttttgta gctacccgcc acatgtggca atttaaattt aaaatagata aaaacataaa 19860 actcaattct tcagttgtag tagcctcatt ataaatgtgg ctagtggctg catcagacag 19920 cgcagatata gaacatttgc atcatcacag aaagttattg tagactgcgc tagagatttc 19980 ctgaaatgtg gcaaaccaaa atatgtattg ttggtgattt tcttacagat agcacaactt 20040 ctacttttat ttttcaggaa ggcgtggttt aaattatatg agtaactttt acatgaagtt 20100 tattttaaat gctcttcata ttttttgtgc tttgtcaggt tttaaatact aactccatat 20160 tatatacttc actcattatc agtgataggt tcttggagac tgcaacttta actgaaacga 20220 tgtacagtag gtccttgaag gacattgttt caggaaaaaa attggttttg ttacatgaca 20280 ttttgctgaa agtcagtttc caaggtcata ttgatgacat taaatgagga cttactttat 20340 cttatttaaa cccaattcag cttatcaccc acatactgcc tagattttga gtaaattaat 20400 ttgcttaaag catagtgcta ataactacta tgttattcaa aaaaggcttt gagtggctat 20460 gaaaatcata ctttatttta cctttatttc acctggtaac ctagtaggca tgtgatgttt 20520 ctaggacaat agtagtataa gtttgggatt tttttagcgc aaatacaatt ccacctttcg 20580 gggaaggtaa ttgaattgaa gtatatttat tgcaacagtg ataactgttt ttagtgaagt 20640 ttctcctttt aactaatgag atacttttgc attccatttt ctacttcaaa atttagatga 20700 tttagacatt tgaagtatgt tttaaaaata ggaacttacc cactaaaaca gtttgacatt 20760 taactttctg atgcatacat gcaaattcaa agtaaataca ctgcttataa gtagtaattt 20820 atttttattt gggaagggct tagcatatgt gttttggaaa agctcccatg tgcttctgat 20880 gcttacctct gcaaaagaga aaagtagcaa taattttggc gaggaatatg ttcagagttt 20940 atcattgtct gtcataatca taaaataatt gtctaatttt gaatatccta acttacagat 21000 aagcattctt tttcaaaata tttgtaattt taatttttgg ctggtggttg caattaatat 21060 ttccagatga gcattctttg aatatcctaa cttacagata agcattcttt ttcaaaatat 21120 ttgtaatttt aatttttggc tggtggttgc tattaatatt tccagatgag cattctaaga 21180 taaagtcatt ataaaatgta cttctaatta aatattggca gctatctgcc aaaaaaaaat 21240 tatgattttt agaatgattc ctttaagtta gtggttctta aaactttgta cacattaaaa 21300 taatcttggg agttaaaaac catgcctgcc aggtacagtg gcatgtagtc ccagctactt 21360 gggagcctga ggcaggattg tttgaaccca ggagtttgag gctgtggtac gctatgcctg 21420 tgcccgtgaa tagccactgc attccaatgt aggcaatata acgagacccc gtctctaaaa 21480 gtaaccttgc ctggatccca tccccagaca tttttattta attgccccta ggaatttgtg 21540 ttttaaaagc tccttagatg agttgaatgt acagccagga tggagaattg atggattaag 21600 ctattagttc tatataatag taaaacattt ccaaaaaacg aaagggaaat tgtagtagag 21660 cacatggtta tatttgtagt tgtatttaaa acttttggaa acatatggaa ctaattgatt 21720 tttcttgtat ttttatccta gggtctctat ggcagtgtaa tagtggcagg aggaaacaca 21780 ctaatacaga gttttactga caggttgaat agagagctgt ctcagaaaac tcctccagta 21840 agttctgttt gttctttaat ggtattcttc agtcatatat ttcctcactg atggtgtaat 21900 tttgtagata agcgtccatt tttcaataga tacatgatat tttgtgtgtg cctggtatag 21960 tatcactaaa gttaatatcc tttaatcgtt ttcctagttg acatctatta gtttctctta 22020 aattatttga atctcattta ttaatattta aatatgtata gtctgctagg cactagtccc 22080 tgcacaccaa gggctcagtc tactaggatg gttagacatg cagaaaatga tgactgtaac 22140 atgctcaaca attcagtatg tcatgaacga ggtgctgttg ggaacaccaa gaagccacta 22200 cttaactctc taggagtatc agaggatagc ctcctgaaga agctatagtt tgaatgaata 22260 gttcaactca ttgctaattt atgaaaggat atctagatgg agggaataaa accatttaca 22320 aaaatactaa gagaagacag gtatgttcca gtaattcaaa gtagttggct tctagtcttt 22380 acgtaagtgg ggaaagcaat atggctagaa agatggatta gtttcctaga gctgccgtaa 22440 caaagtacat gttagtggct tcaaacaaca gaaatttgtt gtcttatagt tcttgaggct 22500 agaagcctca aggtgtcagt ggagctatgc tgaatctcta ggggaaaata cctccttctt 22560 cacaggataa aatctagcag tggactgatg agctcatgtt tgttttaaaa agatcagtgg 22620 gtatattata ataactttta aaagaataga aaaactcggt ttgagaaggt aatttatata 22680 gtacttcggt aacagaatga cagttataat cttttaactt taaaatttct atcagctggg 22740 cgtggtggct cacgcctata atcccagcac tttgggaggc cgaggcagat ggattatgag 22800 gtcagggaga ccagcctggc caacatggtg aaaccccatc tctactaaga atacaaaaat 22860 tagctgggcc tggtggcggg agcctcttaa ttccagctac tcgggaggct gaggcaggag 22920 aattgcttga acccgggagg tggaggttgc agtgaactga gatcacacca ctgcattcca 22980 acagagcaag actccatctc aaaaaaaaaa aaaaataaca aaaattagcc ggacacggtg 23040 gcacgtgcct gtaatcccag ctacttggga ggctgagaca gcagaatcgc ttgaacccag 23100 gaggcggagg ttgcagtaag ccgagatcat gccactgcat tccagtctgg gtgacaaagc 23160 aagactctgg ctcaggaaaa aaaaacaaca acaacaaaac ttcaagtgct ttttttgtaa 23220 ggtgttctgc actgaagatt acatttaaaa aaccttatta gtggttacat atgccctaac 23280 aatatctata aatctgtata tttaatagtc ttttagcttc ccatataaaa taatgtttta 23340 cgtgtgccac atttctatta ttaaaagtga tatctaaata tataggcaca cagttgacat 23400 ctgccttgta ttttctaaat tcttggagat ctagagcata cctgaattat aatactaatc 23460 attagattga ttgattgatt ggagatttat ttatttattt atttacttga gatggagtct 23520 tgctcttgtc ccctaggctg gagtgcagtg gcacgatatc agctcactgt aacctccgcc 23580 tcctgggttc aagtgattct cctacctcag cttcccaagt agctgggatt acaggcatgt 23640 tccaccacac ccggctaatt ttttattttt agtagagatg cagtttctcc gtgctggtca 23700 ggctgatctc aaactcccga cctcaggtga tccacccgcc tcggcctccc aaagtgctgg 23760 gattataggc gtgagccact gcaccggtct ataatactaa tgattagatt tcatagaaag 23820 tccctgaata atgaatacag ataagcatgg cccaagctgt ggtcaaggcc agttagaaac 23880 tatccttgtc ctttaggagg tgataacaat ctctgaaaga acaggaaaaa aattctattt 23940 aatagttacc aatctttctt acctacaaaa acccatgttt accctatccc cagtaccttc 24000 tacccaccca tatcccatac tctacccacc cttgctgcac acatacttat ttcactttga 24060 aaagccccaa aaatatgttc atttatagaa taataggaag atgtcaacaa cttgagaact 24120 gtccccagag gcagattcct tggtaagaga aagaaaaaaa cctcttcata taggaagtga 24180 gatatagggg atagtactgt gcaataaaat tgtgttatca agagaaaatg agagtcagaa 24240 cagaagcact aatttggaag gaaatagtat gaataaaaaa ctaacctgat atctgatggt 24300 tgtgttttta tttagaaggg ttggggtgaa ctaaggaggg attaggatag catgaaagcc 24360 tagaaaggaa gcagttagaa ggttggggag gactacagaa agggagacag attgggatga 24420 taattaggtt ggtgttggat gaaatgaaat aataaagact tagcacagca ccagatttat 24480 agtgttaggt gtggatttgc tattttagga tagaaattgt gaatgctata cttcagtatg 24540 cagcttttta aagtttgtat gttttctcat catataatcg catgttaaaa gccataatca 24600 aagtactttt aaaagtctgt acattagtct aacctatgct tgttatcttg gctatttcaa 24660 aattaccgta ttttaatcag tgtttgaacc acagggagcc attatgaagt ctgtcaaaat 24720 tgaatttcct ggctgggtgc aagtggctca tgcatgtaat cccagcactt tgggaggctg 24780 agatgggccg attgcttgag tgcaaatgtg aagaccagcc tggacaatat ggcgaggaag 24840 accctgtctc tatttgaaaa aaaaaaaaaa aaaaagaatt ttctaagttg agtcacaaga 24900 tttgattgta ctaatgcata ttcttctatt tcagagtatg cggttgaaat tgattgcaaa 24960 taatacaaca gtggaacgga ggtttagctc atggattggc ggctccattc tagcctcttt 25020 ggttagtaga tgagctactt tgcaaaaata ttcttactga attatactaa atttagtaaa 25080 aatacaaaaa ataattccag tgcttcattt gtctgtgcat tttataactg tcaaatgagt 25140 ggaagaccta atggaataac cagttttatg tgttctgatg taacaaaatg cctctgccta 25200 attagtggac atttgtcagc ctaatttcaa tgtcccctct caaacagagg tggaaatatg 25260 ttaatgtatg catgcctttt ctaataatac ccccattggc actggtcagg gcttgtctgg 25320 agtgcattta aaatgaaaac attgcttctc aagttctggt cattccccag tctgcagtga 25380 gatctacagt gaggtctagg aagtcaggaa ttggtcttgg agcaaatggt gaagtcatgg 25440 tgcggggtgt aagatgttgc ttggactacc atctgccttg aataaggaca aaaagtcctt 25500 gtacttttct gcatcctgga cttagagcat ttctcccctt atatacagtt tatatactta 25560 tatctatact gtatatatag ttacttatgt atatacatat atactgtata tatacagttt 25620 atatacatat atatgtatac tgtatataaa gggggaggat gccctttacc tcagagcaac 25680 aaaagtaaat gtcattaagt actcattcaa gccttctgac agtttctgtt attgccttag 25740 gttggcatca agccatcaca cctaaaccct cagtcttcct tgccagatat tttctaaatc 25800 ctgacaatgt aacagataca gaaggactta gtattctttt taaccataaa ggcaaggcta 25860 aatagtgtgt ttggatggtt ctggaggagg gcagaaataa tcgagtacta ttttggggga 25920 cgggactctt aaatgaatta ttcaaagttt aggagttacg aaaataagat attaaaaaaa 25980 acgctggtgc agtggctcac acctataatt ccagcacttt gggaggctga ggcaggagga 26040 tcacaggtgc ccaggagtat gagaccagcc tgggcaacat agtgtgagac cccatctcta 26100 caacaattaa aattaggcaa ggtggcatgc ccctggagtc ccaggctgag gtgggagcat 26160 cccttgaacc aagaagttcg aggttgtaag ctacaatcac gccattgcac tccagcctgg 26220 ctgacagagc aagaccttct ctcaaaaaaa aaaaattttt taagccattt ctagtaagaa 26280 gtaaggcata attatataaa tttctttcca ttttacaggg tacctttcaa cagatgtgga 26340 tttccaagca agaatatgaa gaaggaggga agcagtgtgt agaaagaaaa tgcccttgag 26400 aaagagttcc caagcttcta ccttcctttt gtcaccttac gtttcatagc tttagtatac 26460 tcaggaaaag aatgaccatc ttttgtagaa tgtttataca tttttgcata tttcaatttc 26520 cacttaaatt ttttaaagct ttaactggct ctataaatta agtttgtgct ttccttgaaa 26580 tgcacttatt cttattacaa gcattttata attttgtata aatgtctatt ttctctaaat 26640 attttgcttt cagtaaaatg ctttccaact ctgtttagtg tattaattac cagtggattg 26700 gtagaactgc tttttattga ctagtaaaag ttactgccta tgctttttac cttaggctta 26760 cagaattaaa taaaaattag ccattccaga aatatatttt ggactgttgt gcactgtgat 26820 tactacttta aggactaaat gtatttctca ttattttgaa tcaaagtcct ccgtttatta 26880 acagcaatac ccacatcctc ttcatagcct attaacaaca gaggtaaaac tattattcaa 26940 attcaaaaac tacggtattg cctttgctgt ggcagttacc atcaccttca cactctaagg 27000 tagcaggtga catttaaagc ctgcttaaat gtcagaattt ataaagtggg aatctcatct 27060 gaactttata cctgattttt agaagcaaat tagcttctac caaattagct aattagcatg 27120 ccatattcac acttagaaca actgattagt aaagtcactt gactaaaaac agaatttctt 27180 tataaaccac ttaacatatt tactcctgta cacagactat tcaagaaaaa caaaatggta 27240 aatttaatag ttcagacatc ttagacaaga cttgactttt gggcttcagc aagatgtgga 27300 aactttttta aaagaatttt tgctttcttt ctctctaaat tttccttccg tgctttgatg 27360 cgggctcgtt tctcacgttc cagtctagaa taaaaaaagc gtaacagcaa tttatacaaa 27420 aatatttcct tgttattcaa tactatcaaa atatgcataa atcaattaca tcaaagcttc 27480 aaacatgcca gtccctgtat ttggtgtgtt atatatatta ttaaacttga atagtaatca 27540 ctgtaaacct acacaagtca agagcatctg aaaccctata ccaactatcc ctatttcctg 27600 actagaaaga atgtccagat attatgaacc tgtaacaaat tgggccttaa gttcaatcct 27660 catatgacta agcatcatct cttagcagag tgttattctg tgtatagggg aaatgataag 27720 ctagagtgag tactatttga aagtagggaa ttcccataag tctcaggata tctctcatga 27780 tgccaaaaat aaattcttag gctctggcta gacttactat tctttaaatg agtttgttcc 27840 cacacatcag tatcccaggg tatgacacat ttgctgcata aattacaaca taaattactt 27900 gacctgtagg gtcaacttgg gagttgtaaa aattgaaaat gaaaaaaatc cttgcatacc 27960 aagctctatt tgaattgata tcttacagga tattggtcaa t 28001 <210> SEQ ID NO 5 <211> LENGTH: 24 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: PCR Primer <400> SEQUENCE: 5 gagttcccaa gcttctacct tcct 24 <210> SEQ ID NO 6 <211> LENGTH: 28 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: PCR Primer <400> SEQUENCE: 6 cattctacaa aagatggtca ttcttttc 28 <210> SEQ ID NO 7 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: PCR Probe <400> SEQUENCE: 7 ttgtcacctt acgtttcata gcttt 25 <210> SEQ ID NO 8 <211> LENGTH: 19 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: PCR Primer <400> SEQUENCE: 8 gaaggtgaag gtcggagtc 19 <210> SEQ ID NO 9 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: PCR Primer <400> SEQUENCE: 9 gaagatggtg atgggatttc 20 <210> SEQ ID NO 10 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: PCR Probe <400> SEQUENCE: 10 caagcttccc gttctcagcc 20 <210> SEQ ID NO 11 <211> LENGTH: 622 <212> TYPE: DNA <213> ORGANISM: H. sapiens <220> FEATURE: <400> SEQUENCE: 11 agcaagtgtg gctgagctcc ggggtgtgtg gacgccgctt tgttgcctga gatgaagttg 60 gagcccttgt ttttgacatt ggatcctata ctgtgagagc tggttatgct ggtgaggact 120 gccccaaggt ggattttcct acagctattg gtatggtggt agaaagagat gacggaagca 180 cattaatgga aatagatggc gataaaggca aacaaggcgg tcccacctac tacatagata 240 ctaatgctct gcgtgttccg agggagaata tggaggccat ttcacctcta aaaaatggga 300 tggttgaaga ctgggatagt ttccaagcta ttttggatca tacctacaaa atgcatgtca 360 aatcagaagc cagtctccat cctgttctca tgtcagaggc accgtggaat actatagcaa 420 agagagagaa actgacagag ttaatgtttg aacactacaa catccctgcc ttcttccttt 480 gcaaaactgc agttttgaca gcgtatcctt gaaagagtaa tacctttcct cttgaacttt 540 attcatcatc tacttcacta aacaggataa ccttcaagga aaaggcagtt ttggtgcacc 600 attgtgtgtc tactgtgtta aa 622 <210> SEQ ID NO 12 <211> LENGTH: 886 <212> TYPE: DNA <213> ORGANISM: H. sapiens <220> FEATURE: <400> SEQUENCE: 12 tgttgcctga gatgaagttg gagccctgtt tttgacatgg atcctatact gtgagagctg 60 gttatgctgg tgaggactgc cccaaggtgg attttcctac agctatggta tggtggtaga 120 aagagatgac ggaagcacat taatggaaat agatggcgat aaaggcaaac aaggcggtcc 180 cacctactac atagatacta atgctctgcg tgttccgagg gagaatatgg aggccatttc 240 acctctaaaa aatgggatgg ttgaagactg ggatagtttc caagctattt ggatcatacc 300 tacaaaatgc atgtcaaatc agaagccagt ctccatcctg ttctcatgtc agaggcaccg 360 tggaatacta gagcaaagag agagaaactg acagagttaa tgtttgaaca ctacaacatc 420 cctgccttct tcctttgcaa aactgcagtt ttgacagcct ttattcatca tctacttcac 480 taaacaggat aaccttcagg gaaaaggcag tttggtgcac cattgtgtgt ctactgtgtt 540 aaaggaattt tagtgccaga tttgctaatg gtcgttctac tgggctgatt ttggacagtg 600 gagccactca taccactggc aattccagtc cacgatggta tgtccttcaa acaaggcatg 660 tgaaatcgcc tcttggtgga gactttatta ctatgcaggg gcagagaact cttccaagaa 720 atggattttg gattgggtcc tccatatatg atgggtcaaa gaagtggcgt gaaggatctc 780 cacaactggg aaagaaagag aagtgcgcca ggtacgaggc tgggccaaat tgtgctcggg 840 tcccggttca agcgggagcg ggtggtcact tgtgacaggg ggtgcc 886 <210> SEQ ID NO 13 <211> LENGTH: 1007 <212> TYPE: DNA <213> ORGANISM: H. sapiens <220> FEATURE: <400> SEQUENCE: 13 gtgagctccg gggtgtgtgg acgccgcttt gttgcctgag gtgggtggcg gtggaagtta 60 agggagtcag gggctatcgg ctcctcgaga ctcgcagtcg cggccactgc agtcacttcg 120 ccagttagcc cttagggtag gagtcgcgcc ggcagcagcc atgagcggcg gcgtgtacgg 180 gggagatgaa gttggagccc ttgtttttga cattggatcc tatactgtga gagctggtta 240 tgctggtgag gactgcccca aggtggattt tcctacagct attggtatgg tggtagaaag 300 agatgacgga agcacattaa tggaaataga tggcgataaa ggcaaacaag gcggtcccac 360 ctactacata gatactaatg ctctgcgtgt tccgagggag aatatggagg ccatttcacc 420 tctaaaaaat gggatggttg aagactggga tagtttccaa gctattttgg atcataccta 480 caaaatgcat gtcaaatcag aagccagtct ccatcctgtt ctcatgtcag aggcaccgtg 540 gaatactaga gcaaagagag agaaactgac agagttaatg tttgaacact acaacatccc 600 tgccttcttc ctttgcaaaa ctgcagtttt gacagcattt gctaatggtc gttctactgg 660 gctgattttt ggaccgtgga gccactcata ccactggcaa ttccagtcca cgattggctt 720 atgtccttca aacaaggcat tgtgaaatcc cctcttggct ggggacttta ttactatgca 780 gtgcgaagaa ctcttccaga aatggctttt tgatggttcc tccatttttg gattgcttca 840 aagaaggcgt tctgggaggt ctccccactg gaaaaagggg aagggccggg ccgagtgggg 900 cccttttgtt ggggtcccgg gacccgggta cggggcatac tttagagggg gaaccggtta 960 tccgggtgtt cggggggcaa attcccgggg aaggcggccg gggaacg 1007 <210> SEQ ID NO 14 <211> LENGTH: 708 <212> TYPE: DNA <213> ORGANISM: H. sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 708 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 14 ccagcaagtg tggctgagct ccggggtgtg tggacgccgc tttgttgcct gagatgaagt 60 tggagccctt gtttttgaca ttggatccta tactgtgaga gctggttatg ctggtgagga 120 ctgccccaag gtggattttc ctacagctat tggtatggtg gtagaaagag atgacggaag 180 cacattaatg gaaatagatg gcgataaagg caaacaaggc ggtcccacct actacataga 240 tactaatgct ctgcgtgttc cgagggagaa tatggaggcc atttcacctc taaaaaatgg 300 gatggttgaa gactgggata gtttccaagc tattttggat catacctaca aaatgcatgt 360 caaatcagaa gccagtctcc atcctgttct catgtcagag gcaccgtgga atactagagc 420 aaagagagag aaactgacag agttaatgtt tgaacactac aacatccctg ccttcttcct 480 ttgcaaaact gcagttttga cagcgtatcc ttgaaagagt aatacctttc ctcttgaact 540 ttattcatca tctacttcac taaacaggat aaccttcagg ggccagattt gctaatggtc 600 gttctactgg gctgattttg gacagtggag ccactcatac cacttgcatt ccagtccacg 660 atggctattg tcctcaacaa ggcattggga aatccctctt gctggagn 708 <210> SEQ ID NO 15 <211> LENGTH: 700 <212> TYPE: DNA <213> ORGANISM: H. sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 456, 518, 569 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 15 tttggcggtg gaagttaacg gagtcagggg ctatcgctcc tcgagactcg cagtcgcggc 60 cactgcagtc acttcgccag ttagccctta gggtaggagt cgcgccggca gcagccatga 120 gcggcggcgt gtacggggga gatgaagttg gagcccttgt ttttgacatt ggatcctata 180 ctgtgagagc tggttatgct ggtgaggact gccccaaggt ggattttcct acagctattg 240 gtatggtggt agaaagagat gacggaagca cattaatgga aatagatggc gataaaggca 300 aacaaggcgg tcccacctac tacatagata ctaatgctct gcgtgttccg agggagaata 360 tggaggccat ttcacctcta aaaaatggga tggttgaaga ctgggatagt ttccaagcta 420 ttttggatca tacctacccg tggaatacta gagcanagag agagaaactg acagagttaa 480 tgtttgaaca ctacaacatc cctgccttct tcctttgnca aactgcagtt ttgacagcat 540 ttgctaatgg tcgttctact gggctgatnt tggacagtgg agccactcat accactgcaa 600 ttccagtcca cgatggctat gtccttcaac agggcattgt gaaatcccct cttgctggag 660 actttattac tatgcggtgc agagaactct tccagaaatg 700 <210> SEQ ID NO 16 <211> LENGTH: 2865 <212> TYPE: DNA <213> ORGANISM: H. sapiens <220> FEATURE: <400> SEQUENCE: 16 ccgctttgtt gcctgaggtg ggtggcggtg gaagttaagg gagtcagggg ctatcgctcc 60 tcgagactcg cagtcgcggc cactgcagtc acttcgccag ttagccctta gggtaggagt 120 cgcgccggca gcagccatga gcggcggcgt ggtacggggg agatgaagtt ggagcccttg 180 tttttgacat tggatcctat actgtgagag ctggttatgc tggtgaggac tgccccaagg 240 tggattttcc tacagctatt ggtatggtgg tagaaagaga tgacggaagc acattaatgg 300 aaatagatgg cgataaaggc aaacaaggcg gtcccaccta ctacatagat actaatgctc 360 tgcgtgttcc gagggagaat atggaggcca tttcacctct aaaaaatggg atggttgaag 420 actgggatag tttccaagct attttggatc atacctacaa aatgcatgtc aaatcagaag 480 ccagtctcca tcctgttctc atgtcagagg caccgtggaa tactagagca aagagagaga 540 aactgacaga gttaatgttt gaacactaca acatccctgc cttcttcctt tgcaaaactg 600 cagttttgac agcatttgct aatggtcgtt ctactgggct gattttggac agtggagcca 660 ctcataccac tgcaattcca gtccacgatg gctatgtcct tcaacaaggc attgtgaaat 720 cccctcttgc tggagacttt attactatgc agtgcagaga actcttccaa gaaatgaata 780 ttgaattggt tcctccatat atgattgcat caaaagaagc tgttcgtgaa ggatctccag 840 caaactggaa aagaaaagag aagttgcctc aggttacgag gtcttggcac aattatatgt 900 gtaattgtgt tatccaggat tttcaagctt cggtacttca agtgtcagat tcaacttatg 960 atgaacaagt ggctgcacag atgccaactg ttcattatga attccccaat ggctacaatt 1020 gtgattttgg tgcagagcgg ctaaagattc cagaaggatt atttgaccct tccaatgtga 1080 aggggttatc aggaaacaca atgttaggag tcagtcatgt tgtcaccaca agtgttggga 1140 tgtggatttc caagcaagaa tatgaagaag gagggaagca gtgtgtagaa agaaaatgcc 1200 cttgagaaag agttcccaag cttctacctt ccttttgtca ccttacgttt catagcttta 1260 gtatactcag gaaaagaatg accatctttt gtagaatgtt tatacatttt tgcatatttc 1320 aatttccact taaatttttt aaagctttaa ctggctctat aaattaagtt tgtgctttcc 1380 ttgaaatgca cttattctta ttacaagcat tttataattt tgtataaatg tctattttct 1440 ctaaatattt tgctttcagt aaaatgcttt ccaactctgt ttagtgtatt aattaccagt 1500 ggattggtag aactgctttt tattgactag taaaagttac tgcctatgct ttttacctta 1560 ggcttacaga attaaataaa aattagccat tccagaaata tattttggac tgttgtgcac 1620 tgtgattact actttaagga ctaaatgtat ttctcattat tttgaatcaa agtcctccgt 1680 ttattaacag caatacccac atcctcttca tagcctatta acaacagagg taaaactatt 1740 attcaaattc aaaaactacg gtattgcctt tgctgtggca gttaccatca ccttcacact 1800 ctaaggtagc aggtgacatt taaagcctgc ttaaatgtca gaatttataa agtgggaatc 1860 tcatctgaac tttatacctg atttttagaa gcaaattagc ttctaccaaa ttagctaatt 1920 agcatgccat attcacactt agaacaactg attagtaaag tcacttgact aaaaacagaa 1980 tttctttata aaccacttaa catatttact cctgtacaca gactattcaa gaaaaacaaa 2040 atggtaaatt taatagttca gacatcttag acaagacttg acttttgggc ttcagcaaga 2100 tgtggaaact tttttaaaag aatttttgct ttctttctct ctaaattttc cttccgtgct 2160 ttgatgcggg ctcgtttctc acgttccagt ctgagaaaat ggtccacata aggcaaggca 2220 aagaatcgtt tcctattgta tcttttattt aggtgccaag gtataaccca ctgcttgaac 2280 ttgtgccaga tgattcttcc aaagatgtct cttctccaag caccaggtct agctctttct 2340 tgaccagtct gaagaagcct tagggcatct tctctttcct ggacaacttt atctaatgca 2400 tccatggaat ctactacctt atctaaccgc tctggacttg gcattggcaa tctctgccgc 2460 ttggcctcct gctctagggt tagaagcatg tttctttctt tcagtaagac ataccaaagt 2520 ttgtgtaaat cttcattact tttgttcctt agttgctgac aggtccatgc tgctccagat 2580 tttacttttt cttgccccca gttttttggg tcatcaaaaa attcttctag tcctttcctt 2640 gacaatgtgg tatgaagtaa tctatattgg tgaaaggatg tcacatttgg tgtactctta 2700 ggcaacaaac taagagaaga cctgcaaccc gagtgagcag cgtccttggg atttactagg 2760 gaacaagctg ccttcaggaa cgctgaggct cttctacaaa tacccactag actggtcgca 2820 gccatgtttc taatggagac cgtcagtttc acctaggcca gcaat 2865 <210> SEQ ID NO 17 <211> LENGTH: 1887 <212> TYPE: DNA <213> ORGANISM: H. sapiens <220> FEATURE: <221> NAME/KEY: CDS <222> LOCATION: (310)...(1473) <400> SEQUENCE: 17 gctttgttgc ctgaggtggg tggcggtgga agttaaggga gtcaggggct atcgctcctc 60 gagactcgca gtcgcggcca ctgcagtcac ttcgccagtt agcccttagg taggagtcgc 120 gccggcagca gccatgagcg gcggcgtgta cgggggaggt gagtgagtgc ggccggacga 180 gagagcgcgc cttttcggcg tgatgggaat gaagttggag cccttgtttt tgacattgga 240 tcctatactg tgagagctgg ttatgctggt gaggactgcc ccaaggtgga ttttcctaca 300 gctattggt atg gtg gta gaa aga gat gac gga agc aca tta atg gaa ata 351 Met Val Val Glu Arg Asp Asp Gly Ser Thr Leu Met Glu Ile 1 5 10 gat ggc gat aaa ggc aaa caa ggc ggt ccc acc tac tac ata gat act 399 Asp Gly Asp Lys Gly Lys Gln Gly Gly Pro Thr Tyr Tyr Ile Asp Thr 15 20 25 30 aat gct ctg cgt gtt ccg agg gag aat atg gag gcc att tca cct cta 447 Asn Ala Leu Arg Val Pro Arg Glu Asn Met Glu Ala Ile Ser Pro Leu 35 40 45 aaa aat ggg atg gtt gaa gac tgg gat agt ttc caa gct att ttg gat 495 Lys Asn Gly Met Val Glu Asp Trp Asp Ser Phe Gln Ala Ile Leu Asp 50 55 60 cat acc tac aaa atg cat gtc aaa tca gaa gcc agt ctc cat cct gtt 543 His Thr Tyr Lys Met His Val Lys Ser Glu Ala Ser Leu His Pro Val 65 70 75 ctc atg tca gag gca ccg tgg aat act aga gca aag aga gag aaa ctg 591 Leu Met Ser Glu Ala Pro Trp Asn Thr Arg Ala Lys Arg Glu Lys Leu 80 85 90 aca gag tta atg ttt gaa cac tac aac atc cct gcc ttc ttc ctt tgc 639 Thr Glu Leu Met Phe Glu His Tyr Asn Ile Pro Ala Phe Phe Leu Cys 95 100 105 110 aaa act gca gtt ttg aca gca ttt gct aat ggt cgt tct act ggg ctg 687 Lys Thr Ala Val Leu Thr Ala Phe Ala Asn Gly Arg Ser Thr Gly Leu 115 120 125 att ttg gac agt gga gcc act cat acc act gca att cca gtc cac gat 735 Ile Leu Asp Ser Gly Ala Thr His Thr Thr Ala Ile Pro Val His Asp 130 135 140 ggc tat gtc ctt caa caa ggc att gtg aaa tcc cct ctt gct gga gac 783 Gly Tyr Val Leu Gln Gln Gly Ile Val Lys Ser Pro Leu Ala Gly Asp 145 150 155 ttt att act atg cag tgc aga gaa ctc ttc caa gaa atg aat att gaa 831 Phe Ile Thr Met Gln Cys Arg Glu Leu Phe Gln Glu Met Asn Ile Glu 160 165 170 ttg gtt cct cca tat atg att gca tca aaa gaa gct gtt cgt gaa gga 879 Leu Val Pro Pro Tyr Met Ile Ala Ser Lys Glu Ala Val Arg Glu Gly 175 180 185 190 tct cca gca aac tgg aaa aga aaa gag aag ttg cct cag gtt acg agg 927 Ser Pro Ala Asn Trp Lys Arg Lys Glu Lys Leu Pro Gln Val Thr Arg 195 200 205 tct tgg cac aat tat atg tgt aat tgt gtt atc cag gat ttt caa gct 975 Ser Trp His Asn Tyr Met Cys Asn Cys Val Ile Gln Asp Phe Gln Ala 210 215 220 tcg gta ctt caa gtg tca gat tca act tat gat gaa caa gtg gct gca 1023 Ser Val Leu Gln Val Ser Asp Ser Thr Tyr Asp Glu Gln Val Ala Ala 225 230 235 cag atg ccg act gtt cat tat gaa ttc ccc aat ggc tac aat tgt gat 1071 Gln Met Pro Thr Val His Tyr Glu Phe Pro Asn Gly Tyr Asn Cys Asp 240 245 250 ttt ggt gca gag cgg cta aag att cca gaa gga tta ttt gac cct tcc 1119 Phe Gly Ala Glu Arg Leu Lys Ile Pro Glu Gly Leu Phe Asp Pro Ser 255 260 265 270 aat gta aag ggg tta tca gga aac aca atg tta gga gtc agt cat gtt 1167 Asn Val Lys Gly Leu Ser Gly Asn Thr Met Leu Gly Val Ser His Val 275 280 285 gtc acc aca agt gtt ggg atg tgt gat att gat atc aga cca ggt ctc 1215 Val Thr Thr Ser Val Gly Met Cys Asp Ile Asp Ile Arg Pro Gly Leu 290 295 300 tat ggc agt gta ata gtg gca gga gga aac aca cta ata cag agt ttt 1263 Tyr Gly Ser Val Ile Val Ala Gly Gly Asn Thr Leu Ile Gln Ser Phe 305 310 315 act gac agg ttg aat aga gag ctg tct cag aaa act cct cca agt atg 1311 Thr Asp Arg Leu Asn Arg Glu Leu Ser Gln Lys Thr Pro Pro Ser Met 320 325 330 cgg ttg aaa ttg att gca aat aat aca aca gtg gaa cgg agg ttt agc 1359 Arg Leu Lys Leu Ile Ala Asn Asn Thr Thr Val Glu Arg Arg Phe Ser 335 340 345 350 tca tgg att ggc ggc tcc att cta gcc tct ttg ggt acc ttt caa cag 1407 Ser Trp Ile Gly Gly Ser Ile Leu Ala Ser Leu Gly Thr Phe Gln Gln 355 360 365 atg tgg att tcc aag caa gaa tat gaa gaa gga ggg aag cag tgt gta 1455 Met Trp Ile Ser Lys Gln Glu Tyr Glu Glu Gly Gly Lys Gln Cys Val 370 375 380 gaa aga aaa tgc cct tga gaaagagttc ccaagcttct accttccttt 1503 Glu Arg Lys Cys Pro * 385 tgtcacctta cgtttcatag ctttagtata ctcaggaaaa gaatgaccat cttttgtaga 1563 atgtttatac atttttgcat atttcaattt ccacttaaat tttttaaagc tttaactggc 1623 tctataaatt aagtttgtgc tttccttgaa atgcacttat tcttattaca agcattttat 1683 aattttgtat aaatgtctat tttctctaaa tattttgctt tcagtaaaat gctttccaac 1743 tctgtttagt gtattaatta ccagtggatt ggtagaactg ctttttattg actagtaaaa 1803 gttactgcct atgcttttta ccttaggctt acagaattaa ataaaaatta gccattccag 1863 aaatataaaa aaaaaaaaaa aaaa 1887 <210> SEQ ID NO 18 <211> LENGTH: 1328 <212> TYPE: DNA <213> ORGANISM: H. sapiens <220> FEATURE: <221> NAME/KEY: CDS <222> LOCATION: (165)...(1328) <400> SEQUENCE: 18 tggccggggg ccagcaagtg tggctgagct ccggggtgtg tggacgccgc tttgttgcct 60 gagatgaagt tggagccctt gtttttgaca ttggatccta tactgtgaga gctggttatg 120 ctggtgagga ctgccccaag gtggattttc ctacagctat tggt atg gtg gta gaa 176 Met Val Val Glu 1 aga gat gac gga agc aca tta atg gaa ata gat ggc gat aaa ggc aaa 224 Arg Asp Asp Gly Ser Thr Leu Met Glu Ile Asp Gly Asp Lys Gly Lys 5 10 15 20 caa ggc ggt ccc acc tac tac ata gat act aat gct ctg cgt gtt ccg 272 Gln Gly Gly Pro Thr Tyr Tyr Ile Asp Thr Asn Ala Leu Arg Val Pro 25 30 35 agg gag aat atg gag gcc att tca cct cta aaa aat ggg atg gtt gaa 320 Arg Glu Asn Met Glu Ala Ile Ser Pro Leu Lys Asn Gly Met Val Glu 40 45 50 gac tgg gat agt ttc caa gct att ttg gat cat acc tac aaa atg cat 368 Asp Trp Asp Ser Phe Gln Ala Ile Leu Asp His Thr Tyr Lys Met His 55 60 65 gtc aaa tca gaa gcc agt ctc cat cct gtt ctc atg tca gag gca ccg 416 Val Lys Ser Glu Ala Ser Leu His Pro Val Leu Met Ser Glu Ala Pro 70 75 80 tgg aat act aga gca aag aga gag aaa ctg aca gag tta atg ttt gaa 464 Trp Asn Thr Arg Ala Lys Arg Glu Lys Leu Thr Glu Leu Met Phe Glu 85 90 95 100 cac tac aac atc cct gcc ttc ttc ctt tgc aaa act gca gtt ttg aca 512 His Tyr Asn Ile Pro Ala Phe Phe Leu Cys Lys Thr Ala Val Leu Thr 105 110 115 gca ttt gct aat ggt cgt tct act ggg ctg att ttg gac agt gga gcc 560 Ala Phe Ala Asn Gly Arg Ser Thr Gly Leu Ile Leu Asp Ser Gly Ala 120 125 130 act cat acc act gca att cca gtc cac gat ggc tat gtc ctt caa caa 608 Thr His Thr Thr Ala Ile Pro Val His Asp Gly Tyr Val Leu Gln Gln 135 140 145 ggc att gtg aaa tcc cct ctt gct gga gac ttt att act atg cag tgc 656 Gly Ile Val Lys Ser Pro Leu Ala Gly Asp Phe Ile Thr Met Gln Cys 150 155 160 aga gaa ctc ttc caa gaa atg aat att gaa ttg gtt cct cca tat atg 704 Arg Glu Leu Phe Gln Glu Met Asn Ile Glu Leu Val Pro Pro Tyr Met 165 170 175 180 att gca tca aaa gaa gct gtt cgt gaa gga tct cca gca aac tgg aaa 752 Ile Ala Ser Lys Glu Ala Val Arg Glu Gly Ser Pro Ala Asn Trp Lys 185 190 195 aga aaa gag aag ttg cct cag gtt acg agg tct tgg cac aat tat atg 800 Arg Lys Glu Lys Leu Pro Gln Val Thr Arg Ser Trp His Asn Tyr Met 200 205 210 tgt aat tgt gtt atc cag gat ttt caa gct tcg gta ctt caa gtg tca 848 Cys Asn Cys Val Ile Gln Asp Phe Gln Ala Ser Val Leu Gln Val Ser 215 220 225 gat tca act tat gat gaa caa gtg gct gca cag atg ccg act gtt cat 896 Asp Ser Thr Tyr Asp Glu Gln Val Ala Ala Gln Met Pro Thr Val His 230 235 240 tat gaa ttc ccc aat ggc tac aat tgt gat ttt ggt gca gag cgg cta 944 Tyr Glu Phe Pro Asn Gly Tyr Asn Cys Asp Phe Gly Ala Glu Arg Leu 245 250 255 260 aag att cca gaa gga tta ttt gac cct tcc aat gta aag ggg tta tca 992 Lys Ile Pro Glu Gly Leu Phe Asp Pro Ser Asn Val Lys Gly Leu Ser 265 270 275 gga aac aca atg tta gga gtc agt cat gtt gtc acc aca agt gtt ggg 1040 Gly Asn Thr Met Leu Gly Val Ser His Val Val Thr Thr Ser Val Gly 280 285 290 atg tgt gat att gat atc aga cca ggt ctc tat ggc agt gta ata gtg 1088 Met Cys Asp Ile Asp Ile Arg Pro Gly Leu Tyr Gly Ser Val Ile Val 295 300 305 gca gga gga aac aca cta ata cag agt ttt act gac agg ttg aat aga 1136 Ala Gly Gly Asn Thr Leu Ile Gln Ser Phe Thr Asp Arg Leu Asn Arg 310 315 320 gag ctg tct cag aaa act cct cca agt atg cgg ttg aaa ttg att gca 1184 Glu Leu Ser Gln Lys Thr Pro Pro Ser Met Arg Leu Lys Leu Ile Ala 325 330 335 340 aat aat aca aca gtg gaa cgg agg ttt agc tca tgg att ggc ggc tcc 1232 Asn Asn Thr Thr Val Glu Arg Arg Phe Ser Ser Trp Ile Gly Gly Ser 345 350 355 att cta gcc tct ttg ggt acc ttt caa cag atg tgg att tcc aag caa 1280 Ile Leu Ala Ser Leu Gly Thr Phe Gln Gln Met Trp Ile Ser Lys Gln 360 365 370 gaa tat gaa gaa gga ggg aag cag tgt gta gaa aga aaa tgc cct tga 1328 Glu Tyr Glu Glu Gly Gly Lys Gln Cys Val Glu Arg Lys Cys Pro 375 380 385 1328 <210> SEQ ID NO 19 <211> LENGTH: 1842 <212> TYPE: DNA <213> ORGANISM: H. sapiens <220> FEATURE: <221> NAME/KEY: CDS <222> LOCATION: (137)...(1426) <400> SEQUENCE: 19 ccgctttgtt gcctgaggtg ggtggcggtg gaagttaagg gagtcagggg ctatcgctcc 60 tcgagactcg cagtcgcggc cactgcagtc acttcgccag ttagccctta gggtaggagt 120 cgcgccggca gcagcc atg agc ggc ggc gtg tac ggg gga gat gaa gtt gga 172 Met Ser Gly Gly Val Tyr Gly Gly Asp Glu Val Gly 1 5 10 gcc ctt gtt ttt gac att gga tcc tat act gtg aga gct ggt tat gct 220 Ala Leu Val Phe Asp Ile Gly Ser Tyr Thr Val Arg Ala Gly Tyr Ala 15 20 25 ggt gag gac tgc ccc aag gtg gat ttt cct aca gct att ggt atg gtg 268 Gly Glu Asp Cys Pro Lys Val Asp Phe Pro Thr Ala Ile Gly Met Val 30 35 40 gta gaa aga gat gac gga agc aca tta atg gaa ata gat ggc gat aaa 316 Val Glu Arg Asp Asp Gly Ser Thr Leu Met Glu Ile Asp Gly Asp Lys 45 50 55 60 ggc aaa caa ggc ggt ccc acc tac tac ata gat act aat gct ctg cgt 364 Gly Lys Gln Gly Gly Pro Thr Tyr Tyr Ile Asp Thr Asn Ala Leu Arg 65 70 75 gtt ccg agg gag aat atg gag gcc att tca cct cta aaa aat ggg atg 412 Val Pro Arg Glu Asn Met Glu Ala Ile Ser Pro Leu Lys Asn Gly Met 80 85 90 gtt gaa gac tgg gat agt ttc caa gct att ttg gat cat acc tac aaa 460 Val Glu Asp Trp Asp Ser Phe Gln Ala Ile Leu Asp His Thr Tyr Lys 95 100 105 atg cat gtc aaa tca gaa gcc agt ctc cat cct gtt ctc atg tca gag 508 Met His Val Lys Ser Glu Ala Ser Leu His Pro Val Leu Met Ser Glu 110 115 120 gca ccg tgg aat act aga gca aag aga gag aaa ctg aca gag tta atg 556 Ala Pro Trp Asn Thr Arg Ala Lys Arg Glu Lys Leu Thr Glu Leu Met 125 130 135 140 ttt gaa cac tac aac atc cct gcc ttc ttc ctt tgc aaa act gca gtt 604 Phe Glu His Tyr Asn Ile Pro Ala Phe Phe Leu Cys Lys Thr Ala Val 145 150 155 ttg aca gca ttt gct aat ggt cgt tct act ggg ctg att ttg gac agt 652 Leu Thr Ala Phe Ala Asn Gly Arg Ser Thr Gly Leu Ile Leu Asp Ser 160 165 170 gga gcc act cat acc act gca att cca gtc cac gat ggc tat gtc ctt 700 Gly Ala Thr His Thr Thr Ala Ile Pro Val His Asp Gly Tyr Val Leu 175 180 185 caa caa ggc att gtg aaa tcc cct ctt gct gga gac ttt att act atg 748 Gln Gln Gly Ile Val Lys Ser Pro Leu Ala Gly Asp Phe Ile Thr Met 190 195 200 cag tgc aga gaa ctc ttc caa gaa atg aat att gaa ttg gtt cct cca 796 Gln Cys Arg Glu Leu Phe Gln Glu Met Asn Ile Glu Leu Val Pro Pro 205 210 215 220 tat atg att gca tca aaa gaa gct gtt cgt gaa gga tct cca gca aac 844 Tyr Met Ile Ala Ser Lys Glu Ala Val Arg Glu Gly Ser Pro Ala Asn 225 230 235 tgg aaa aga aaa gag aag ttg cct cag gtt acg agg tct tgg cac aat 892 Trp Lys Arg Lys Glu Lys Leu Pro Gln Val Thr Arg Ser Trp His Asn 240 245 250 tat atg tgt aat tgt gtt atc cag gat ttt caa gct tcg gta ctt caa 940 Tyr Met Cys Asn Cys Val Ile Gln Asp Phe Gln Ala Ser Val Leu Gln 255 260 265 gtg tca gat tca act tat gat gaa caa gtg gct gca cag atg cca act 988 Val Ser Asp Ser Thr Tyr Asp Glu Gln Val Ala Ala Gln Met Pro Thr 270 275 280 gtt cat tat gaa ttc ccc aat ggc tac aat tgt gat ttt ggt gca gag 1036 Val His Tyr Glu Phe Pro Asn Gly Tyr Asn Cys Asp Phe Gly Ala Glu 285 290 295 300 cgg cta aag att cca gaa gga tta ttt gac cct tcc aat gta aag ggg 1084 Arg Leu Lys Ile Pro Glu Gly Leu Phe Asp Pro Ser Asn Val Lys Gly 305 310 315 tta tca gga aac aca atg tta gga gtc agt cat gtt gtc acc aca agt 1132 Leu Ser Gly Asn Thr Met Leu Gly Val Ser His Val Val Thr Thr Ser 320 325 330 gtt ggg atg tgt gat att gat atc aga cca ggt ctc tat ggc agt gta 1180 Val Gly Met Cys Asp Ile Asp Ile Arg Pro Gly Leu Tyr Gly Ser Val 335 340 345 ata gtg gca gga gga aac aca cta ata cag agt ttt act gac agg ttg 1228 Ile Val Ala Gly Gly Asn Thr Leu Ile Gln Ser Phe Thr Asp Arg Leu 350 355 360 aat aga gag ctg tct cag aaa act cct cca agt atg cgg ttg aaa ttg 1276 Asn Arg Glu Leu Ser Gln Lys Thr Pro Pro Ser Met Arg Leu Lys Leu 365 370 375 380 att gca aat aat aca aca gtg gaa cgg agg ttt agc tca tgg att ggc 1324 Ile Ala Asn Asn Thr Thr Val Glu Arg Arg Phe Ser Ser Trp Ile Gly 385 390 395 ggc tcc att cta gcc tct ttg ggt acc ttt caa cag atg tgg att tcc 1372 Gly Ser Ile Leu Ala Ser Leu Gly Thr Phe Gln Gln Met Trp Ile Ser 400 405 410 aag caa gaa tat gaa gaa gga ggg aag cag tgt gta gaa aga aaa tgc 1420 Lys Gln Glu Tyr Glu Glu Gly Gly Lys Gln Cys Val Glu Arg Lys Cys 415 420 425 cct tga gaaagagttc ccaagcttct accttccttt tgtcacctta cgtttcatag 1476 Pro * ctttagtata ctcaggaaaa gaatgaccat cttttgtaga atgtttatac atttatgcat 1536 atttcaattt ccacttaaat ttatttaaag ctttaactgg ctctataaat taagtttgtg 1596 ctttccttga aatgcactta ttcttattac aagcatttta taattttgta taaatgtcta 1656 ttttctctaa atattttgct ttcagtaaaa tgctttccaa ctctgtttag tgtattaatt 1716 accagtggat tggtagaact gcttttattg actagtaaaa gttactgcct agtcttttta 1776 ccttaggctt acagaattaa ataaaaatta gccattccag aaatataaaa aaaaaaaaaa 1836 aaaaaa 1842 <210> SEQ ID NO 20 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Oligonucleotide <400> SEQUENCE: 20 gctcatggct gctgccggcg 20 <210> SEQ ID NO 21 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Oligonucleotide <400> SEQUENCE: 21 gccgccgctc atggctgctg 20 <210> SEQ ID NO 22 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Oligonucleotide <400> SEQUENCE: 22 ctcacagtat aggatccaat 20 <210> SEQ ID NO 23 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Oligonucleotide <400> SEQUENCE: 23 gtgcttccgt catctctttc 20 <210> SEQ ID NO 24 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Oligonucleotide <400> SEQUENCE: 24 aggtgaaatg gcctccatat 20 <210> SEQ ID NO 25 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Oligonucleotide <400> SEQUENCE: 25 ctatcccagt cttcaaccat 20 <210> SEQ ID NO 26 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Oligonucleotide <400> SEQUENCE: 26 ggaaactatc ccagtcttca 20 <210> SEQ ID NO 27 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Oligonucleotide <400> SEQUENCE: 27 ctggcttctg atttgacatg 20 <210> SEQ ID NO 28 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Oligonucleotide <400> SEQUENCE: 28 tagtattcca cggtgcctct 20 <210> SEQ ID NO 29 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Oligonucleotide <400> SEQUENCE: 29 actctgtcag tttctctctc 20 <210> SEQ ID NO 30 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Oligonucleotide <400> SEQUENCE: 30 cagggatgtt gtagtgttca 20 <210> SEQ ID NO 31 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Oligonucleotide <400> SEQUENCE: 31 gcagttttgc aaaggaagaa 20 <210> SEQ ID NO 32 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Oligonucleotide <400> SEQUENCE: 32 aaactgcagt tttgcaaagg 20 <210> SEQ ID NO 33 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Oligonucleotide <400> SEQUENCE: 33 gaacgaccat tagcaaatgc 20 <210> SEQ ID NO 34 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Oligonucleotide <400> SEQUENCE: 34 cagtagaacg accattagca 20 <210> SEQ ID NO 35 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Oligonucleotide <400> SEQUENCE: 35 cagcccagta gaacgaccat 20 <210> SEQ ID NO 36 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Oligonucleotide <400> SEQUENCE: 36 aaaatcagcc cagtagaacg 20 <210> SEQ ID NO 37 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Oligonucleotide <400> SEQUENCE: 37 tgtccaaaat cagcccagta 20 <210> SEQ ID NO 38 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Oligonucleotide <400> SEQUENCE: 38 tccactgtcc aaaatcagcc 20 <210> SEQ ID NO 39 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Oligonucleotide <400> SEQUENCE: 39 atagccatcg tggactggaa 20 <210> SEQ ID NO 40 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Oligonucleotide <400> SEQUENCE: 40 aggacatagc catcgtggac 20 <210> SEQ ID NO 41 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Oligonucleotide <400> SEQUENCE: 41 gttgaaggac atagccatcg 20 <210> SEQ ID NO 42 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Oligonucleotide <400> SEQUENCE: 42 gccttgttga aggacatagc 20 <210> SEQ ID NO 43 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Oligonucleotide <400> SEQUENCE: 43 acaatgcctt gttgaaggac 20 <210> SEQ ID NO 44 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Oligonucleotide <400> SEQUENCE: 44 atttcacaat gccttgttga 20 <210> SEQ ID NO 45 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Oligonucleotide <400> SEQUENCE: 45 agtaataaag tctccagcaa 20 <210> SEQ ID NO 46 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Oligonucleotide <400> SEQUENCE: 46 aagagttctc tgcactgcat 20 <210> SEQ ID NO 47 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Oligonucleotide <400> SEQUENCE: 47 aggaaccaat tcaatattca 20 <210> SEQ ID NO 48 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Oligonucleotide <400> SEQUENCE: 48 gacctcgtaa cctgaggcaa 20 <210> SEQ ID NO 49 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Oligonucleotide <400> SEQUENCE: 49 gaagcttgaa aatcctggat 20 <210> SEQ ID NO 50 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Oligonucleotide <400> SEQUENCE: 50 gaattcataa tgaacagttg 20 <210> SEQ ID NO 51 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Oligonucleotide <400> SEQUENCE: 51 aaataatcct tctggaatct 20 <210> SEQ ID NO 52 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Oligonucleotide <400> SEQUENCE: 52 tagagacctg gtctgatatc 20 <210> SEQ ID NO 53 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Oligonucleotide <400> SEQUENCE: 53 atacttggag gagttttctg 20 <210> SEQ ID NO 54 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Oligonucleotide <400> SEQUENCE: 54 accgcatact tggaggagtt 20 <210> SEQ ID NO 55 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Oligonucleotide <400> SEQUENCE: 55 ttgcaatcaa tttcaaccgc 20 <210> SEQ ID NO 56 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Oligonucleotide <400> SEQUENCE: 56 tagaatggag ccgccaatcc 20 <210> SEQ ID NO 57 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Oligonucleotide <400> SEQUENCE: 57 gaaaggtacc caaagaggct 20 <210> SEQ ID NO 58 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Oligonucleotide <400> SEQUENCE: 58 tgttgaaagg tacccaaaga 20 <210> SEQ ID NO 59 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Oligonucleotide <400> SEQUENCE: 59 acatctgttg aaaggtaccc 20 <210> SEQ ID NO 60 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Oligonucleotide <400> SEQUENCE: 60 aatccacatc tgttgaaagg 20 <210> SEQ ID NO 61 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Oligonucleotide <400> SEQUENCE: 61 acactgcttc cctccttctt 20 <210> SEQ ID NO 62 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Oligonucleotide <400> SEQUENCE: 62 ttctacacac tgcttccctc 20 <210> SEQ ID NO 63 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Oligonucleotide <400> SEQUENCE: 63 attttctttc tacacactgc 20 <210> SEQ ID NO 64 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Oligonucleotide <400> SEQUENCE: 64 agggcatttt ctttctacac 20 <210> SEQ ID NO 65 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Oligonucleotide <400> SEQUENCE: 65 aactctttct caagggcatt 20 <210> SEQ ID NO 66 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Oligonucleotide <400> SEQUENCE: 66 attctacaaa agatggtcat 20 <210> SEQ ID NO 67 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Oligonucleotide <400> SEQUENCE: 67 agtggaaatt gaaatatgca 20 <210> SEQ ID NO 68 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Oligonucleotide <400> SEQUENCE: 68 accaatccac tggtaattaa 20 <210> SEQ ID NO 69 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Oligonucleotide <400> SEQUENCE: 69 ctggaatggc taatttttat 20 <210> SEQ ID NO 70 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Oligonucleotide <400> SEQUENCE: 70 cttcatctca ggcaacaaag 20 <210> SEQ ID NO 71 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Oligonucleotide <400> SEQUENCE: 71 gatgaataaa gttcaagagg 20 <210> SEQ ID NO 72 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Oligonucleotide <400> SEQUENCE: 72 ccttgaaggt tatcctgttt 20 <210> SEQ ID NO 73 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Oligonucleotide <400> SEQUENCE: 73 tgaataaagg ctgtcaaaac 20 <210> SEQ ID NO 74 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Oligonucleotide <400> SEQUENCE: 74 cacagtagac acacaatggt 20 <210> SEQ ID NO 75 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Oligonucleotide <400> SEQUENCE: 75 attagcaaat ctggcactaa 20 <210> SEQ ID NO 76 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Oligonucleotide <400> SEQUENCE: 76 tgtggagatc cttcacgcca 20 <210> SEQ ID NO 77 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Oligonucleotide <400> SEQUENCE: 77 ctcaggcaac aaagcggcgt 20 <210> SEQ ID NO 78 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Oligonucleotide <400> SEQUENCE: 78 gttccccctc taaagtatgc 20 <210> SEQ ID NO 79 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Oligonucleotide <400> SEQUENCE: 79 tggcccctga aggttatcct 20 <210> SEQ ID NO 80 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Oligonucleotide <400> SEQUENCE: 80 attagcaaat ctggcccctg 20 <210> SEQ ID NO 81 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Oligonucleotide <400> SEQUENCE: 81 tagtattcca cgggtaggta 20 <210> SEQ ID NO 82 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Oligonucleotide <400> SEQUENCE: 82 aatccacatc ccaacacttg 20 <210> SEQ ID NO 83 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Oligonucleotide <400> SEQUENCE: 83 accgtagttt ttgaatttga 20 <210> SEQ ID NO 84 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Oligonucleotide <400> SEQUENCE: 84 gttctaagtg tgaatatggc 20 <210> SEQ ID NO 85 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Oligonucleotide <400> SEQUENCE: 85 attagaaaca tggctgcgac 20 <210> SEQ ID NO 86 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Oligonucleotide <400> SEQUENCE: 86 ccaacttcat tcccatcacg 20 <210> SEQ ID NO 87 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Oligonucleotide <400> SEQUENCE: 87 tccaacttca tctcaggcaa 20 <210> SEQ ID NO 88 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Oligonucleotide <400> SEQUENCE: 88 cacccacctc aggcaacaaa 20 <210> SEQ ID NO 89 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Oligonucleotide <400> SEQUENCE: 89 gcggttacaa accccacacg 20 <210> SEQ ID NO 90 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Oligonucleotide <400> SEQUENCE: 90 ttgagaaatt gtttctatga 20 <210> SEQ ID NO 91 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Oligonucleotide <400> SEQUENCE: 91 tgacatgcat tttgtaggta 20 <210> SEQ ID NO 92 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Oligonucleotide <400> SEQUENCE: 92 tcgtacatac ttcaagagga 20 <210> SEQ ID NO 93 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Oligonucleotide <400> SEQUENCE: 93 gatgatgaat aaagctgtaa 20 <210> SEQ ID NO 94 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Oligonucleotide <400> SEQUENCE: 94 ccaaaactgc cttttccctg 20 <210> SEQ ID NO 95 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Oligonucleotide <400> SEQUENCE: 95 ggctgctcac ctggcactaa 20 <210> SEQ ID NO 96 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Oligonucleotide <400> SEQUENCE: 96 atcacacatc ccaacacttg 20 <210> SEQ ID NO 97 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Oligonucleotide <400> SEQUENCE: 97 aaatccacat ctgttgaaag 20 <210> SEQ ID NO 98 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: H. sapiens <220> FEATURE: <400> SEQUENCE: 98 cgccggcagc agccatgagc 20 <210> SEQ ID NO 99 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: H. sapiens <220> FEATURE: <400> SEQUENCE: 99 cagcagccat gagcggcggc 20 <210> SEQ ID NO 100 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: H. sapiens <220> FEATURE: <400> SEQUENCE: 100 attggatcct atactgtgag 20 <210> SEQ ID NO 101 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: H. sapiens <220> FEATURE: <400> SEQUENCE: 101 gaaagagatg acggaagcac 20 <210> SEQ ID NO 102 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: H. sapiens <220> FEATURE: <400> SEQUENCE: 102 atatggaggc catttcacct 20 <210> SEQ ID NO 103 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: H. sapiens <220> FEATURE: <400> SEQUENCE: 103 atggttgaag actgggatag 20 <210> SEQ ID NO 104 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: H. sapiens <220> FEATURE: <400> SEQUENCE: 104 tgaagactgg gatagtttcc 20 <210> SEQ ID NO 105 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: H. sapiens <220> FEATURE: <400> SEQUENCE: 105 catgtcaaat cagaagccag 20 <210> SEQ ID NO 106 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: H. sapiens <220> FEATURE: <400> SEQUENCE: 106 agaggcaccg tggaatacta 20 <210> SEQ ID NO 107 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: H. sapiens <220> FEATURE: <400> SEQUENCE: 107 gagagagaaa ctgacagagt 20 <210> SEQ ID NO 108 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: H. sapiens <220> FEATURE: <400> SEQUENCE: 108 tgaacactac aacatccctg 20 <210> SEQ ID NO 109 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: H. sapiens <220> FEATURE: <400> SEQUENCE: 109 ttcttccttt gcaaaactgc 20 <210> SEQ ID NO 110 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: H. sapiens <220> FEATURE: <400> SEQUENCE: 110 cctttgcaaa actgcagttt 20 <210> SEQ ID NO 111 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: H. sapiens <220> FEATURE: <400> SEQUENCE: 111 gcatttgcta atggtcgttc 20 <210> SEQ ID NO 112 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: H. sapiens <220> FEATURE: <400> SEQUENCE: 112 tgctaatggt cgttctactg 20 <210> SEQ ID NO 113 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: H. sapiens <220> FEATURE: <400> SEQUENCE: 113 atggtcgttc tactgggctg 20 <210> SEQ ID NO 114 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: H. sapiens <220> FEATURE: <400> SEQUENCE: 114 cgttctactg ggctgatttt 20 <210> SEQ ID NO 115 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: H. sapiens <220> FEATURE: <400> SEQUENCE: 115 tactgggctg attttggaca 20 <210> SEQ ID NO 116 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: H. sapiens <220> FEATURE: <400> SEQUENCE: 116 ggctgatttt ggacagtgga 20 <210> SEQ ID NO 117 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: H. sapiens <220> FEATURE: <400> SEQUENCE: 117 ttccagtcca cgatggctat 20 <210> SEQ ID NO 118 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: H. sapiens <220> FEATURE: <400> SEQUENCE: 118 gtccacgatg gctatgtcct 20 <210> SEQ ID NO 119 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: H. sapiens <220> FEATURE: <400> SEQUENCE: 119 cgatggctat gtccttcaac 20 <210> SEQ ID NO 120 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: H. sapiens <220> FEATURE: <400> SEQUENCE: 120 gctatgtcct tcaacaaggc 20 <210> SEQ ID NO 121 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: H. sapiens <220> FEATURE: <400> SEQUENCE: 121 gtccttcaac aaggcattgt 20 <210> SEQ ID NO 122 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: H. sapiens <220> FEATURE: <400> SEQUENCE: 122 tcaacaaggc attgtgaaat 20 <210> SEQ ID NO 123 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: H. sapiens <220> FEATURE: <400> SEQUENCE: 123 ttgctggaga ctttattact 20 <210> SEQ ID NO 124 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: H. sapiens <220> FEATURE: <400> SEQUENCE: 124 atgcagtgca gagaactctt 20 <210> SEQ ID NO 125 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: H. sapiens <220> FEATURE: <400> SEQUENCE: 125 tgaatattga attggttcct 20 <210> SEQ ID NO 126 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: H. sapiens <220> FEATURE: <400> SEQUENCE: 126 ttgcctcagg ttacgaggtc 20 <210> SEQ ID NO 127 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: H. sapiens <220> FEATURE: <400> SEQUENCE: 127 atccaggatt ttcaagcttc 20 <210> SEQ ID NO 128 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: H. sapiens <220> FEATURE: <400> SEQUENCE: 128 caactgttca ttatgaattc 20 <210> SEQ ID NO 129 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: H. sapiens <220> FEATURE: <400> SEQUENCE: 129 agattccaga aggattattt 20 <210> SEQ ID NO 130 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: H. sapiens <220> FEATURE: <400> SEQUENCE: 130 gatatcagac caggtctcta 20 <210> SEQ ID NO 131 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: H. sapiens <220> FEATURE: <400> SEQUENCE: 131 cagaaaactc ctccaagtat 20 <210> SEQ ID NO 132 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: H. sapiens <220> FEATURE: <400> SEQUENCE: 132 aactcctcca agtatgcggt 20 <210> SEQ ID NO 133 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: H. sapiens <220> FEATURE: <400> SEQUENCE: 133 gcggttgaaa ttgattgcaa 20 <210> SEQ ID NO 134 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: H. sapiens <220> FEATURE: <400> SEQUENCE: 134 ggattggcgg ctccattcta 20 <210> SEQ ID NO 135 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: H. sapiens <220> FEATURE: <400> SEQUENCE: 135 agcctctttg ggtacctttc 20 <210> SEQ ID NO 136 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: H. sapiens <220> FEATURE: <400> SEQUENCE: 136 tctttgggta cctttcaaca 20 <210> SEQ ID NO 137 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: H. sapiens <220> FEATURE: <400> SEQUENCE: 137 gggtaccttt caacagatgt 20 <210> SEQ ID NO 138 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: H. sapiens <220> FEATURE: <400> SEQUENCE: 138 cctttcaaca gatgtggatt 20 <210> SEQ ID NO 139 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: H. sapiens <220> FEATURE: <400> SEQUENCE: 139 aagaaggagg gaagcagtgt 20 <210> SEQ ID NO 140 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: H. sapiens <220> FEATURE: <400> SEQUENCE: 140 gagggaagca gtgtgtagaa 20 <210> SEQ ID NO 141 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: H. sapiens <220> FEATURE: <400> SEQUENCE: 141 gcagtgtgta gaaagaaaat 20 <210> SEQ ID NO 142 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: H. sapiens <220> FEATURE: <400> SEQUENCE: 142 gtgtagaaag aaaatgccct 20 <210> SEQ ID NO 143 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: H. sapiens <220> FEATURE: <400> SEQUENCE: 143 aatgcccttg agaaagagtt 20 <210> SEQ ID NO 144 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: H. sapiens <220> FEATURE: <400> SEQUENCE: 144 atgaccatct tttgtagaat 20 <210> SEQ ID NO 145 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: H. sapiens <220> FEATURE: <400> SEQUENCE: 145 tgcatatttc aatttccact 20 <210> SEQ ID NO 146 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: H. sapiens <220> FEATURE: <400> SEQUENCE: 146 ttaattacca gtggattggt 20 <210> SEQ ID NO 147 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: H. sapiens <220> FEATURE: <400> SEQUENCE: 147 ataaaaatta gccattccag 20 <210> SEQ ID NO 148 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: H. sapiens <220> FEATURE: <400> SEQUENCE: 148 ctttgttgcc tgagatgaag 20 <210> SEQ ID NO 149 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: H. sapiens <220> FEATURE: <400> SEQUENCE: 149 aaacaggata accttcaagg 20 <210> SEQ ID NO 150 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: H. sapiens <220> FEATURE: <400> SEQUENCE: 150 gttttgacag cctttattca 20 <210> SEQ ID NO 151 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: H. sapiens <220> FEATURE: <400> SEQUENCE: 151 accattgtgt gtctactgtg 20 <210> SEQ ID NO 152 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: H. sapiens <220> FEATURE: <400> SEQUENCE: 152 tggcgtgaag gatctccaca 20 <210> SEQ ID NO 153 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: H. sapiens <220> FEATURE: <400> SEQUENCE: 153 acgccgcttt gttgcctgag 20 <210> SEQ ID NO 154 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: H. sapiens <220> FEATURE: <400> SEQUENCE: 154 aggataacct tcaggggcca 20 <210> SEQ ID NO 155 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: H. sapiens <220> FEATURE: <400> SEQUENCE: 155 caagtgttgg gatgtggatt 20 <210> SEQ ID NO 156 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: H. sapiens <220> FEATURE: <400> SEQUENCE: 156 tcaaattcaa aaactacggt 20 <210> SEQ ID NO 157 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: H. sapiens <220> FEATURE: <400> SEQUENCE: 157 gccatattca cacttagaac 20 <210> SEQ ID NO 158 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: H. sapiens <220> FEATURE: <400> SEQUENCE: 158 ttgcctgaga tgaagttgga 20 <210> SEQ ID NO 159 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: H. sapiens <220> FEATURE: <400> SEQUENCE: 159 tttgttgcct gaggtgggtg 20 <210> SEQ ID NO 160 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: H. sapiens <220> FEATURE: <400> SEQUENCE: 160 cgtgtggggt ttgtaaccgc 20 <210> SEQ ID NO 161 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: H. sapiens <220> FEATURE: <400> SEQUENCE: 161 tcatagaaac aatttctcaa 20 <210> SEQ ID NO 162 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: H. sapiens <220> FEATURE: <400> SEQUENCE: 162 tacctacaaa atgcatgtca 20 <210> SEQ ID NO 163 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: H. sapiens <220> FEATURE: <400> SEQUENCE: 163 tcctcttgaa gtatgtacga 20 <210> SEQ ID NO 164 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: H. sapiens <220> FEATURE: <400> SEQUENCE: 164 ttacagcttt attcatcatc 20 <210> SEQ ID NO 165 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: H. sapiens <220> FEATURE: <400> SEQUENCE: 165 cagggaaaag gcagttttgg 20 <210> SEQ ID NO 166 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: H. sapiens <220> FEATURE: <400> SEQUENCE: 166 ttagtgccag gtgagcagcc 20 <210> SEQ ID NO 167 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: H. sapiens <220> FEATURE: <400> SEQUENCE: 167 caagtgttgg gatgtgtgat 20 <210> SEQ ID NO 168 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: H. sapiens <220> FEATURE: <400> SEQUENCE: 168 ctttcaacag atgtggattt 20 

What is claimed is:
 1. A compound 8 to 80 nucleobases in length targeted to a nucleic acid molecule encoding BAF53, wherein said compound specifically hybridizes with said nucleic acid molecule encoding BAF53 (SEQ ID NO: 4) and inhibits the expression of BAF53.
 2. The compound of claim 1 comprising 12 to 50 nucleobases in length.
 3. The compound of claim 2 comprising 15 to 30 nucleobases in length.
 4. The compound of claim 1 comprising an oligonucleotide.
 5. The compound of claim 4 comprising an antisense oligonucleotide.
 6. The compound of claim 4 comprising a DNA oligonucleotide.
 7. The compound of claim 4 comprising an RNA oligonucleotide.
 8. The compound of claim 4 comprising a chimeric oligonucleotide.
 9. The compound of claim 4 wherein at least a portion of said compound hybridizes with RNA to form an oligonucleotide-RNA duplex.
 10. The compound of claim 1 having at least 70% complementarity with a nucleic acid molecule encoding BAF53 (SEQ ID NO: 4) said compound specifically hybridizing to and inhibiting the expression of BAF53.
 11. The compound of claim 1 having at least 80% complementarity with a nucleic acid molecule encoding BAF53 (SEQ ID NO: 4) said compound specifically hybridizing to and inhibiting the expression of BAF53.
 12. The compound of claim 1 having at least 90% complementarity with a nucleic acid molecule encoding BAF53 (SEQ ID NO: 4) said compound specifically hybridizing to and inhibiting the expression of BAF53.
 13. The compound of claim 1 having at least 95% complementarity with a nucleic acid molecule encoding BAF53 (SEQ ID NO: 4) said compound specifically hybridizing to and inhibiting the expression of BAF53.
 14. The compound of claim 1 having at least one modified internucleoside linkage, sugar moiety, or nucleobase.
 15. The compound of claim 1 having at least one 2′-O-methoxyethyl sugar moiety.
 16. The compound of claim 1 having at least one phosphorothioate internucleoside linkage.
 17. The compound of claim 1 having at least one 5-methylcytosine.
 18. A method of inhibiting the expression of BAF53 in cells or tissues comprising contacting said cells or tissues with the compound of claim 1 so that expression of BAF53 is inhibited.
 19. A method of screening for a modulator of BAF53, the method comprising the steps of: a. contacting a preferred target segment of a nucleic acid molecule encoding BAF53 with one or more candidate modulators of BAF53, and b. identifying one or more modulators of BAF53 expression which modulate the expression of BAF53.
 20. The method of claim 19 wherein the modulator of BAF53 expression comprises an oligonucleotide, an antisense oligonucleotide, a DNA oligonucleotide, an RNA oligonucleotide, an RNA oligonucleotide having at least a portion of said RNA oligonucleotide capable of hybridizing with RNA to form an oligonucleotide-RNA duplex, or a chimeric oligonucleotide.
 21. A diagnostic method for identifying a disease state comprising identifying the presence of BAF53 in a sample using at least one of the primers comprising SEQ ID NOs 5 or 6, or the probe comprising SEQ ID NO:
 7. 22. A kit or assay device comprising the compound of claim
 1. 23. A method of treating an animal having a disease or condition associated with BAF53 comprising administering to said animal a therapeutically or prophylactically effective amount of the compound of claim 1 so that expression of BAF53 is inhibited.
 24. The method of claim 23 wherein the disease or condition is a hyperproliferative disorder. 